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ABSTRACT
Obesity is a global pandemic and its comorbidities are the top causes of preventable death in
America. Brown and inducible beige fat can significantly contribute to energy expenditure,
possibly leading to weight loss, and is considered a novel approach to combat obesity. Browning
of white adipocytes can be achieved using cold exposure, β[beta]-adrenergic receptor (β-AR) and
peroxisome proliferator-activated receptor gamma (PPAR[gamma])-agonists, and some
nutritional and pharmaceutical agents. Trans-resveratrol (Res) and indomethacin (Indo) have
shown promising abilities to promote browning.
Res has been shown to induce browning in vitro and in vivo; however, its rapid metabolism
and poor aqueous solubility reduce bioavailability, limiting its clinical utility. Therefore, two forms
of nanocarriers were synthesized to encapsulate Res (RNano and RLipo). Both forms led to
enhanced aqueous solubility, chemical stability, and sustained release patterns (Chapter III).
Both RNano and RLipo significantly enhanced browning of murine 3T3-L1 adipocytes as shown
by increased uncoupling protein 1 (Ucp1) and PPAR coactivator-1 alpha (Pgc1 [alpha]) mRNA
expression when stimulated by β-AR-agonist, isoproterenol.
To further enhance Res effectiveness, a ligand for delta-decorin ([delta]DCN), a receptor
specific to adipose stromal cells (ASCs) within white adipose tissue (WAT), was incorporated into
nanocarriers (L-NR) (Chapter IV). Freshly isolated ASCs from the inguinal WAT of C57Bl/6J mice
were used to confirm DCN protein expression, enhanced uptake of the ligand-bound
nanocarrier, and augmented browning using two different differentiation models.
Finally, the browning and brown adipogenic capacity of the non-steroidal anti-inflammatory
drug, Indo, was tested using murine 3T3-L1, human primary subcutaneous (HPsubQ), and
human brown (HBr) adipocytes. Indo is shown to have strong partial-PPAR-agonist activities
(Chapter V). It was found that Indo dose-dependently promoted browning in 3T3-L1 and HPsubQ
adipocytes as well as enhanced brown adipogenesis in HBr adipocytes via its PPAR-agonist
activity as demonstrated by increased UCP1 expression, mitochondrial biogenesis, proton leak,
and respiratory capacity.
In conclusion, we have shown enhanced browning capacity of Res using nanocarriers, which
is augmented by the addition of ASC-targeting peptides as well as browning and brown
adipogenesis induced by Indo. Given these results, these compounds can be considered novel
browning agents to help combat obesity.
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CHAPTER I:

INTRODUCTION

1

Obesity affects millions of people worldwide and its associated metabolic complications lead
to illness and many unfortunate fatalities.1 Obesity can be attributed to a complex interplay of
modifiable (lifestyle, behavioral) and non-modifiable (age, gender, race, genetics) factors, and
even some interplay between these factors (i.e., epigenetics).2 However, in the simplest form,
weight gain occurs when energy intake exceeds energy expenditure (EE), leading to excess
energy being stored in the form of fat in the adipose tissue.3 A common attribute of obesity is
excess intrabdominal fat storage, which is characteristic of metabolic syndrome and the ensuing
dyslipidemia and insulin resistance.4 However, normal adipose tissue has many crucial
functions as fundamental as fat storage and insulation, and as critical as playing roles in wholebody metabolism and energy balance.5 Two primary depots of fat are defined as white adipose
tissue (WAT) and brown adipose tissue (BAT). WAT provides the body’s largest storage site for
energy in the form of triglycerides (TGs), but also functions to release adipokines which can
self-signal (autocrine), locally (paracrine), and systemically (endocrine).6 BAT is shown to play a
pivotal role in EE by rapidly metabolizing lipids and glucose to produce heat instead of energy.7
This heat-generating process is known as non-shivering thermogenesis and can be primarily
attributed to BAT’s very high expression of uncoupling protein 1 (UCP1) which functions to
dissociate the electron chemical gradient in oxidative phosphorylation; the substrates normally
used to generate ATP are released as heat instead. 7 Brown-like or beige adipocytes are said to
have functions and thermogenic capacity comparable to BAT but arise within or are induced
from WAT. Just like BAT, UCP1 also aids in the thermogenic function of beige adipocytes,
therefore, serving as a marker for these cells.8 Due to its manifestation (de novo) or
transformation (transdifferentiation) within WAT, but having comparable metabolic and genetic
attributes to BAT, beige adipocytes have emerged as a desirable therapeutic target for
metabolic research.9 Creating a more energy insufficient WAT and increasing EE has made
beige adipocytes a sought after means to combat obesity.8, 9
Adipose stromal cells (ASCs) within WAT can be differentiated into beige adipocytes in
response to various stimuli, such as peroxisome proliferator-activated receptor (PPAR)agonists, beta-adrenergic receptor (-AR)-agonists, cold exposure, as well as some nutritional
and pharmaceutical compounds.10-12 Agents which can mimic these agonists or work through
these pathways could also activate the brown fat program in WAT.10 Indomethacin (Indo) is a
non-steroidal anti-inflammatory drug (NSAID) which has been shown to work as a partial PPAR
agonist, similar to that of the full agonist, rosiglitazone (Rosi).13 Rosi is a type of
thiazolidinedione (TZD) which are commonly used as insulin sensitizing drugs in the treatment
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of type 2 diabetes mellitus.14 Rosi has been shown to induce the browning program in WAT,
suggesting that Indo could also induce browning through similar mechanisms.12
Trans-resveratrol (Res) is another compound which has been shown to induce browning in
vitro,15-18 animal studies,19-21 as well as in human clinical trials.22, 23 Unfortunately, there are
many claims from in vitro and animal studies which remain unsubstantiated or inconsistent as
compared to clinical trials.24, 25 This could primarily be pinpointed to Res poor aqueous solubility
and low bioavailability due to its rapid intestinal and hepatic metabolism.26, 27 Nanotechnology
has been used previously to encapsulate bioactive compound to improve their chemical
stability, solubility, and bioavailability.28-31 Moreover, the addition of ligands or peptides on the
surface of nanocarriers can be used to target specific cells or tissues, further reducing excess
metabolism and removal.32, 33 Recently, an extracellular matrix protein and isoform of decorin
lacking glycanation (DCN) was found to be isolated to WAT-ASCs.34 The interaction of DCN
and the peptide which can home this receptor provides a technique which can be exploited to
develop a drug-delivery system for treating obesity.
In this dissertation, we will use biocompatible and biodegradable nanocarriers encapsulated
with Res (Rnano) in order to overcome critical limitations previously discussed. To enhance
targeting specificity, we will incorporate an ASC-targeting ligand on the surface of Rnano (LNR). We hypothesize that (1) nanoparticle encapsulation and ligand-coating will increase
aqueous solubility and chemical stability of Res (Chapter III and IV); (2) As compared to Rnano,
L-NR will have a higher binding affinity and uptake by DCN-transduced 3T3-L1 cells as well as
murine stromal cells isolated from inguinal fat pads of C57Bl/6J mice (Chapter IV); (3) L-NR
greater than Rnano greater than free-Res will have ability to brown 3T3-L1 adipocytes as well
as murine primary stromal cells in vitro (Chapter III and IV); and (4) Indo will have the ability to
promote browning of murine 3T3-L1 and human primary subcutaneous white adipocytes as well
as human brown adipocytes in a manner similar to Rosi. The structure of this dissertation is
outlined in Figure 1.1.
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1.2 APPENDIX

Figure 1.1. Dissertation project flow diagram.
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CHAPTER II:
LITERATURE REVIEW

7

2.1

DEFINING OBESITY AND RECOGNIZING ITS PREVALENCE
As a consequence of accessibility and excess consumption of energy-dense foods

compounded by a lack of physical exertion, obesity, and its comorbidities continue to be among
the leading causes of death and illness in the United States (U.S.) and is becoming a major
issue globally.1-3 Obesity in America is considered to be at pandemic levels, and despite
continued efforts, it is still growing.4 A 2017 report from the Center for Health and Disease
(CDC) estimated that 71.6% of U.S. adults were overweight or obese and among these, 39.8%
were obese.5 This number is up from the most recent National Health and Nutrition Examination
Survey (NHANES) data brief which states that in 2015-2016, 69% of U.S. adults were
overweight or obese and 34.9% were obese.3
Obesity is technically defined by having a body mass index (BMI) of greater than 30, which
is calculated using height and body weight (BW) alone (BMI = kg/m2).6 However, many factors
weigh into the variances of BMI, including race, sex, age, hydration and disease status, etc.

6,7

Although useful in most adults, without other anthropometric measures, BMI has several
limitations. For example, BMI can overestimate body fat percent (BF%) in very lean and
muscular individuals as well as underestimate BF% in elderly individuals that have severely lost
lean body mass.8 Moreover, individuals could be categorized as having a “normal BMI”, but
carry more abdominal fat, known as visceral adipose tissue, which is highly associated with
insulin resistance and other metabolic diseases.9, 10 Therefore, waist circumference (WC) is
used in conjunction with BMI to provide a better assessment of metabolic health than BMI
alone.11 A WC of >35 inches for women and >40 inches for men indicate abdominal obesity
(apple/android distributed fat) and is therefore associated with obesity-related metabolic
diseases.12
Obesity itself is not a fatal disease; rather, its comorbidities top the list of causes of
preventable deaths.5 Obesity’s associated diseases include type 2 diabetes mellitus (T2DM),
cardiovascular disease (CVD), metabolic disease, and some types of cancer.13 Creating a
negative energy-balanced state by way of consuming an energy-restrictive, well-balanced diet
with an emphasis on plant-based foods, along with including regular physical activity, although
the foremost and best-characterized means to treat and prevent obesity, is not always feasible.6
Extreme and even moderate weight loss can be difficult to achieve and even more difficult to
maintain.14 Other weight loss methods, such as bariatric surgeries, can be extreme and
invasive, and not all individuals may meet the requirements for these surgeries, but still need
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help.14 Certain disease states, disability, and aging are among many obstacles which may
further hinder progress.14
There is no one single cause for obesity; rather, it is a collection of multiple factors including
genetics, behavior, lifestyle, environment, and even the interplay of genetics and environment
(epigenetics) which work in concert.15, 16 To better understand obesity pathology, it is critical to
understand adipose tissue biology and function, as well as its dysfunction.
2.2

ADIPOSE TISSUE BIOLOGY AND FUNCTION
Adipose tissue (AT) is an integral organ with specialized physical, metabolic, and endocrine

functions. Physically, AT helps provide insulation and cushion to internal organs, providing
another layer to the body’s ‘physical barrier’ from the outside world.17 Previously thought to be
an inert tissue, AT is now recognized as a high-rolling player in whole-body metabolism, storing
and releasing lipids based on energy needs, helping to control appetite, as well as helping to
regulate angiogenesis, blood pressure, immune function, and energy expenditure (EE).18 Its
activity as an endocrine/secretory organ can be considered a relatively recent discovery, in the
history of AT biology.19, 20
While the normal function of AT acts as a critical energy buffer, extreme excess of AT
(obesity) leads to dysfunction (insulin resistance and the ensuing inflammatory response). 21 AT
is primarily composed of lipid-laden adipocytes with remarkable, but limited expandability.22
Based on energy demands, pluripotent stem cells from mesenchymal origin can differentiate
into adipocytes with the proper stimulation.23 Although adipocytes comprise most of the total
volume of AT, they only make up about 25% of the total cell population.24 The stromal vascular
fraction (SVF) of AT is also composed of a variety of cell types, including immune cells such as
macrophages, lymphocytes, and pericytes as well as preadipocytes (or adipose stromal cells
(ASCs)), fibroblasts, endothelial cells, and blood cells all of which highly impact its metabolic
function24 and may be the primary source of AT secretory factors.25
Two primary types of fat which are widely recognized can be classified as white adipose
tissue (WAT) and brown adipose tissue (BAT). One of WAT’s primary functions which is
considered the ‘classically characterized AT role’, is to store fat for future use, whereas BAT
generates heat via non-shivering thermogenesis (NST).26 The relatively recent discovery of a
third type of fat, called beige fat, has emerged and is shown to have similar functions as BAT,
but found within WAT.26, 27 With a relatively greater abundance of mitochondria and enhanced
thermogenic capacity, the inducibility of beige adipocytes from WAT by using various
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nutraceutical and pharmaceutical compounds has become a promising approach to use as an
anti-obesity therapy.26 Adipose biology, physiology, function, and dysfunction in the context of
obesity, as well as regulation of white, brown, and beige fat, is reviewed here.
2.2.1

White adipose tissue and adipocytes

As previously discussed, the primary functions of WAT include insulation, mechanical
cushion, and storage.28 Although WAT does not conduct heat well, the extra layer provides
internal organs insulation and protection from trauma.28 WAT also provides the largest reservoir
of energy in the human body.28 AT is not found in discrete compartments, rather it is distributed
throughout the body and can be found in, on, and around most organs.29 With that said, there
are major depots of fat, including under the skin, or subcutaneous adipose tissue (SAT), as well
as around the organs, or visceral adipose tissue (VAT).29 SAT typically comprises about 7090% of total body fat, whereas VAT comprises about 10-30%.24, 29 The over-expansion of VAT
is highly associated with dyslipidemia and insulin resistance.30
WAT controls energy balance primarily by managing the storage and release of free fatty
acids (FFA).31 FFA are stored in adipocytes as triglycerides (TG) into lipid droplets (LD) which
then accumulate and merge to form large unilocular LDs.31 This process of lipogenesis, lipid
accumulation, differentiation, and maturation is known as adipogenesis.18, 32 LDs are coated in
various types of LD-associated proteins including adipophilin, TIP47, OXPAT/MLDP, S3-12, and
the most abundant of these are isoforms of perilipin (PLIN).33 These LD-associated proteins
stabilize LDs, incorporate new TGs, and prevent TG release in energy-replete states while
maximizing hormonally stimulated lipolysis with the help of hormone-sensitive lipase (HSL) and
adipose TG lipase (ATGL) during energy-depleted states.33 Mature adipocytes in WAT are said
to originate from mesenchymal stem cells (MSCs) not expressing myogenic factor 5 [(Myf5)negative], which then undergoes two phases during adipogenesis: determination and
differentiation.18, 34, 35 A pluripotent stem cell which has committed to adipocyte lineage loses the
ability to differentiate into other cell types (i.e., chondrocytes, osteocytes, myocytes, etc).36, 37
Once cells are committed, a series of morphological and biochemical changes marks the
inception of adipocyte differentiation, during which the cell acquires the equipment necessary to
synthesize and store lipids, respond to insulin for nutrient uptake and storage, and to synthesize
and secrete adipocyte-specific factors.18, 38
During adipogenesis, peroxisome proliferator-activated receptor gamma (PPAR) and
CCAT-enhancer-binding proteins (C/EBPs) play critical roles in the adipogenic transcription
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cascade.39, 40 PPAR is known as the master regulator of adipogenesis and has two protein
isoforms; PPAR1 (55 kDa), which is constitutively expressed and PPAR2 (57 kDa), an ATspecific isoform.41, 42 Interestingly, PPAR2 expression is inversely correlated with BMI and
weight, whereas higher expression of PPAR1 in SAT is associated with hyperinsulinemia and
insulin resistance.43 At any rate, it is known that PPAR and C/EBPs display critical cross-talk
with each other as well as other transcription factors such as kruppel-like factor (KLF)-5 and
KLF-15 and sterol response element binding protein (SREBP) to promote adipogenesis.44-46
Figure 2.1. demonstrates positive and negative regulators of adipogenesis (all figures for
Chapter II are located in 2.7 Appendix).
From experience with cultured preadipocytes, it is understood that a combination of
hormones is required to promote terminal differentiation.38, 50 When murine preadipocyte cell
line, 3T3-L1 cells, are exposed to signals such as insulin, insulin-like growth factor 1 (IGF-1),
and cyclic AMP (cAMP), they undergo mitotic clonal expansion (MCE) after having reached
confluence prior to succumbing to growth arrest and subsequent differentiation.38, 50
Interestingly, there is cAMP-dependent ligand activity during the first two days of differentiation
in 3T3-L1 cells, thereby also requiring cAMP Response Element Binding protein (CREB).18, 46
This is said to be needed to induce differentiation, but elevated levels of cAMP are not needed
to maintain PPAR-dependent differentiation.51 For this reason, 3-isobutyl-1-methylxanthine
(IBMX) is used, among other differentiation-stimulating agents, in the induction media of 3T3-L1
cells.52 IBMX is a phosphodiesterase (PDE)-inhibitor and is therefore called the “cAMP elevating
agent”.53 This cAMP-dependent differentiation is only present within the first 48 h, making the
timing of reagent exposure critical.54 The differentiation cocktail of IBMX, insulin, and
dexamethasone (a corticosteroid which activates glucocorticoid receptor (GR)) causes a
transient but dramatic increase in C/EBP/ which further commits the cells to differentiate and
causes a cell cycle switch (G1 → S phase).54-56 Glycogen synthase kinase 3 beta (GSK3) and
mitogen-activated protein kinase (MAPK) then further activate C/EBP by
hyperphosphorylation, leading to induction of PPAR and C/EBP expression and activation.57,
58

PPAR and C/EBP then activate their downstream differentiation targets, including a positive

feedback loop further activating themselves.59 Cyclin D3 then phosphorylates and further
activates C/EBP which inhibits proliferation and the cells enter the final steps of
differentiation.59
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2.2.2

Adipose tissue as an endocrine organ

The relatively recent discovery of adipocyte-specific secretory proteins has led to the
conclusion that AT is much more than a storage site for fuel, rather, it is a specialized organ with
critical endocrine functions.60 WAT produces a number of secretory factors such as adipokines
and chemokines, among others, which are shown to have both local and systemic effects.60
Synthesis and secretion of adipokines such as leptin, adiponectin, visfatin, resistin, omentin,
among others acts as signals to convey the status of body fat depots and plays roles in wholebody energy regulation.61, 62 These adipokines have a multitude of downstream effects ranging
from affecting WAT insulin sensitivity, angiogenesis, inflammation, adipocyte differentiation, and
energy balance.62, 63 Other biologically active peptides and inflammatory cytokines are released
from both the adipocytes and other cells within the AT microenvironment including monocyte
chemoattractant protein 1 (MCP1), lipocalin 2, fibroblast growth factor 21, retinol-binding protein
4 (RBP4), tumor necrosis factor-alpha (TNF).64, 65 However, among these adipose-secreted
factors, leptin is highly recognized to both be preventative and a contributing factor in the
context of obesity and is therefore discussed further.66
Leptin is primarily synthesized and secreted by AT, although it can be synthesized by some
other tissues, and secretion typically occurs in proportion to AT abundance, but its secretory
patterns can be altered based on food intake.66 Leptin is highly intertwined in whole-body
metabolism by regulating food intake and increasing EE.63 Regulation of EE by leptin is caused
by stimulated secretion of norepinephrine (NE) which leads to thermogenesis.67, 68 Leptin helps
to regulates food intake by suppressing appetite by signaling the leptin receptor (or obesity
receptor (Ob-Rb)); which is a member of the class I cytokine receptor family located in the
hypothalamus.69 This signaling relays an energy replete state to the hypothalamus, reducing the
hunger-response.66 Leptin resistance occurs in obesity in response to excess leptin secretion
overwhelming the Ob-Rb, which effectively diminishes response to the anorexigenic hormone,
leading to hyperphagia.70 In fact, mutations in or forced genetic deficiency of leptin production
(ob/ob) in mice leads to obesity and T2DM development in mice.71
2.2.3

Adipose tissue dysfunction

Inflated and dysfunctional AT is a key player in metabolic disturbances, specifically,
enlarged VAT, or central adiposity, is indicative of metabolic syndrome.72 Metabolic syndrome
(MS) is a disorder characterized by a culmination of insulin resistance, atherogenic
dyslipidemia, elevated blood pressure (BP), and a proinflammatory and prothrombotic state.73
Individuals with MS are at greater risks for developing fatty liver, asthma, sleep apnea and other
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sleep disorders, polycystic ovarian syndrome, gallstones, and some forms of cancer.73
Excessive accumulation of TGs and adipocyte hypertrophy leads to a hypoxic environment with
increased oxidative stress.74 The differences in SAT and VAT and their mediated inflammatory
response is substantial, VAT being the primary offender. Visceral adipocytes have a critical
death size that is much less than that of their SAT counterparts, leading to greater macrophage
infiltration.75, 76 Adipocyte apoptosis leads to elevated production of inflammatory mediators such
as leptin, resistin, and RBP4.77, 78 These signals initiate a type 1 pro-inflammatory immune
response which is characterized by aggregating CD4+ T helper type 1 (Th1) cells, cytotoxic
CD8+ cells, and pro-inflammatory classically-activated macrophages (M1).64 Visceral adipocytes
are quick to release FFA from stored TGs, leading to rapid increases FFA concentrations in the
liver.79 This rapid influx of FFA in the liver stimulates gluconeogenesis and TG synthesis without
clearance of insulin.79 The ensuing development of dyslipidemia, hyperglycemia, and
hyperinsulinemia are all contributing factors to the increased risk of metabolic diseases
associated with inflated VAT.79
Although there is some debate of whether it is the cause or consequence of, it is understood
that insulin resistance is a key underlying factor in the pathology and physiology of AT
dysfunction.80 AT synthesizes and secretes several cytokines which are shown to work both as
a result and a cause of insulin resistance including TNF, interleukin (IL)-6, IL-1, and
transforming growth factor-beta.64, 79 Of these, TNF, which is primarily secreted from
macrophages in these inflammatory conditions, is a key modulator of the pro-inflammatory
immune response in diet-induced obesity (DIO) and contributes to decreased glucose uptake
and insulin resistance.64 It does this by inhibiting both the insulin receptor (IR) and IR substrate
(IRS) proteins, which through the phosphoinositol-3-kinase (PI3K) signaling pathway, reduces
translocation of glucose transporter (GLUT4) to the cell surface.79 By inhibiting the response to
the anti-lipolytic hormone, insulin, the net effect of TNF on adipocytes is an increase in lipolysis
and a decrease in lipogenesis, thereby increasing the release of FFA into plasma.64, 79
Increased non-esterified fatty acids in plasma leads to the hyperlipidemic metabolic dysfunction,
which is also highly associated with insulin resistance.25, 81
Adipocyte hypertrophy and over-accumulation of TGs together with decreased vasculature
and hypoxic environment due to both a lack of oxygen availability and increased need triggers
cell death inducible factors and pro-inflammatory adipokines such as RBP4, leptin, and
resistin.64 From this, a pro-inflammatory cascade is set into motion triggering a type 1 (proinflammatory) immune response from WAT-residing immune cells.64 Leptin causes T-helper
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cells polarization to type 1 (Th0 → Th1), which causes the release of TNF and interferon-,
contributing to insulin resistance. Other adipokines recruit and activate pro-inflammatory
classically-activated macrophages (M1), cytotoxic CD8+ T cells, and natural killer T cells, which
further release pro-inflammatory cytokines and collectively form crown-like structures (CLS).64
The vicious cycle is established with CLS-mediated phagocytosis of apoptotic adipocytes, which
leads to antigen presentation and further mediates the release of pro-inflammatory cytokines,
impairing insulin action.64 When anti-inflammatory mediators are brought into this dysregulated
environment, they are also transformed and polarized into type-1 immune cell mediators. For
example, anti-inflammatory alternatively activated macrophages (M2) in this setting will lose
their ability to store iron which empties into AT, leading to increased production of reactive
oxygen species caused by iron-mediated lipid peroxidation.64 M2s in this environment will also
lead to collagen synthesis and deposition in AT, leading to fibrosis and exacerbating already
critical circumstances.64
Contrary to popular belief, inhibiting differentiation or inducing cell death as a means to treat
or prevent obesity, in an already hypoxic and inflamed AT environment would only serve to
augment already metabolically dysfunctional circumstances.82 The AT expandability hypothesis
claims that it is the failure of AT expansion that leads to the metabolic detriments associated
with obesity, rather than obesity and fat tissue itself.22 This is further supported by the existence
of ‘metabolically healthy obese' individuals, who have excessive fat stores and BMI that
categorize them as obese but do not have the associated metabolic diseases.83, 84 Furthermore,
it is suggested that the majority of individuals with T2DM are obese; however, many obese
individuals do not have T2DM.82-84 Again, this evidence suggests that the inflammation induced
by insulin resistance is the primary contributor to the metabolic disturbances associated with
obesity, rather than AT itself.
Therefore, treating AT with insulin-sensitizing compounds without inhibiting differentiation
may improve metabolic outcomes.85, 86 Pharmaceutical agents such as thiazolidinediones
(TZDs) are associated with this very outcome; although there are some drawbacks to its use,
including some weight gain due to edema and increase in adiposity.85-88 Their pleiotropic nature
has led to many therapeutic outcomes that cannot be directly accounted for by any one single
mechanism.85-88 However, it is partly due to both the insulin-sensitizing effect and the increase
in adiposity which leads to improved metabolic outcomes.86, 87 In fact, individuals taking TZDs
show improvements in blood lipid profiles, blood pressure, glycemic control, endothelial
function, and decreased inflammation markers.86, 87 Some TZDs have also been shown to
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induce a more thermogenic, brown-fat-like profile in WAT, which has led to increased energy
utilization and weight loss.89
2.2.4

Brown adipose tissue and adipocytes

BAT was previously thought to be present, but limited to small mammals and infant-humans
only.90 However, the use of positron-emission-tomography and computed tomography (PET-CT)
in combination with 18F-fluorodeoxyglucose (18F-FDG) led to the discovery of functional BAT in
adult humans as well.90-92 PET-CT scan after administration of 18F-FDG revealed the
anatomical locations of BAT in humans (cervical, supraclavicular, axillary, paravertebral,
periadrenal, subscapular) 89 and mice (interscapular, axillary, perirenal).93, 94 Figure 2.2.
demonstrates anatomical locations of WAT and BAT in both human and mice. Due to its
relatively small volume in the human adult, it was assumed this tissue could not have an impact
on overall EE.95 Quite contrarily, it was shown to utilize more glucose per gram than any other
tissue and significantly contribute to whole-body EE.92, 94 Some studies have shown that BAT
preferably utilizes intracellular fuel sources in response to short term cold exposure (CE), having
minimal plasma-substrate utilization.96 However, other studies have shown thermogenically
active BAT in mice had increased uptake of FFA from TG-rich lipoproteins which led to greater
hepatic clearance of cholesterol remnants.97, 98 This was shown to improve blood lipid profiles,
reducing the rate of dyslipidemia and atherosclerosis development.98-100 Clinical observations
have shown that the amount of BAT has an inverse relationship with BMI and is positively
correlated with leanness and euglycemia, pointing towards its potential therapeutic use in
obesity and diabetes.101-104
The means by which BAT can elicit these beneficial effects is through its specialized
function of producing heat via adaptive NST.26, 27, 105, 106 The inner mitochondrial membrane
(IMM) of BAT has very high expression of uncoupling protein 1 (UCP1), which drives increased
proton leak across the mitochondrial membrane, dissociating the chemical gradient from ATP
synthesis during oxidative phosphorylation.106 Therefore, instead of generating ATP, these
electron transport chain (ETC) substrates are released in vain as heat, helping to maintain
thermoneutrality in times of acute and chronic CE without having to rely on muscle-shiveringgenerated heat alone.96, 106 Uncoupling of the ETC is visually demonstrated in Figure 2.3. Due
to its very high expression and association with the thermogenic capacity of BAT, UCP1 is used
as a hallmark of BAT and thermogenesis.107 BAT has been shown to help maintain body
temperature in thermoneutrality at rest (obligatory thermogenesis), when acutely exposed to
cold during long-term ambient temperature exposure (facultative thermogenesis), and in
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response to long-term CE (adaptive thermogenesis).108, 109
BAT is a highly vascularized and sympathetically innervated tissue which contains brown
adipocytes with multilocular LDs and numerous mitochondria.94 The high vascularization of BAT
allows increased access and delivery of plasma substrates such as glucose, lipids, and oxygen
for rapid consumption and oxidation, as well as providing efficient means for heat distribution to
the whole body.26, 106 BAT is also surrounded by a dense network of sympathetic nerves, which
secretes NE when prompted, inducing lipolysis and fatty acid beta-oxidation (FAO) via beta-3adrenergic receptor (3-AR) stimulation.110 cAMP is a second messenger that is generated in
response to 3-AR stimulation which activates protein kinase A (PKA).110 Activated PKA
phosphorylates and activates lipolytic enzymes, such as HSL and ATGL, leading to TG
hydrolysis and release of glycerol and FFA which will be further broken down in FAO.110 Surface
area is a critical limitation for lipolysis; therefore, having small multilocular LDs increases the
surface area and accessibility for lipase interaction, promoting more efficient lipolysis.31, 111
Increased FFA release from lipolysis is then shuttled to BAT’s enriched network of mitochondria
for FAO. Mitochondrial biogenesis in BAT is regulated by a transcriptional cascade primarily
controlled by PPAR coactivator 1 alpha (PGC1), which can work in conjunction with nuclear
respiratory factor 1 (NRF1) to further promote the thermogenic response in BAT.112, 113
Adipocytes in BAT originate from the somatic multipotent Myf5-positive precursor population
which can also give rise to myocytes.26 Due to this, BAT and myocytes have similar gene
expression profiles. Several transcription factors are shown to help regulate brown fat cell fate.
Bone morphogenic protein 7 (BMP7) is shown to trigger the commitment of the precursor cells
into brown-fat lineage as well as activate the full-blown brown-fat adipogenic program, including
activation of positive regulatory domain-containing protein 16 (PRDM16) and PGC1, and is
required for expression of UCP1.114 Early B-cell factor-2 (EBF2) is an embryonic brown
preadipocyte specific marker and can recruit PPAR to promote brown-fat selective genes such
as PRDM16.115, 116 PRDM16 is a zinc-finger protein which binds to and coregulates PPAR,
PPAR, C/EBP, and PGC1 to further promote brown-fat-specific gene expression.117-122
Differentiation of brown-fat committed precursor cells can be induced by a variety of
factors.123-125 As previously discussed, CE can induce NST, or adaptive thermogenesis, causing
NE-stimulated increase in cAMP levels.108 cAMP then works through a P38-MAPK-mediated
signaling cascade leading to lipolysis and the resulting heat generation from UCP1 expressing
mitochondria leaking protons during FAO.126, 127 Through a similar pathway, leptin was shown to
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mediate UCP1 expression in BAT through sympathetic nervous system (SNS) stimulation.128
The thyroid hormone (TH) is another example of an internal regulator of the brown-fat program.
Pituitary stimulation of the thyroid gland causes synthesis and secretion of the inactive form of
TH, thyroxin (T4).129 T4 traverses the bloodstream to target tissues expressing deiodinase
iodothyronine type 2 (DIO2) which converts T4 to the biologically active form, triiodothyronine
(T3).129 BAT has a very high expression of DIO2130 which is downregulated by T4 and
upregulated by SNS activation (i.e., cold stimulation).131 The TH can upregulate UCP1 via two
mechanisms: (1) the UCP1 promoter contains a TH receptor  (TH-R) regulatory region, which
directly upregulates UCP1 expression,132, 133 and (2) the TH-R helps to regulate -AR
expression, which sensitizes BAT to SNS activation.134 It has also been shown that thyroidstimulating hormone receptor (TSH-R) also induces the brown-fat program, enhances
thermogenesis and UCP1 expression, and protects from hypothermia in hypothyroid
conditions.135 Transcriptional regulation of the TH is primarily achieved through activation of
thyroid response elements (TREs) as well as other genes, which can heterodimerize with PPAR
in the PPRE and further induce thermogenesis.136
Exogenous treatment with -AR agonists, such as isoproterenol (ISO), forskolin, and other
more-specific agonists can induce similar UCP1 driven thermogenesis programs in BAT.137
High-calorie diets have also been shown to activate the thermogenic program in BAT as a
compensatory mechanism, pointing towards its protective capacity against the harmful
metabolic effects of DIO.106 Studies suggest -AR signaling is required for diet-induced
thermogenesis.138 Exercise-induced activation of the PGC1 pathway leads to the production of
myokines such as irisin and meteorin-like protein (METRNL), which activate UCP1-thermogenic
program in BAT, leading to an increase in EE.105, 139, 140 PPAR agonists, such as TZDs, are also
shown to further promote the expansion of BAT depots.89, 141 Several bioactive compounds have
demonstrated abilities to target or work through similar pathways as described above, further
promoting the thermogenic program in BAT.142
2.2.5

Beige and brite adipocytes

Recently, a third type of fat cell has been characterized which has similar characteristics as
brown adipocytes but is primarily induced and arises within WAT.26, 27, 105, 106, 143 These cells
have accumulated many names over the years, including “brite” (brown-in-white), beige,
inducible or recruitable brown, as well as brown adipocyte-like cells.138 Due to its inducibility,
plasticity, and distinct characteristics, the terminology used throughout the rest of this review is
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“beige adipocytes”. Similar to brown adipocytes, beige adipocytes have a smaller cell size,
multilocular LDs, and higher cellular respiration as a result of their greater number and function
of mitochondria expressing UCP1.138
As previously discussed, brown adipocytes have many small (multilocular) LDs which are
important to facilitate expedited lipolysis by increasing the surface area accessible to lipases.31
In response to CE or -AR stimulation, FFAs are released and used to generate heat via UCP1dependent uncoupling of oxidative phosphorylation in the mitochondria.31 This is associated with
increased expression of LD-associated proteins such as Cidea, Perilipin, ATGL, HSL, and
adipose differentiation related protein, which are highly expressed in BAT.31 Interestingly,
expression of these proteins in addition to an increase in expression of both lipogenesis and
lipolysis proteins are also critical during the browning process of WAT. This is a process
described as "the futile cycle of TAG hydrolysis and re-synthesis".31 In this process, lipolysis
induced by CE and -AR stimulation breaks down the unilocular LD; however, lipogenesis
proteins, such as fatty acid synthase (FASN) and glycerol kinase (GYK), act to recycle the FFA
to form TGs which are stored within newly formed microLDs (mLDs).31 This process helps to
transform the unilocular LD morphology of white adipocytes into a more brown-like multilocular
LD morphology so that UCP1-positive beige adipocytes have many smaller LDs.31 Similar to
BAT, these small LDs formed within beige adipocytes have greater surface area allowing for a
more efficient lipolysis and downstream heat production.31 Interestingly, PPAR-agonists are
shown to promote this TAG-cycling process further by inducing expression and activity of
GYK.31, 144 Reducing FFA release into serum by recycling them within adipocytes is one of the
many theories of how PPAR-agonists elicit its therapeutic effects in the context of insulin
resistance and T2DM.144
Beige adipocytes share characteristics and thermogenic capacity similar to brown
adipocytes; however, there are several distinguishing features that make them separate cell
types. The first of these distinctions being that beige adipocytes are shown to originate from
Myf5-negative MSCs similar to and within WAT, whereas it has been long accepted that brown
adipocytes are from Myf5-positive precursor cells in BAT.145 Interestingly, this has recently been
challenged by a study by using lineage-tracing which demonstrated that Myf5-positive
precursors could give rise to both white and brown fat cells.34, 146, 147 In fact, it is suggested that
the distribution of adipocytes from Myf5-lineage can be modified based on genetic, behavioral,
environmental, dietary, and other factors, and it should not be considered a discerning factor for
BAT.34, 146 Another distinguishing characteristic of BAT is mitochondrial abundance; whereas
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classical brown adipocytes have abundant mitochondria with high constitutive expression of
UCP1 with or without various stimulants, beige adipocytes require 3-AR stimulation in order to
induce and maintain expression of brown-like gene markers.148-150 Beige adipocytes are also
shown to have genetic markers that are distinct from both WAT and BAT.145 Figure 2.4.
demonstrates WAT, BAT, and beige differences visually.
The process of inducing beige adipocyte formation in WAT is known as “browning” and was
first reported in 1984 when a study utilizing CE in mice resulted in the development of brown-fat
characteristics in the parametrial fat pad.154 Since then, a number of compounds that can induce
the browning program have been reported, many of which can also induce brown
adipogenesis.27, 155, 156 These include, but are not limited to, CE, -AR (i.e., NE, ISO) and PPAR
agonists (i.e., TZDs), as well as some dietary bioactive compounds and pharmaceutical
agents.27, 155, 156 Inguinal WAT (or SAT) is especially susceptible to browning, even with mild
stimulation of these compounds.106 As previously discussed, EBF2 is a brown-fat specific
marker and also controls the browning program in WAT.116 BMP7 is another agent that can
induce the thermogenic program in BAT as well as a subpopulation of SVF isolated from WAT
expressing Sca1+, CD45-, and Mac1-.147 Interestingly, there are subpopulations of both white
and beige adipogenic precursor cells within WAT having distinct gene expression patterns.145
However, there is also evidence suggesting that beige adipocytes arise from the browning of
mature white adipocytes.143, 157 For this reason, there is much debate on whether beige
adipocytes arise from de novo synthesis from beige adipogenic precursor cells or
transdifferentiation from mature white adipocytes.
2.2.5.1 De novo synthesis or transdifferentiation?
De novo synthesis or transdifferentiation of beige adipocytes has been a topic of discussion
for decades. However, it seems that groups that support inter-conversion also support and
acknowledge the existence of beige-fat precursor cells with a distinct genetic lineage, whereas,
groups that support de novo differentiation may oppose the concept of transdifferentiation.106
The evidence for both sides is briefly reviewed here.
As previously discussed, there is solid evidence of competent beige adipogenic precursor
cells present in both human and murine WAT. These beige precursor cells express their own
set of beige-fat-specific markers including CITED1, CD137, TMEM26, TBX1, among others.106,
145

Pulse-chase fate-mapping is a popular experiment used to label pre-existing mature

adipocytes to better understand adipocyte dynamics. Utilizing this method of experimentation, a
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study labeled mature adipocytes in WAT of mice with -galactosidase (-gal) and measured gal staining following one to three days of CE or 3-AR agonist treatment.158 The results of this
study revealed that newly formed beige adipocytes were -gal-negative, pointing towards beigeadipocyte de novo synthesis rather than recruitment from mature adipocytes, although the
developmental defects of these triple transgenic mice and consumption of a high-fat diet (HFD)
were possible confounders of the study outcomes. In another study, transgenic mice having
WAT-specific overexpression of cyclooxygenase 2 (COX-2) induced de novo BAT recruitment in
WAT and 3-AR-agonist-stimulated-thermogenesis was diminished in COX-2-deficient mice.159
That said, this study did not differentiate whether the thermogenesis seen was from UCP1positive precursor cells (“de novo" synthesis) or mature adipocytes undergoing browning and
may have been using the term interchangeably.
There is ample evidence for de novo differentiation as the mechanism for beige adipocyte
formation; however, it does not completely rule out the possibility of transdifferentiation.
Evidence suggests the inter-conversion of white-to-beige may be the dominant, but not the only,
mechanism when it comes to browning of WAT.106 A study treating mice with CL-316,243, a 3specific-AR agonist, showed increased thermogenesis and browning, but with little change in
DNA content or adipocyte number, pointing towards transdifferentiation.160 Another study
demonstrated that cold acclimation of wild-type (WT) C57Bl/6J mice led to an increase in
browning and a concomitant decrease in white adipocytes with no significant changes in total
adipocyte number, and no signs of apoptosis or mitosis, again, pointing towards
transdifferentiation.161 In fact, several studies have shown most beige adipocytes arise from
non-dividing cells, suggesting mature adipocytes may be the most feasible source.161-163 Using
lineage tracing, it was reported that CE led to de novo differentiation of brown adipocytes from
resident PDGFR precursor cells in BAT, whereas essentially all beige adipocytes were derived
from mature adipocytes in WAT.164 Interestingly, it was found that a tissue's microenvironment
may play a critical role in an adipocyte's ability to transdifferentiate. This includes vascular and
neural density, SVF cell types in the area, as well as the extra-cellular matrix (ECM)
composition.143
Arguments for both sides are compelling yet still controversial; however, what is typically
agreed upon is WAT's metabolic plasticity, or the ability to rapidly transform to meet metabolic
needs, which is especially notable in SAT. A lineage-tracing study found that mature adipocytes
in WAT undergoing CE and subsequent rewarming can inter-convert between fully mature white
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and brown adipocyte phenotypes.165 This bi-directional switch demonstrates that regardless of
the mechanism, beige adipocytes formed from CE or other stimulation can undergo warm
adaptation and lose expression of UCP1 but are retained in WAT and can be induced again to
regain the thermogenic profile. This further supports the well-accepted notion that beige
adipocytes are inducible but require constant adrenergic stimulation to support the brown-like
phenotype.
There are also substantial age and species-specific differences in the amount of BAT and
beige adipocytes. Analogous to what was previously assumed, infants and young mammals
have a greater amount of BAT for heat-generation until sufficient insulation is accumulated.166
Furthermore, BAT found in infant humans and rodents is shown to take on a more beigeadipocyte phenotype in the older age.94, 166-168 In fact, this “bona fide” classical BAT has not yet
been found to exist in adult humans, which further demonstrates both the species and age
differences in the context of BAT.169 Additionally, young mammals have a larger pool of stem
cells which can be prompted to de novo differentiate into beige adipocytes or white adipocytes,
depending on the environment raised.106, 145 This may be an important point in the debate of de
novo vs transdifferentiation of beige adipocytes; de novo differentiation may be more relevant to
the young mammals which have greater number of precursor cells, whereas transdifferentiation
may be critical to older mammals and in obesity, where there is already a substantial number of
mature adipocytes.
2.2.5.2 Regulation of beige adipocyte formation
Transcription factors and regulatory pathways that control brown adipocyte formation also
play critical roles in beige adipocyte formation, including UCP1, PPAR, PGC1, and PRDM16
which are further reviewed here.
The nuclear receptor PPAR is known as the master regulator of differentiation due to its
critical actions as a transcription factor for white, brown, and beige adipocyte differentiation
(especially during the late-stages), maintenance, and survival.200-202 C/EBP is shown to be
required to maintain PPAR expression, and although PPAR is shown to promote
differentiation in both BAT and WAT, studies have shown there may be depot-specific binding
sites on PPAR.201 PPAR involvement in adipogenesis was further demonstrated using
genome-wide mapping techniques, where it was shown to bind to the promoters of adipogenic
genes in both mice203-205 and humans.206, 207 PPAR-agonists, such as TZDs, have been shown
to have potent browning effects.89 PPAR-agonists/TZDs, such as Rosi, was shown to activate
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the PPAR-receptor while also promoting association with DNA leading to upregulation or
downregulation of target gene transcription.208 This has been shown by several groups using
Rosi and other TZDs analogs which revealed suppressed expression of 3-AR,209 resistin,210
leptin,211, 212 as well as PPAR itself, without affecting adipogenesis.208, 213, 214
PPAR has six functional domains, termed “A to F”; N-terminal A/B domain is responsible
for transcriptional activation and is called the “activation-function 1” (AF1) domain, the C domain
is known as the DNA-binding domain (DBD), followed by the hinge D domain, and the Cterminal E/F domain is the ligand-binding domain (LBD).215 The E/F domain also contains the
ligand-binding pocket (LBP), an AF-2 domain, and also contains regions important for
dimerization.215 For PPARs to bind to DNA, they must first form a heterodimeric complex with
retinoid X receptor alpha (RXR) primarily located in PPAR response element (PPRE)
regions.215 Regulation of PPARs occurs through ligand binding and post-translational
modifications (PTMs).215 Binding of LBD causes conformational changes which can affect
downstream interactions with co-repressors and coactivators.215 Without a ligand-bound, PPAR
is bound to co-repressors (i.e., nuclear receptor corepressor (N-CoR) and silencing mediator of
retinoid and thyroid receptor (SMRT)) which acts to silence the transcription of target genes.195
Whereas ligand binding leads to conformational change and recruitment of coactivators (i.e.,
steroid receptor coactivator (SRC) family and PGC1).195 Histone-modifying enzymes (i.e.,
histone acetyltransferases (HATs) and histone deacetylases (HDACs)) form multiprotein
complexes with PPAR and its coactivators and corepressors, respectively, which modify
chromatin structure, thereby regulating transcription.195, 216 Both the type and location of PTMs
can affect PPAR activity. In general, phosphorylation and acetylation of PPAR has
metabolically detrimental downstream effects, seeing as studies showing dephosphorylation
and deacetylation is associated with recruitment of browning co-factors and coactivators,
promoting insulin sensitivity, as well as increased oxidative capacity, EE, and BAT-associated
genes in WAT.173, 217-220
Specifically, and of interest to this review, TZDs and NAD-dependent deacetylase sirtuin-1
(SIRT1) have elicited beneficial effects via PTMs of PPAR. Rosi was shown to inhibit cyclindependent kinase (CDK)-5-dependent phosphorylation of serine 273 in PPAR which promoted
insulin sensitivity in adipocytes.218 Rosi dose-dependently deacetylated PPAR and increased
the interaction of SIRT1 and PPAR which further led to decreased PPAR acetylation.173 TZDs
and SIRT1 mediated deacetylation of lysine 293 and 268 were required to recruit PRDM16 to
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PPAR, which induced induction of BAT genes.173 In fact, one study revealed that treating
adipocytes with TZDs led to the accumulation of PRDM16 protein via stabilization and
prolonging the half-life, which allowed induction of browning and brown-fat development.171 It
seems likely that the alterations in PTMs led to increased activity of PPAR and reduced
receptor turnover, resulting in PRDM16-stabilization and subsequent browning.
PRDM16 is an essential determining factor for inducing the brown fat program174 and has
also been shown to induce browning in WAT.221 In fact, PRDM16 deficient WAT has reduced
thermogenic gene expression and diminished beige adipocyte formation in response to 3-AR
and PPAR agonists, whereas overexpression leads to beige adipocyte formation.221 Increased
stabilization by deacetylated PPAR allows PRDM16 to partner with PGC1 to coactivate the
PPAR-RXR heterodimerized complex bound to the PPRE which induces mitochondrial
biogenesis and the expression of thermogenic genes, such as UCP1.174
PGC1 is known as a master regulator of mitochondrial biogenesis and coactivation of
PPAR and PPAR, which are bound to the UCP1 promoter region, and therefore, induces
thermogenesis, oxidative metabolism, and energy-expenditure related genes.126, 222-224 Although
PPAR activation can induce the browning program, many of the factors that induce browning
actually modulate PGC1 activity.225 PGC1 is recognized as the central regulator of 3-ARmediated thermogenesis via activation of the P38-MAPK signaling pathway.126 In addition to
PPAR, PGC1 also coactivates interferon regulatory factor 4 (IRF4), which leads to enhanced
thermogenic gene expression, cold tolerance, and EE.226 PGC1 plays major roles in wholebody energy-expenditure by helping to regulate glucose and lipid metabolism in both skeletal
muscle,227 and adipose tissue.172, 228 Interestingly, adipocyte-specific loss of PGC1 reduces the
browning capacity of WAT and leads to insulin resistance.228 Whereas adenovirally-induced
PGC1 expression in primary human white adipocytes led to enhanced thermogenesis as
evidenced by increased UCP1 and ETC-component expression as well as enhanced FAO.172 In
adipocytes, PGC1 regulates the expression of respiratory chain components such as
cytochrome complex (CYTC)172 and mitochondrial structural components such as mitofusin 2
(MFN2).172, 229, 230 PGC1-mediated mitochondrial biogenesis was also shown to be potently
activated by direct interaction with NRF1, further mediating the thermogenic program in BAT
and beige adipocytes.113, 172, 230

23

2.2.6 Nutritional, pharmacological, and nutraceutical interventions for browning and
brown adipogenesis in humans
Due to its targeting of the pertinent tissue and strong evidential support, browning of WAT
and activation of BAT is a promising strategy to prevent and treat obesity in humans. The sheer
volume and sensitivity to browning agents make SAT a desirable target for many nutrient and
pharmaceutical-based drugs.231 However, many of the studies mentioned so far were primarily
performed in rodents and/or in vitro using cell culture, which may have limitations in
translatability or efficacy in humans. Large variations in metabolism, environment, and genetics
as well as determining human-relevant doses make clinical applications of experimental findings
difficult.232 Contrary to popular belief, the current standard scale used for rodent-to-human
conversion, body surface area (BSA), is actually not recommended by the Federal Drug
Administration (FDA) to determine therapeutic dosage range.232 Using pharmacologically active
doses (PADs) as well as other scientifically validated approaches which use physiologic and
pharmacokinetic data to more accurately estimate human-equivalent doses (HED) is now
recommended instead of BSA.232 With that said, there are many single-target drugs and multitarget functional foods that have been used as anti-obesity therapies in human clinical trials.
Unfortunately, aside from issues of maintaining compliance, many currently used
pharmaceutical interventions have several undesirable off-target effects, including hypertension,
sleep disorders, depression, and even heart disease, while other phytotherapeutic agents may
not show immediate efficacy.233 Nevertheless, human trials utilizing bioactive food ingredients
have shown increases in daily EE as much as 2-5%.234 Furthermore, promising future
compounds are awaiting clinical trial testing which could, alone or synergistically with other
compounds, have a thermogenic effect upwards of 10-15% increased EE.235-237 An increase in
the total daily EE of 10-15% would be sufficient to facilitate weight loss, especially in the context
of obesity.6 There are many studies that demonstrate dietary, nutritional, polyphenolic, and/or
bioactive compounds to have an impressive capacity to induce browning, resveratrol is one of
particular interest and will be discussed further in 2.3.
2.3

RESVERATROL AS A NUTRITIONAL INTERVENTION TO COMBAT OBESITY

2.3.1

Resveratrol overview

Resveratrol (trans-3,4’,5-trihydroxystilbene, Res) is a well-studied naturally occurring
polyphenolic compound, which is typically found in the skins and seeds of a number of dietary
sources including grapes, berries, peanuts, and wine, as well as the inedible portions of
Japanese giant knotweed.238-240 Chocolate and cocoa-containing products are lesser-known
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sources of Res, but are actually one of the most concentrated, second only to red wine and
grape juices, and end up comprising the most total Res in the diet due to the sheer quantity of
consumption.241 Polyphenols are organic chemicals containing multiple phenol structural units
which can be further broadly categorized into flavonoids, such as anthocyanins and tannins, and
non-flavonoids, such as stilbenes.242 Res is categorized as the latter. 242 Interestingly, Res and
other flavonoids are also known as “phytoalexins” which are compounds formed as an innate
immune defense mechanism by the plant in response to microbial infections as well as UV
radiation, giving Res its antibiotic and antioxidant properties.243
Wine is a popular dietary source of Res; the bitter compounds present in grape-skins give
what is referred to as “structure” to the flavor and mouth-feel of wine.244, 245 Because of this,
grape-growers encourage the formation of these by intentionally stressing the vines.246 Red
wine, in particular, is a concentrated source of Res, due to maceration, fermentation, and
incorporation of the whole-grape.247 On the other hand, white wines do not incorporate the skins
and grapes used for juices are cultured so that the skins are sweet, therefore having less Res
content.247 For example, concentrations of free-Res and piceid (the 3-beta-glucoside metabolite
of Res) found in Concord grape or cranberry juices were found to be within the 1.5 – 1000 nM/g
range, whereas Italian red wine was found to be within the 8 – 24 M.247 Interestingly, the
alcohol that develops during the fermentation of wine acts as a solvent which promotes the
extraction and chemical stability of Res, while aging wine in oak and acacia wooden barrels may
lead to additional phenols present.248, 249 Observational studies have shown a J-shaped curve
associated with the relative risk of disease incidence and wine consumption; with moderate
consumption being at lower risk than both non-consumption and high-consumption.250-253 One of
the first of these correlations was seen in an epidemiologic observational study of a population
in southern France.254 The results of this study revealed a very low incidence of CVD despite
having high-CVD-risk lifestyle behaviors (i.e., high intake of saturated fat, smoking, and alcohol
intake).255 The now well-accepted conundrum was called "The French Paradox" coined by the
television show, 60 Minutes in 1991, which was later attributed to their low-stress lifestyle and
relatively frequent but moderate consumption of red wine.256-259 A similar scenario is seen in the
Mediterranean population, which in addition to having a diet rich in omega-3 from fish and
nutrient-dense fruits and vegetables, wine is also a central component of.250, 260 The lowincidence of CVD and general health of the population made following the "Mediterranean Diet"
a popular disease-fighting and health-promoting trend in the mid-to-early 1990s and is still
followed today.260-262
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2.3.2

Resveratrol structure and function

There are two structural conformations known of Res, cis- and trans- form.263 Trans-Res is
the biologically active form, but can easily be converted to cis- when exposed to UV light,
making storage conditions important.263 Due to its abundance and biological relevance, transRes will be used in this review and will be simply referred to as Res.
The beneficial correlational observations, its abundance in nature, and accessibility in the
diet led to increased interest in Res especially in the early 1990s and became a popular target
used for research. Since then, Res has emerged as a robust therapeutic compound conferring
beneficial effects and protection against a wide-spread set of conditions and diseases ranging
from anti-aging,264, 265 neuroprotective,266-269 cardioprotective,270, 271 anti-tumorigenic,272-274 and
anti-obesogenic.275
2.3.3

The many beneficial effects of resveratrol

The structure of Res lends itself to the many beneficial aspects; the most dominant of which
is most likely Res’ potent anti-inflammatory actions. As previously mentioned, Res has many
subcategories and alias’, one of these being a phytoalexin, which due to it being a compound
made by the plant-immune-defense mechanism, by nature, has anti-inflammatory, antimicrobial,
and antioxidant properties.243, 276 Res is also a non-flavonoid stilbene; the tetrameric stilbene
oligomers are known inhibitors of matrix metalloproteinases (MMPs), which are responsible for
the breakdown of collagen which is highly implicated in aging and cancer.277-279
In fact, Res is shown to work through many pathways to inhibit cancer; inhibition of
cytochrome P450 family 1 member A1 (CYP1A1),280 promoted DNA stability, and antiinflammatory actions suppress tumor initiation, inhibition of COX-2 and induction of apoptosis
helps when tumor is already present but prior to metastasis, and suppression of angiogenesis
and MMPs when tumor becomes invasive.281, 282 There are many other known ways which Res
is shown to be beneficial in cancer, but it is not the focus of this review. In similar pathways, Res
is also shown to be anti-atherogenic; upregulation of nitric oxide (NO) leads to vasodilation and
lowers BP,283 and reduced production of adhesion molecules and endothelial-cell cytokines, 283,
284

COX inhibition, and decreased levels of oxidized low-density lipoproteins (oxLDLs)285 leads

to retarded plaque progression.286 The anti-inflammatory effects of Res in obesity is discussed
in its own section below.
Res wears many hats, one of them includes actions as a phytoestrogen, with its primary
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target and action being an estrogen receptor (ER)-agonist.287 In general, there are mixed
reviews on phytoestrogens, due to their potential beneficial effects on bone health and
chemoprotective capacity, and nearly equivalent adverse effects on certain types of cancer. 288
Although the consensus on phytoestrogen’s effects on health and disease often fluctuates, the
phytoestrogen effect of Res has primarily yielded positive results. An epidemiological
observational study revealed a dose-dependent relationship of bone-density and consumption
of wine,289, 290 which could be attributed to increased BMP expression in bone stimulated by
Res.291, 292 Although ER activation in the context of breast cancer can be deleterious, Res
actually acts as an anti-tumorigenic compound via actions as an ER-antagonist in the breast
tissue, which is attributed to its pleiotropic, dose, timing, and tissue-dependent effects.293-295 It is
through these pathways, among others, that Res is shown to elicit its beneficial effects on
metabolic diseases, which is discussed in greater detail here.
2.3.4

The anti-obesity effects of resveratrol

2.3.4.1 The link between resveratrol and calorie restriction
Due to obesity being a disease of excess energy, an obvious lifestyle intervention for weight
loss is calorie restriction (CR). Reducing intake at any point below EE should lead to weight
loss. The more technical definition for CR used as a nutritional intervention for weight loss is the
reduction of energy intake of 10-40% of ad libitum levels without causing malnutrition to
occur.296 Studies using budding yeast S. cerevisiae,264 worms Caenorhabditis elegans and fruit
flies Drosophila melanogaster,265 rodents, and rhesus monkeys have shown CR to enhance
longevity, improve stress resistance, and delay the onset of aging-related diseases.297, 298
Although CR showed some benefit in human studies, such as lowered risk for CVD, metabolic
diseases, and some cancers, long-term CR in human studies is difficult to achieve and maintain,
primarily due to lack of compliance.299
Although not fully understood, the molecular mechanisms through which CR confers
metabolic benefits are mainly attributed to its relief of oxidative damage to cells and tissues,
which is otherwise hypothesized to be a primary mechanism for the inevitable deterioration of
cells and tissues in aging.300 The relief of oxidative damage has been shown to work in several
tissues in rodents301-303 and overall reduced markers were found in humans in a 20% kcal
deficit.304, 305 One of the first breakthrough discoveries of the molecular targets of aging and CR
was made in 1999 when the silent information regulator 2 (Sir2) gene in yeast, was found to be
a pivotal regulator in the aging process.264, 306, 307 Later, the mammalian ortholog of Sir2, NAD-
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dependent deacetylase SIRT1, was found to elicit the same aging-related effects.264 Although
somewhat controversial, SIRT1 is suggested to be a critical mediator in the CR-induced
signaling pathways.264, 307, 308-310 The activation of SIRT1 by CR was shown to help regulate EE
by modulating glucose and fat utilization tissues with metabolic functions.311 Using fluorescentlabeled substrates in an in vitro screening, several small molecules were identified as activators
of SIRT1, Res being the most potent.264 After this discovery, all of the beneficial effects seen in
previous CR studies were then shown to be induced by Res treatment as well. Res treatment in
lower-level organisms (i.e., yeast, worms, flies) was shown to extend lifespan,264, 265 and Res
treatment in rodents proved beneficial effects on both lifespan and metabolic health.275, 299 Mice
fed a HFD and then supplemented with Res were protected against DIO and also showed
improved blood-lipid profile as well as enhanced glycemic control.275 The results of these
studies left the door wide open for utilizing Res as a therapeutic agent for a wide variety of
metabolic diseases, as well as mechanism of action exploration.
2.3.4.2 The molecular targets and effects of resveratrol in obesity
Due to the many beneficial effects of Res, great efforts have been made to identify the
molecular targets of Res within biological systems.312 Whether a molecule simply binds to the
cell surface, is taken up via endocytosis, or some other receptor-mediated pathway critically
alters its downstream effects and molecular targets.312, 313 Res has been shown to interact with
both intracellular (IC) and extracellular molecules, therefore, most likely in a dose- and tissuedependent manner, Res could trigger signaling pathways by binding to cell-surface receptors,
activating IC factors, or even mediating effects directly in/on the nucleus.312, 313 In the context of
obesity and adipose tissue, Res has been shown to have multiple downstream molecular
targets and effects. Many studies have implicated Res to work via regulating pathways involved
in adipogenesis and apoptosis,314 lipogenesis and lipolysis,315-317 as well as EE, plasma
substrate utilization, and FAO.318, 319 Recent evidence suggests Res can promote browning and
brown adipogenesis leading to enhanced insulin sensitivity and weight loss.320 Res has been
shown to work through many of the same pathways implicated in the BAT activation and beige
adipocyte formation, leading to upregulated UCP1 expression via signaling pathways including
SIRT1, PPAR, PGC1, and 5’AMP-activated protein kinase (AMPK).321 The pathways Res is
implicated in WAT, BAT, and beige adipocytes, specifically, are further discussed below.
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2.3.4.2.1

Resveratrol and WAT

Many studies demonstrate Res to be beneficial in the context of obesity by inhibiting
differentiation and promoting apoptosis in adipocytes via downregulation of critical adipogenesis
regulatory factors such as PPAR, C/EBP, and C/EBP.39 Res was shown to inhibit 3T3-L1
preadipocyte proliferation and initiation of differentiation through cell-cycle arrest during the Sphase, preventing DNA synthesis.314 Similarly, another study demonstrated that treating 3T3-L1
preadipocytes within the first 24 h of adipogenesis led to proliferation arrest and impaired MCE
by suppressing entry of the G2/M phase of the cell cycle and suppression of expression of
cyclin-A and CDK-2, which are critical cell-cycle regulators.322 Through activation of the major
cellular-energy sensing network, AMPK, Res can sufficiently shut down differentiation via
activation of cell-signaling cascades which shifts to energy-saving metabolic processes.323, 324 A
study utilizing potent Res analogs (RSVA) also demonstrated inhibition in 3T3-L1 preadipocyte
differentiation via interfering with MCE.325 RSVA successfully attenuated adipogenesis-related
transcription factors such as PPAR and C/EBP as well as adipocyte-specific genes such as
FASN, fatty acid-binding protein (FABP4), RANTES, and resistin.325 A study utilizing porcine
preadipocytes showed Res may mediate suppression of proliferation and differentiation via
SIRT1-mediated suppression of FOXO, PPAR2, and other adipocyte-specific genes.326
Studies have also shown Res to have “beneficial” effects on obesity by inducing apoptosis in
adipocytes as mediated by caspases and other cell-death inducible factors.327 Whereas
intermediate-level concentrations (i.e., 20-50 M) are sufficient to inhibit adipogenesis, higher
concentrations (i.e., 40-200 M) are required to induce apoptosis in adipocytes.328 A study
utilizing 3T3-L1 preadipocytes demonstrated that 40-80 M of Res led to the induction of
apoptosis via a SIRT1-dependent mechanism.314 SIRT1 upregulated AMPK which
downregulated cell-survival protein expression, AKT and Survivin, and induced cell-death
mediators, caspase-3 and caspase-9.314 Primary porcine preadipocytes treated with 200 M of
Res led to preadipocyte apoptosis as shown by cell viability assays, which were accompanied
by increased apoptotic gene expression including caspase-3, and b-cell lymphoma (BCL)
associated x (BAX), as well as downregulation of anti-apoptotic genes such as BCL-2, P53, and
NF-B.329
Res is also shown to elicit beneficial metabolic effects by promoting insulin sensitivity and
plasma substrate utilization in WAT via a variety of mechanisms. As previously mentioned, Res
has potent phytoestrogenic properties. It is through this capacity, Res activates ER which then
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works through a PI3K-AKT signaling pathway to induce GLUT4 expression, translocation, and
activity.330 Res is also shown to work through AMPK to enhance translocation of GLUT4, which
would then lead to increased IC uptake and clearance of blood-glucose.331-333 Res activation of
the SIRT1-AMPK axis led to increased protein expression of SIRT1, increased phosphorylation
and activation of AMPK causing phosphorylation of AKT (p-AKT).332 Downstream
consequences of elevated p-AKT led to translocation and degradation of transcription factor,
FOXO1, causing reduced expression of adipokine, resistin, and enhanced insulin sensitivity.332
Res can also help to regulate blood sugar by inducing glycogen synthase expression and
activity with simultaneous suppression of glycogen phosphorylase.334 This results in an
accumulation of glycogen in the liver, promoting clearance of plasma glucose.334
Working as a PDE-inhibitor, Res increases cAMP levels, which induces lipolytic and inhibits
anti-lipolytic processes, further reducing lipid accretion.335, 336 Res also works directly on
inhibiting lipogenesis; thereby indirectly (through SIRT1) inhibiting adipogenesis.328, 337, 338
PGC1 is induced via SIRT1 activation by Res, leading to increased mitochondrial biogenesis
and oxidative phosphorylation.275, 339, 340 Res was also shown to activate lipolysis via SIRT1mediated suppression of PPAR.341 Res was shown to significantly induce AMPK activity in both
HFD-induced obese rats342-344 and obese Zucker rats,345 further demonstrating beneficial
metabolic outcomes.
Res has also been shown to work through regulating critical enzymes in lipogenesis and
lipolysis pathways. Through AMPK activation, Res successfully reduces acetyl-CoA carboxylase
(ACC) activity via inhibitory phosphorylation by AMPK, increasing FAO and inhibiting FA
synthesis.346 It has also been shown that Res downregulates expression of critical lipogenesis
enzymes ACC and FASN, as well as decreased lipoprotein lipase (LPL) expression in Sprague
Dawley rats fed a HFD supplemented with Res.347 Several studies have also shown the ability of
Res to increase lipolytic enzymes expression, including ATGL and HSL in murine, porcine, and
human cultured adipocytes.317, 348 A study utilizing 3T3-L1 cells as well as mouse embryonic
fibroblasts (MEF) cells with increasing doses of Res (5, 10, 20 M) throughout differentiation
also observed lowered TG accumulation and reduced lipogenesis-associated-genes in both cell
types.349 More specifically, 20 M of Res led to enhanced flux through the FAO pathway by
increasing mRNA expression of carnitine palmitoyltransferase 1 (CPT1), the rate-limiting
enzyme in mitochondrial FAO, and reducing mRNA expression of receptor-interacting protein
140, which is an inhibitor of oxidative metabolism.349
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It was also demonstrated that Res elicits beneficial effects on fat mass, inflammation, and
adipogenesis in vivo.350 This study utilized C57Bl/6J mice fed a HFD supplemented with 0.4%
Res and showed significantly reduced body and VAT weight gain and also showed decreased
inflammatory markers associated with VAT, such as TNF and MCP1.350 In this study, Res
supplemented mice had lower levels of blood glucose, TG, FFA, and cholesterol, as well as
suppressed markers of adipogenesis, including PPAR2, C/EBP, SREBP-1c, FASN, LPL,
FABP4, and leptin.350 Another study also demonstrated that Res treatment led to decreased
inflammation markers in adipocytes; Res dose-dependently decreased MCP1 and IL-6, as well
as a dose-dependent increase in adiponectin when TNF-challenged (10 ng/mL) 3T3-L1
adipocytes were treated with 10, 25, and 50 M of Res.351 Res was shown to dose-dependently
inhibit adipogenesis by suppressing C/EBP and PPAR expression as well as elicit antiinflammatory benefits by reducing MMP-2 and MMP-9 activity in 3T3-L1 preadipocytes.277 Res
has also been shown to work to reduce weight gain and appetite control in non-human primates
(NHP).352
All of the studies mentioned in this section demonstrate Res’ protective metabolic effects in
WAT by decreasing inflammation, preventing lipid accumulation, and enhancing lipid clearance.
The lipid and glucose clearing mechanisms and pathways are summarized in Figure 2.5.
2.3.4.2.2

Resveratrol and BAT

Not only has Res shown to elicit beneficial effects on metabolic parameters by reducing
WAT mass and inflammation and improving insulin sensitivity, but it is also shown to enhance
the thermogenic program in BAT. Although primarily focused on the anti-aging capacity of Res,
Lagouge et al reported that supplementing 4 g/kg of Res for 15 weeks in C57Bl/6J mice fed a
HFD led to weight loss, increased aerobic capacity, and increased tolerance to CE when mice
were housed in 4C for 6 h.275 This was coupled with the observation of induced oxidative
phosphorylation and mitochondrial biogenesis genes, including CYTC, SIRT1, and PGC1, and
also demonstrated protection from DIO and insulin resistance. Later, another study using rats
fed a HFD supplemented with Res for 6 weeks demonstrated increased whole-body EE and
increased gene expression of brown-fat enriched markers including UCP3, SIRT1, COX-2,
PPAR/, PGC1, and mitochondrial-transcription-factor-A (TFAM) as compared to rats fed the
HFD alone.359 Rats fed a standard chow diet supplemented with Res for two months
demonstrated improved blood glucose and lipid profiles, increased oxygen consumption rate,
enhanced EE, and increased expression of BAT-enriched markers including UCP1, SIRT1,
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PTEN, and BMP7.360 As previously discussed, BMP7 is a critical mediator of the brown-fat
program and induces the early regulators of BAT including PRDM16,174 PGC1,224 as well as
increased PPAR and P38-MAPK and PGC1-dependent mitochondrial biogenesis and
activation of UCP1.114, 360 BMP7 is also shown to be responsible for triggering the brown-fat
lineage in MSCs.114 Therefore, the ability for Res to further increase BMP7 demonstrates its
ability to promote BAT activity and explains its ability to enhance EE and thermogenesis.
Many of the same pathways by which Res leads to beneficial effects and reduce WAT are
also shown to induce BAT. Although it has been questioned whether Res and other small
molecules work as direct SIRT1 activators, it has been shown time and time again that Res at
least works through this pathway to elicit its effects on BAT.361, 362 Res either works to directly or
indirectly activate SIRT1 activity, which functions to de-acylate many downstream targets
including PGC1 and PPAR, leading to enhanced BAT thermogenesis.340, 363, 364 Evidence from
a study utilizing mice with whole-body deletion of SIRT1 led to a complete reversal of the
thermogenic effect of Res, which further serves to substantiate that Res mediates its beneficial
effects by working through SIRT1.365 Interestingly, many studies suggest Res acts as a potent
PDE-inhibitor which increases IC-cAMP levels, activating energy-sensing networks in the
cell.335, 336, 366, 367 Elevated cAMP activates the cAMP-effector protein, EPAC1, leading to
increased IC levels of Ca2+.367 Increased IC levels of Ca2+ causes phospholipase C and
ryanodine receptor Ca2+-release-channel to activate CamKK and AMPK signaling pathway.367
The primary effect of this signaling cascade is to increase NAD+ causing activation of SIRT1
and its downstream activities. Several studies suggested PDE4 to be a potential specific target
of Res, as the administration of PDE4-specific pharmacological inhibitors caused the same
downstream effects of Res.365-367 Another study used both in vitro and in vivo approaches;
utilizing CD1 mice on a 45% HFD supplemented with 0.1% Res for 4 weeks as well as SVF
isolated from the iBAT of CD1 mice.368 The results from the in vivo study demonstrated that the
BAT from Res-treated mice had enhanced brown-fat markers, including PRDM16, UCP1, and
CYTC as well as greater oxygen consumption and Res-treated brown adipocytes had smaller
multilocular LD compared to the controls. The results from the in vitro study demonstrated that
10 M of Res was sufficient to enhance oxygen consumption and increase expression of
PGC1 and pyruvate dehydrogenase (PDH) in addition to increased UCP1, PRDM16, and
CYTC. The beneficial effects of Res seen in the in vivo and in vitro studies were attributed to
AMPK1, as evidenced by inhibitor and knock out studies reducing Res' beneficial effects. In
conclusion, many studies confirm the ability of Res to enhance BAT activity.
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2.3.4.2.3

Resveratrol and beige adipocytes

In addition to the effects on WAT and BAT, Res has been reported to be beneficial in
promoting the formation of beige adipocytes within WAT, which were thought to contribute to the
effects of Res on weight and body fat loss, and increased thermogenesis.
A study reported that 25 M Res in maturing 3T3-L1 cells decreased lipid accumulation by
43% and decreased cell viability by 25%, which were accompanied by decreased mRNA levels
of PPAR, C/EBP, SREBP1c, FASN, HSL, LPL, and upregulated the mRNA expression of
genes regulating mitochondrial activity, such as SIRT3, UCP1, and MFN2.357 The author’s
conclusion from the results of this study suggested a browning effect of Res; however, it is
important to pair the observations with mitochondrial functionality and cellular bioenergetic
assays to ensure cell health in addition to confirming thermogenic induction. Another study
examining MEF cells with increasing doses of Res (5, 10, 20 M) during differentiation observed
increased mitochondrial DNA (mtDNA), increased CYTC and UCP1 expression, as well as
reduced expression of resistin and RBP4 compared to controls.349 The results of this MEF study
suggest that Res enhances oxidative capacity and insulin sensitivity. Res has been shown to
induce the development of beige adipocyte formation in vitro371 and in vivo372 mostly
demonstrating Res beneficial effects are mediated through the AMPK-SIRT1-PGC1 axis and
PPAR activation.
One of the first studies completed in vivo showing Res to promote beige adipocyte formation
was shown by the Du group.372 CD1 female mice fed a 45% HFD supplemented with 0.1% Res
for 4 weeks had increased beige adipocyte number within inguinal WAT (iWAT), which was
accompanied by significant weight loss. The adipocytes formed within this "beiged" iWAT were
smaller and had multilocular LDs with many mitochondria expressing UCP1 and showed
evidence for enhanced FAO, demonstrating Res' capacity to induce brown-like fat cell formation
within WAT. Furthermore, they also isolated SVF from the iWAT and demonstrated enhanced
oxygen consumption, increased phosphorylation of AMPK1, and increased brown markers
such as UCP1, PRDM16, CIDEA, EVOLVE3, PGC1, and PDH, when these SVF cells were
treated with 10 M Res. To further explore and confirm the mechanism by which Res was able
to promote browning, they used AMPK inhibitor, compound C, as well as AMPK1 knock out,
both of which were sufficiently abolished Res' browning ability. Consistently, the enhanced
metabolic rate and decrease in fat mass seen in WT C57BL/6J mice fed a HFD supplemented
with Res (400 mg/k/d) for 12 weeks were abolished in AMPK1-/- mice, but not in AMPK2-/-
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mice.373 Both of these studies demonstrate the importance of AMPK1 in mediating Res
browning effects.
Not all studies were able to show that Res caused browning of WAT. A study using rats fed
an obesogenic diet with high-sucrose (20%) and fat (24%) supplemented with Res (15 mg/kg/d)
was able to show increased CIDEA and UCP1 expression in BAT but failed to see beige
adipocyte formation in WAT or overall weight loss.374 Interestingly, when 30 mg/kg/d of another
well-known polyphenolic compound, Quercetin, was added to the same diet, it showed a
synergistic effect with Res in promoting the formation of adipocytes with multilocular LD and
UCP1 expression within WAT. Compared to similar in vivo experiments supplementing HFD or
chow diets with Res, 15 mg/kg/d seems to be a somewhat low dose. This may suggest
moderate doses of Res to be most beneficial to preventing HFD-associated outcomes, rather
than high-sucrose containing diets, further potentiating that the effects of Res could be species,
dose, and diet-specific.
Interestingly, the effects of Res are shown to be transgenerational.375 It has been
established that maternal obesity leads to increased risk of obesity, insulin resistance, and other
detrimental metabolic diseases in human offspring.376 Similarly, maternal HFD impairs BAT
function and leads to obesity in the offspring of mice.377 However, WT C57Bl/6J mothers fed a
HFD supplemented with Res (0.2%) during gestation and lactation led to BAT metabolic
recovery, promotion of beige adipocyte formation within WAT, and protection from obesity in
offspring.377 When the offspring pups from Res-treated mothers were later challenged with a
HFD, they exhibited increased brown-fat markers, such as UCP1, PRDM16, CIDEA, and
PGC1 as well as increased beige-fat specific markers, such as CD137 and TMEM26.
Furthermore, these offspring showed overall increased whole-body EE, lowered adiposity, and
increased insulin sensitivity in adulthood.377
2.3.4.2.4

Resveratrol and human clinical trials

As previously discussed, the presence of both brown fat95, 379 and beige fat145 which have
both been found to be inducible and functional, significantly promote thermogenesis, EE, as well
as other beneficial effects on metabolic health in humans.380 The promising effects seen in vitro
and animal studies have led researchers to try to find ways to promote and induce browning and
brown adipogenesis in humans. There are many different agents which have been shown to
induce browning and brown adipogenesis in humans, many of which have ended up being
unsustainable or have potentially harmful side effects, for example, CE and sympathomimetics,
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respectively.380, 381 Both strategies were shown to promote BAT activity and induce beige-fat
formation in WAT in the neck382 and SAT.383, 384 The effects of Res on inducing BAT activity and
beige adipocyte formation, as well as promoting metabolic health in vitro and in vivo have been
promising; however, the inconsistent results in human clinical trials makes determining if the
results will be translatable for treating human obesity and metabolic conditions questionable.385,
386

The use of Res in human clinical trials is further discussed here.
The following studies showed some beneficial effects of Res treatment on human health, in

the context of metabolic diseases. A two-part randomized double-blind placebo-controlled
clinical trial utilizing 11 obese, but otherwise healthy men were given 150 mg Res daily for 30
days.387 Although no changes in overall body weight or temperature were seen, the Res-group
demonstrated CR mimetic effects with enhanced lipid clearance, better blood-lipid profiles,
reduced blood pressure, lower inflammatory markers, higher muscle-mitochondrial respiration,
as well as activation of AMPK-SIRT1-PGC1 axis in muscle tissue.387 In another publication, the
same group further analyzed additional outcomes in this same cohort of Res-supplemented
men and reported enhanced adipogenesis as well as adipocytes with overall smaller diameter in
WAT.388 Unfortunately, this study did not measure brown or beige-fat specific markers in WAT;
however, the smaller size of the WAT adipocytes points towards a potentially healthier and
more metabolically active tissue.388 When considered in conjunction with the activated muscle
tissue, may explain the beneficial results seen in lipid clearance, blood pressure, and
inflammation.387, 388 Another randomized double-blind placebo-controlled clinical trial using 24
patients with MS supplemented with 500 mg of Res three times daily for 90 days reported a
significant decrease in overall BW, BMI, WC, fat mass, as well as AUC of total circulating insulin
and total insulin secretion.389 This study demonstrated the beneficial effects of higher and
multiple doses of Res on metabolically ill patients. Similarly, another study utilizing older adults
(avg. 723 years) with previously determined impaired glucose tolerance were given 1-2 g Res
daily for 4 weeks reported enhanced insulin sensitivity and increased glucose clearance.390
Furthermore, a randomized double-blind placebo-controlled clinical trial using 10 patients with
T2DM given 3 g of Res daily for 12 weeks reported increased SIRT1 and pAMPK/AMPK ratio
expression in muscle as well as increased EE.391 Although the study did not take AT biopsy
samples or measure AT gene expression profiles, the author’s conclusion of this study was that
Res may have exercise mimetic beneficial effects in patients with insulin resistance.
Unfortunately, there are almost just as many clinical trials using Res to treat obesity and
other metabolic diseases in humans with either negative or inconsequential results. A very
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thorough randomized double-blind placebo-controlled clinical trial using 24 obese healthy male
patients who were given 500 mg Res daily for 4 weeks showed no significant effects on blood
pressure, insulin sensitivity, resting EE, VAT accumulation, nor inflammatory markers. 392 A
randomized double-blind placebo-controlled clinical trial using non-obese postmenopausal
women without glucose intolerance supplemented with 75 mg of Res daily for 12 weeks showed
no differences in insulin sensitivity and no difference in expression of the "typical" Res molecular
targets (i.e., AMPK, SIRT1, NAMPT, or PGC1) in either AT nor muscle.393 Finally, a
randomized clinical trial using overweight and obese male patients with non-alcoholic fatty liver
disease (NAFLD) were given 3 g of Res daily for 12 weeks.394 This study not only concluded no
beneficial effects of Res but reported increased liver stress in the Res group as shown by
elevated liver enzymes.394 It seems the majority of human clinical trials use Res
supplementation with doses ranges anywhere from 75 mg – 5 g, the majority of which fall in the
500 mg – 1 g range. As discussed later in this review, much of oral-doses of Res is highly
metabolized and excreted by the liver and kidneys, possibly making larger doses more
hepatotoxic or at least increase stress on the liver. This study which utilizes a somewhat large
dose of Res (3 g) in individuals with malfunctioning liver and already experiencing liver stress,
seems like the study was already set up for failure.394
Discrepancies in outcomes can be both confusing and frustrating for researchers and
consumers alike. There may be many reasons the disparities between in vitro, animal studies,
and human clinical trials exist; however, the following is what the literature determines to be
among the most likely reasons:
First, there are large differences in the concentration of Res used among cell culture, animal
studies, and human clinical trials. Not only is the dose itself different, but, as previously
discussed, the formulas used for human dose-equivalency are often outdated or still
controversial.232 Rodent studies are shown to use Res in ranges from 1-400 mg/kg of body
weight per day, the most effective dose showing beneficial effects on metabolic health is in the
higher range (0.4 g/kg*BW/d). Using direct conversion, without considering BSA or PAD, this
would be equivalent to treating a 70 kg adult with 28 g Res per day. Although using BSA-based
formulas are not recommended,232 a BSA-based formula, the Raegan Shaw formula,395
determines the rodent's dose of 400 mg/kg*BW/d would be equivalent to 10.8 mg/kg*BW/d
which turns out to be approximately 756 mg/d for a 70 kg adult.396 This ends up being within an
average range of what many studies use. This considered, in both normal weight and obese
individuals supplemented with up to 5 g/d were shown to be well-tolerated without significant
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negative side effects or toxicity. With that said, well-tolerated and safe are not synonymous and
higher doses do not always equivalate to greater outcomes.397 Its ability to interfere with
medication has also not been established, so very high Res intake should be approached with
caution.397
Second, both the age differences and time duration of studies are verifiably difficult to
compare between rodents and humans, with the lifespan difference of rodents and humans
being the primary obstacle. Although there are many formulas and methods which can
determine equivalence factors for matching rodent and human age,398 many studies do not
always take this into account. One very simple method uses direct conversion of life
expectancy; the lifespan of rodents, lab rats, for example, is approximately 3 years, whereas
worldwide human life expectancy is approximately 80 years, and a simple calculation provides a
conversion factor of approximately 27.6 human days is equivalent to 1 rat day.398 So far, the
human clinical trials using Res have shown to range from 4 to 12 weeks, whereas rodent
studies have shown to range from 4 weeks and up to 6 months. This would be equivalent to
approximately 2 – 13 years for humans, meaning the human study lengths would be considered
relatively short. Similarly, many studies and much of the target population for humans would be
adults and older adults (i.e., 40-70 years), whereas many studies utilize mice and rats which are
young,399 further making it difficult to translate in vivo results.
Lastly, the low aqueous solubility and bioavailability of orally-administered Res are likely
among the greatest constraining factors. Res solubility in water is very low at approximately
0.03 mg/mL,400 which would be equivalent to any physiological fluid, whereas in other solvents
such as ethanol it is shown to be very high at 50 mg/mL.401 Although it has been shown that
humans can have at least 70% absorption and uptake of Res in the gut, post-absorption firstpass hepatic metabolism is extensive, leaving little free-Res in the serum, regardless of dose.402
This metabolism and bioavailability are further discussed in 2.3.4.2.5.
2.3.4.2.5

Metabolism, pharmacokinetics, and bioavailability of resveratrol

Bioavailability (BA) is technically defined as the ability, degree, and rate in which the
administered drug is absorbed systemically.403 In the case of Res, the term refers to the ability
for the free form of trans-Res to be absorbed and circulate systemically. What will be discussed
further here, is Res very high absorption rate, but very low BA due to its rapid hepatic and
intestinal metabolism by phase II enzymes into water-soluble conjugates.313, 402, 404, 405 As
discussed later, the majority of these derivatized products are seen in the urine and feces within
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a short time after administration, making the rapid metabolism of Res a critical rate-limiting step
in the BA of Res.406
One of the first evaluations of Res absorption and BA completed in humans was done by
Goldberg et al,407 which evaluated if Res BA was altered by various food matrices in healthy
subjects. The results of this study determined that there was little to no difference in absorption
of different types of Res from liquids (whether Res was natural or added) and that food,
especially foods high in fat, leads to a short delay in absorption, whereas Res from capsules
delays absorption and causes Res to remain in the gastrointestinal (GI) system longer.407
Interestingly, another study showed that Res BA in humans shows greater interindividual
variability, whereas gender and age were not shown to have a direct effect on BA.408
To better understand Res BA, understanding its digestion, absorption, and circulation
patterns are important. There are two proposed mechanisms for absorption in the human GI
which is shown to vary based on concentration. At very high concentrations, Res is primarily
absorbed via simple/passive diffusion across brush-border membrane in the small intestines,409
with the possible formation of a complex with membrane transporters such as integrins.313
However, at lower concentrations, Res uptake occurs via mediated apical transport into the
enterocyte (i.e., ATP-binding cassette transporters).404, 409, 410 When inside enterocytes, Res is
conjugated into metabolites to allow for IC aqueous solubility.404, 409, 410 In the plasma, Res can
be found in 3 forms, including the free form as well as Res-conjugated with sulfate and
glucuronide,313 of these, sulfate conjugates comprise the majority of metabolites found in the
plasma.411 In addition to the sulfate and glucuronide conjugated Res, several other Res
metabolites have been recovered in the urine, including the cis- form of Res and cis-Resmetabolites, with sulfate conjugates comprising the majority of metabolites in urine as well.411, 412
The BA of the cis- form of Res is shown to be lower than the trans- form due to it undergoing
glucuronidation 5-10 times faster.405 It is theorized the majority of the conjugates formed after
being absorbed in GI and into circulation is the glucuronide form;413 however, it has also been
shown the primary metabolite formed within intestinal cells is the sulfate-conjugated Res.404 The
addition and removal of sulfates, glucuronides, and glycosyl groups by phase II enzymes help to
promote the aqueous solubility of Res as well as acting as a marker for removal by the liver and
kidneys.406 However, when glycosyl groups are removed and replaced by hydrogen atoms,414
the resulting aglycone form of Res is shown to be BA and its presence in the serum is highly
accredited to enterohepatic recirculation.415
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Free-Res has been shown to circulate unbound; however, it is primarily found bound to
albumin, so much so it has been hypothesized to be a natural reservoir for Res.313, 416 Res is
also shown to be bound to LDLs, meaning cells expressing receptors for these plasma-proteins
can dissociate Res, while also meaning another vehicle for transport to the liver.416 It has also
been shown that Res binding affinity to LDLs may mediate its beneficial antioxidant effects on
LDLs, endothelial cells, and cells which take up LDLs.417, 418
Many pharmacokinetic studies have been completed in an attempt to determine the optimal
dose and timing based on its metabolism. A dose-escalating study giving 10 healthy volunteers
a single dose of 0.5, 1, 2.5, and 5 g of oral Res tested both urine and plasma free-Res and
metabolite levels.419 The results of this study showed that 77% of both free- and metabolite
forms of Res were detected in urine at 4 h after the lowest dose administered, and that the peak
levels of free-Res at the highest dose were 539  384 ng/mL which is approximately 2.4 M/L
after 1.5 h.419 When metabolites were included in this peak plasma levels, it was much higher
(3-8 fold higher). Another study using up to 150 mg 6 times a day only reported a peak plasma
level (Cmax) 63.8 ng/mL with a half-life of approximately 1-3 h for a single dose and 2-5 h with
repeat dosing.420 Using a more “dietary relevant dose” of 25 mg oral and intravenous (IV)
administration of 14C-labeled-Res showed peak plasma of Res and metabolites to be 491  90
ng/mL (~2 M) with a half-life of approximately 9.2  0.6 h.402 One of the highest BA forms of
Res used in many of these kinetic studies was seen when using 5 g of orally administered
micronized Res in 40 healthy volunteers.421 The results of this study revealed a plasma Cmax of
free-Res alone to be 967 ng/mL (~ 4.2 M), whereas, with free-Res and metabolites, the plasma
Cmax was up to 18 M.
Interestingly, there have been some studies to reveal there were some gender and species
differences with Res-metabolite formation and excretion. A dose-escalation study in rats given
high-doses of Res (300, 1000, and 3000 mg/kg*BW) revealed male rats had a peak plasma of
576, 991, and 2728 ng/mL respectively, whereas female rats had peak plasma of 333, 704, and
1137 ng/mL respectively (1.1 g/mL  5 M).422 Results of one study revealed the free-Res and
metabolites in the urine of rodents was only 1.5% of what was initially administered intragastrically,423 whereas the free-Res metabolites found in human urine was at least 24.6% of
what was originally administered orally.424 There were five different types of Res-metabolites
recovered in human urine: Res-mono-sulfate, mono-sulfate dihydro-Res, mono-glucuronide
dihydro-Res, as well as two isomeric forms of Res mono-glucuronide.425 Interestingly, some
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studies have shown the synergistic relationship of Res in combination with other polyphenols,
such as enhanced browning with the addition of quercetin374 and increased free-Res plasmaconcentration with the addition of piperine.426 In the latter mentioned study, it was demonstrated
that the addition of orally administered piperine (10 mg/kg) with Res (100 mg/kg) in C57Bl/6J
mice led to more than 200% increased exposure to Res and over 1500% greater concentrations
of free-Res in plasma when compared to Res administered alone.426 The results here and in
other synergistic-relationship studies may at least partially be due to what one study reveals as
reduced sulfation and glucuronidation of Res when administered in combination with other
polyphenols, improving its BA and possibly its effectiveness.425
A comprehensive review of over 25 different pharmacokinetic studies revealed doses given
to healthy subjects ranged from as little as 1 mg and up to 5 g Res per day which was given
either as single doses or over a period of a month.263 Given the results of these studies, it
seems like the highest concentration seen in human plasma (without including metabolites),
was approximately 4.2 M after a mega-dose of 5 g of micronized Res; however, most studies
showed within the nanomolar range to around 2 M. This considered, the doses given in vitro or
in animal studies are typically much higher.299 Even though there are such great discrepancies
and variances in dose between cell/animal studies and human clinical trials, there are still many
health benefits associated with Res use in humans.299, 427 Although there is limited evidence to
prove Res promotes BAT activation and beige adipocyte formation in humans, there is still a
large body of evidence to support the beneficial effects of Res on other diseases and health
parameters.299, 427 This effect has now been coined as the "Resveratrol Paradox", which
describes Res high activity and beneficial effects despite this rapid metabolism and low BA.397,
428

This has led some researchers to determine whether Res-metabolites themselves may have

some beneficial function.
2.3.4.2.6

Can resveratrol metabolites have a beneficial effect?

Identifying different types of metabolites and using Res-metabolites as treatments in studies
have been shown in both animals (pigs)428 as well as humans.429, 430 However, the use of
metabolites in research is limited due to the lack of suitable standards.431, 432 With that said,
some studies are showing beneficial effects of Res-metabolites including a study by Lasa et al
which showed that Res and Res-metabolites produced an anti-adipogenic effect in 3T3-L1 cells
at 25 M.433 This study showed that while Res, trans-Res-4’-O-glucuronide, and trans-Res-3-Osulfate reduced C/EBP mRNA expression in mature 3T3-L1 adipocytes, only trans-Res-3-O-
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sulfate alone also reduced C/EBP, PPAR, and LPL expression.433 Res was able to induce
SIRT1, ATGL, and PGC1 expression in mature 3T3-L1 adipocytes, whereas trans-Res-3-Oglucuronide reduced FASN and increased SIRT1 expression, and trans-Res-4’-O-glucuronide
increased HSL and SIRT1 expression as well.433 More recently, this same group attempted to
identify potential microRNAs (miRNAs) which were responsible for mediating Res and Resmetabolites’ anti-adipogenic effect.434 This study used 25 M of free-form of Res as well as 3
Res-metabolites: trans-res-3-O-sulfate (3S), trans-Res-3’-O-glucuronide (3G), and trans-Res-4’O-glucuronide (4G) to treat differentiating 3T3-L1 preadipocytes.434 The results of their study
revealed that free-Res and the glucuronide metabolites upregulated miR-155, which then led to
downregulation of C/EBP and its downstream adipogenesis targets.434 Interestingly, sulfatemetabolites did not mediate their anti-adipogenic effect through any of the 23 miRNAs tested (all
of which were previously shown to have predicted or validated downstream adipogenesis
targets), but did so through other pathways.434 Therefore, it seems that both Res and its
metabolites are responsible for some of the anti-adipogenic and anti-obesity effects previously
discussed.
Other studies utilizing Res metabolites were primarily focused on cancer, especially colon
cancer. A study done by Aires et al demonstrated that sulfate and glucuronide conjugates are
likely to play a role in the Res-mediated anti-carcinogenic effect on human metastatic colon
cancer cells.435 Similarly, another study using Res and Res-metabolites showed beneficial
effects on colon cancer patients.436 These effects are suggested to work via a synergistic
interplay between Res and its metabolites to have overall greater effects than Res itself.432 It is
suggested the extensive metabolism and subsequent accumulation of Res and Res-metabolites
in human intestinal epithelial cell line, Caco-2, was a primary mechanism for its chemoprotective
effect in these cells.404 Another Res derivative has recently been described, called 3,5,4’trimethoxystilbene (BTM-0512), was shown to have greater stability and oral bioavailability than
free-Res which may have led to the enhanced browning and weight loss observed.378, 437
Pharmacometabonomic studies have shown significant interactions of the gut microbiome
and drug metabolism in humans.438 Specifically, the beneficial effects of microbiome metabolic
byproducts of Res have been investigated and some of these studies have demonstrated these
to have beneficial effects on health in vitro, in animal studies, and in humans.439-442 The gutmicrobiota derived dihydro-Res (DH-RES) along with similar analogs have been studied in
humans.443 One study demonstrated that using as little as 100 nM of Res or DH-RES, but not
Res-metabolites, led to decreased FABP4 expression in macrophages in response to oxLDL
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exposure.444 Interestingly, this study demonstrated that Res and its metabolites have a
hormetic-like response,444 which is used to describe nutritional, pharmacological, or
environmental agents that have a dose-dependent-biphasic response.445 This hormetic
response of Res demonstrates that a low-dose stimulation may have a beneficial effect,
whereas the high-dose may have an inhibitory or toxic effect.445 This further demonstrates Res’s
pleiotropic downstream effects, which are tissue, dose, and time-dependent.
Overall, it seems the results observed using Res treatment in vitro and in vivo are not
always translatable to human clinical trials, primarily due to its rapid metabolism and therefore
low BA. That said, if low BA of Res is the primary limitation for its use in human clinical trials, it
is imperative to explore other avenues to optimize BA. As previously discussed, there have
been several attempts at improving the BA of Res, including alterations in the food matrix in
which Res is administered,407 utilizing micronized powders,421 as well as combining with other
bioactive compounds and polyphenols in hopes for a synergistic effect.374 Nanoparticles and the
use of nanotechnology is also a promising strategy to improve BA and possibly targeting
capacity in humans.446
2.4

NANOPARTICLES CONTAINING RESVERATROL AS A NUTRACEUTICAL

INTERVENTIONN FOR OBESITY
2.4.1

What is nanotechnology?

Nanotechnology can be described as the study and control of microscopic material (usually
100 nm or smaller).447 The use of nanotechnology as therapeutic agents is a practice known as
‘nanomedicine', and its use in pharmaceutical applications has been exponential and so far,
very successful.448, 449 There have been a countless number of compounds loaded into the
nanoparticles for various disease applications including several types of cancer, diabetes, liver
fibrosis, neurodegenerative and bone diseases, atherosclerosis, obesity, and many more.448, 449
These nano-scale molecules are generated to be biodegradable and biocompatible for
enhanced BA in vitro and in vivo as well as for therapeutic use in humans.447 Nanocarriers can
be generated using several different bio-materials and formulations, giving each of them
advantages for various applications.447 Included in the various forms of nanocarriers are
liposomes, solid lipid nanoparticles, micelles, emulsions, and polymeric nanoparticles which will
briefly be discussed further here.
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2.4.2

Types of nanocarriers

Liposomes, or nanoliposomes (the nanometric size of liposomes),450 are primarily
composed of phospholipids whose hydrophilic heads and hydrophobic tails form a bilayed lipid
membrane.447 The structure of liposomes allows it to carry both hydrophilic and hydrophobic
compounds; hydrophobic compounds can be loaded between the lipid bilayers, whereas
hydrophilic compounds can be loaded within the aqueous central compartment.451 Since its
initial formulation and use in the mid-1960s, liposomes have been used in several arenas such
as the food and cosmetic industry, drug delivery, and diagnostic testing, and has also been FDA
approved to treat several diseases.452-456 Smaller and uniform-sized nanocarriers are optimal for
use in clinical and laboratory settings; however, liposome size can be highly variable.455, 457
Microfluidization is a common process that can create the smaller sized nanoliposomes which
have advantages over larger liposomes by creating a larger area for nanoliposomes to interact
with the target, therefore enhancing its BA.450 Although smaller sized nanoliposomes enhance
the BA by increasing surface area interaction, it also reduces the loading capacity of
hydrophobic molecules due to limited space between the bilayed lipid membranes.458 Coating
with inert polymers, such as poly(ethylene glycol) (PEG)459 can help to stabilize nanoliposomes
and reduce clearance by the reticuloendothelial system460 or disintegration by electrostatic
interactions.461, 462 PEG is widely used in nanoparticle preparation for the hydrophilic shell
portion due to its hydrophobicity, low toxicity and immunogenicity, and biocompatibility.463-466
Solid lipid nanoparticles (SLNs) are a popular type of nanocarrier also having a hydrophilic
shell and hydrophobic lipid core which has a high melting temperature and is solid at room
temperature.467 The lipid core is usually composed of solid FFA, TGs, and waxes, or some
combination,468, 469 stabilization and dispersion of the lipids is assisted by the use of surfactants
such as phospholipids and bile salts, among others.468 The advantage of using SLNs is that it
has very high biocompatibility and has been shown to provide reproducible results without the
use of organic solvents.467 Unfortunately, however, it has relatively low loading capacity and is
shown to leak its contents during storage.469 A similar compound known as nanostructured lipid
carriers (NLCs) was synthesized to overcome the limitations of SLNs.467 NLCs have similar
beneficial characteristics as SLNs, including being small, stable, biodegradable, and
biocompatible, but have the advantage of increased loading capacity.467 Imperfect crystals are
formed by varying the types of solid-lipid particles (i.e., use of mono-, di-, and tri-glycerides
instead of just TGs) used for synthesizing the NLCs, reducing leakage and enhancing
compatibility with insoluble compounds.470-473 Interestingly, SLNs and NLCs are used to help
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improve BA of bioactive components which are hydrophobic by ways of absorption, digestion,
and circulation within the body.474, 475 Due to the composition of these nanocarriers, when orally
administered, enteral digestion takes up the SLNs and NLCs into lacteal-lymphatic
transportation which allows entry into systemic circulation via the jugular and left subclavian
vein, thereby bypassing the first-pass through the liver.474-476 This effectively enhances the BA of
the nanocarriers as well as the components they are carrying.
Similar to SLN and NLCs, emulsions have a hydrophilic shell and hydrophobic lipid core.477
However, whereas the SLN and NLCs have a solid lipid core, emulsions have a liquid lipid core
which is a result of the dispersion and formation of a solution between two otherwise immiscible
liquids.477 Emulsions are also stabilized using surfactants and emulsifiers, which are then able to
reduce surface tension and increase medium viscosity.478, 479 To remain small and
thermodynamically stable, smaller emulsions require more surfactants and higher energy input
to lower interfacial tension.480 Oral administration of the small emulsions is shown to increase
the BA of bioactive compounds,481, 482 which disperse in the GI and have large size-to-surface
area equivalency and therefore improve aqueous solubility.483
Similar to SLNs, NLCs, and emulsions, but without having a solid nor liquid lipid core,
micelles are formed using amphiphilic colloids such as phospholipids when critical micelle
concentrations and temperatures are met.484, 485 The advantages of using micelles to
encapsulate and transport hydrophobic compounds include an increase of aqueous solubility,
extended circulation time, and lower toxicity.486, 487
Although there are several other formulations of nanocarriers, the last reviewed here are
polymeric nanocarriers, which are also biocompatible and biodegradable polymers, which
have been FDA approved and have low toxicity.488 Polymeric nanocarriers include poly(lacticco-glycolic acid) (PLGA), PEG, and polycaprolactone (PCL), and can be made by several
different processes, including of solvent evaporation, emulsification-diffusion, and
nanoprecipitation.489, 490
2.4.3

Nanocarriers enhance resveratrol solubility, bioavailability, and targeting capacity

Nanotechnology is a novel method of delivery which can enhance Res aqueous solubility
and BA and can also be used to enhance targeting capacity, further enhancing its BA and antiobesity therapeutic activity. Nanoparticle encapsulated Res has been used in several studies to
demonstrate these improvements in various disease states, which are further discussed here.
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Liposomes have been commercially used in the food and supplement industry to help
promote solubility and BA of proteins, enzymes, vitamins, and even flavors.455 Liposomes are
shown to enhance Res chemical and photostability, as evidenced by preventing isomerization
from trans- to cis- when exposed to 16 min of UV radiation by seven to one when compared to
free-Res.491 Liposomes were also shown to have 95% encapsulation efficiency and enhanced
physical stability of Res, which was shown by no significant change in particle size,
polydispersity (measures molecular weight distribution), nor zeta potential (electrokinetic
potential of the nanoparticle versus the medium) after 2 months in 4C storage conditions.501 As
previously discussed, however, liposomes have limited loading capacity for hydrophobic
molecules such as Res.458 This presents a major disadvantage for using liposome as a vehicle
for Res delivery in vitro, in animal studies, and in human studies.
SLNs have been used to encapsulate Res and was also shown to enhance solubility,
chemical and physical stability, and BA by providing protection from enzymatic degradation and
metabolism in vivo.502 SLN-encapsulated with Res has also been shown to extend and provide
sustained release over time, which was attributed to a diffusion-controlled mechanism.495 A
study using SLN composed of glyceryl-behenate encapsulated with Res demonstrated a
sustained release pattern as well as an increased concentration of the SLN-Res as compared to
free-Res in the brain tissue of adult Wistar rats.495 The primary implications of this study
demonstrate SLN help drugs to cross the blood-brain barrier (BBB), which is a primary obstacle
for the delivery of cytotoxic drugs for the treatment of neoplastic tissues.495 Similar to liposomes,
SLN was also shown to help prevent Res isomerization when exposed to UV light.503 SLN also
enhances IC delivery and reduces cytotoxicity; SLN-Res less than 180 nm in diameter were
quickly internalized and distributed throughout IC compartments without inducing cytotoxicity,
unlike free-Res, which was shown to be slightly cytotoxic when in solution.496
Similar to SLNs, polymeric nanoparticles have been shown to enhance Res solubility and
BA and provide a controlled and steady release pattern via diffusion.465 A combination of PCL:
PLGA-PEG-based nanoparticles was shown to have high encapsulation capacity (73-98%) and
released Res continuously over the course of 24 h which led to a greater chemoprotective effect
in prostate cancer cell lines.466
Many of these nanocarriers can be modified via the addition of specific formulations of lipids
as well as additions of peptides and ligands to enhance their targeting specificity, thereby
augmenting treatment effect and BA.504 As previously mentioned, alteration of the lipid-
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formulation of the SLN (i.e., addition of compritol as the lipid core) allowed SLNs to cross BBB
and target brain tissue in rats.495 On the other hand, there are some types of lipid-based
formulations which can effectively bypass the BBB, therefore avoiding the brain and reach the
desired destination without being targeted and removed by the reticuloendothelial system.505
Incorporation or conjugation of these targeting molecules on the surface of liposomes, SLNs,
and polymeric nanoparticles can help to target cell-surface receptors or ECM proteins which are
only expressed in a certain tissue or cell type.504, 506
In conclusion, nanocarriers can help to improve BA and solubility, extend release time, and
enhance Res targeting capacity and effectiveness. These show promise for the therapeutic use
to treat obesity and other metabolic disorders. However, there are several limitations in the
wide-spread use of nanoparticles due to the fact their synthesis is time-consuming and
expensive, and future studies are still needed to determine their longitudinal safety and
effectiveness.507, 508
2.5

THE ANTI-OBESITY POTENTIAL OF INDOMETHACIN

2.5.1

Indomethacin introduction: Structure, history, and function

Indomethacin (Indo) is a type of nonsteroidal anti-inflammatory drug (NSAID) which
primarily functions as a prostaglandin G/H synthase 1 and 2, also known as COX-1 and -2,
inhibitor.509, 510 COX-1/-2 functions to catalyze the conversion of membrane phospholipidderived fatty acids into bioactive lipid cell-signaling molecules known as prostaglandins (PGs) or
eicosanoids.510, 511 These fatty acids are cleaved from sn-2 positions of the phospholipids via
enzymatic hydrolysis by phospholipase A2 (PLA2), primarily releasing arachidonic acid (AA) but
can also include polyunsaturated fatty acids.509 PGs mediate a number of autocrine and
paracrine activities in which the downstream effects can be substrate-, isoform-, and tissuespecific.512 Some of these activities and downstream effects include, but are not limited to,
vasodilation and constriction, blood clotting, cell growth and differentiation, GI secretions (i.e.,
stomach acid, mucus, bicarbonate, etc), as well as pro- and anti-inflammatory and pain sensory
signals.512 COX inhibitors primarily function by binding and antagonizing COX, thereby
preventing innate ligands and substrates from entering the active catalytic site, effectively
diminishing the production of PGs.510
Both isoforms of COX are widely expressed throughout the body; however, COX-1 is
constitutively expressed, whereas COX-2 is strictly inducible in response to stress, injury, and
inflammation.513, 514 Therefore, anucleate cells (i.e., erythrocytes such as red blood cells) cannot
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induce the expression of COX-2.513 Although both isoforms are involved, COX-1 more-so than
COX-2 is involved in production PGs which regulate GI secretions helping to maintain the
protective mucosal barrier, as well as promoting epithelial cell and tight-junction health and
function.515-519 It is for this reason that the use of dual COX inhibitors has been highly implicated
in toxicities including excessive bleeding, ulceration, and mucosal permeability and
inflammation.513, 515 Although Indo is a non-selective COX inhibitor, it has a predilection for
inhibiting COX-1 over COX-2,510 therefore, having a higher risk for toxicities as compared to
other NSAIDs.513
The chemical name for Indo is 1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid
and its chemical classification is as an indole-acetic acid derivative.514 Indoles are aromatic
heterocyclic organic compounds having a bicyclic structure composed of a 5-carbon pyrrole ring
fused with a 6-carbon benzene ring.520 Indo was one of the first NSAIDs synthesized after
acetyl-salicylic acid (aspirin) in the mid-1960s by the director of Merck Sharp & Dohme, Carl
Stevenson, and was shown to have potent analgesic, antipyretic, and anti-inflammatory
properties.513, 514 Indo was generated in response to the observation that serotonin has potent
anti-inflammatory properties, and tryptophan, which is a precursor to serotonin, has an indole
structure.513, 521 Indo has since become a well-studied FDA-approved drug that is used to treat
and relieve inflammatory states of the body such as fever, pain, swelling, stiffness, in addition to
more serious disease states including pleurisy, pericarditis, and gout.522 Typical
recommendations for intake ranges from 25-50 mg two to three times daily, depending on the
severity of the condition, as prescribed by a physician.523
2.5.2

Indomethacin pharmacology: absorption, metabolism, and pharmacokinetics

Indo is shown to work through several transporters including multidrug-resistant protein524,
525

and solute carrier organic anion transporter family member 1A2.526, 527 Absorption of Indo in

the GI is rapid and has a very high BA, with approximately 100% absorbed after oral
administration.514 Whereas plasma concentrations of Indo are linear and dose-proportional, the
half-life and systemic clearance is dose-dependent.514, 528 A dose-escalation study using single
doses of Indo at 25, 50, and 75 mg resulted in a peak plasma concentration of 1.54, 2.65, and
4.92 g/mL, respectively, in fasting subjects after 1.5 h.529 Due to Indo's high BA, it is suggested
to be unlikely to undergo first-pass hepatic metabolism.530 However, Indo-bound to albumin,
when transported to the liver, is subjected to phase II enzymatic hepatic metabolism which
creates inactive metabolites.530 Indo-metabolites are primarily excreted in the urine (~60%),
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followed by feces (33%), as well as bile.523, 530 Although the half-life of Indo is variable based on
dose and enterohepatic recirculation, the estimated average is approximately 4.5 h.523, 530
2.5.3

Indomethacin non-COX-inhibitor mechanisms

Although the FDA-approved indication for Indo is its action as a dual-COX inhibitor, it also
has other mechanisms for reducing the inflammatory response and other off-target effects.514
Indo’s anti-inflammatory and analgesic effects are primarily contributed to its inhibition of PG
production, whereas its antipyretic effects have been attributed to actions in the hypothalamus
which override PG signals, resulting in vasodilation and increased blood flow, allowing heat to
be distributed and dissipated.522 Unlike other NSAIDs, Indo has been shown to not only block
COX from producing PGs, but it is also shown to inhibit the action of PLAs, thereby reducing
substrate for COX enzymatic activity.531 Although the American Society of Health-System
Pharmacists 2015, which is cited by both National Institute of Health (NIH) supported drugdatabases PubChem and ToxNet, suggest that Indo may work as a PDE-inhibitor, increasing IC
concentrations of cAMP, potentially playing a role in the anti-inflammatory response, there was
no other supporting literature.510, 532, 533 In fact, most literature suggests that treatment with
pharmacologically-designed PDE-inhibitors helps to mitigate the effects of Indo, thereby having
opposing mechanisms.534-536 The majority of early Indo literature focused on its COX inhibitory
functions;509 however, relatively recent studies have shown Indo as well as other NSAIDs to
have off-target effects, such as activation of PPARs.537-542
2.5.4

Indomethacin activates PPARs

Several studies have shown NSAIDs, including Indo, to bind to and activate PPARs. By
using a PPAR competitive binding assay, Lehmann et al revealed Indo successfully displaced
a TZD with a half-maximal inhibitory concentration (IC50) of 100 M.540 This study also
demonstrated that Indo is able to activate PPAR greater than other NSAIDs and to a lesser
extent PPAR at 100 M in NHP kidney cells (i.e., CV-1).540 Similarly, Puhl et al demonstrated
that Indo significantly binds to and activates PPAR, as shown by displacement assays (Indo
IC50 = 21.3 M) and a PPAR reporter gene assay (Indo half-maximal effective concentration
(EC50) = 21 M) done in human cervical cancer cells (i.e., HeLa), respectively.541 However, it
was also shown that Indo did not activate and bind to PPAR greater than other tested NSAIDs
(binding affinity = sulindac > diclofenac > Indo > ibuprofen ; activation = diclofenac > Indo >
ibuprofen).541 Although diclofenac was shown to elicit the half-maximal response at a lower dose
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than Indo (diclofenac EC50 = 1.69 M), Indo ≥ 10 M was more efficient in activating PPAR
than any other NSAID tested at the same concentration.541 Furthermore, this study revealed that
Indo displayed binding modes similar to that of strong partial agonists, whereas diclofenac acted
as a weak partial agonist and sulindac displayed toxicity preventing completion of the assay.541
For example, diclofenac was shown to work as a weak partial agonist by binding to PPAR in
the LBP near the -sheets and helix 3, whereas Indo was shown to bind similar to that of a full
agonist by occupying the C-terminal helix H12 as well as partial agonist site, H3 of PPAR.541
Although Indo is not able to replicate the “U-shape” conformation of TZDs which occupies and
bridges two sub-pockets of the LBP, Indo was still shown to closely interact with the “strong”
H12 site with a higher affinity than the “partial” H3 site separately, stabilizing H12 and likely
accounting for its “strong” partial agonist capacity.541, 543-546
A partial agonist can be described as a substance that binds to and activates its target
receptor but does not reach the maximal response capable of a full agonist and can even act as
an antagonist or not function if the receptor is already bound.547 The latter description of a partial
agonist was demonstrated in a study done by Adamson et al which demonstrated that although
diclofenac had an affinity to PPAR 50-times greater than other NSAIDs, it antagonized
beneficial effects seen by Rosi in adipocytes, prostate cancer cells, and NHP kidney cells.548
This study also demonstrated that Indo significantly activated PPAR at 500 M in NHP kidney
fibroblasts (i.e., COS-1).548 Cho et al also found that Indo promoted PPAR binding to
coactivators in a ligand- and dose-dependent manner,538 and later used Indo in another study as
a positive control for testing other PPAR ligands.537 Lastly, Jaradat et al showed that Indo
significantly activated PPAR in CV-1 cells greater than the two ibuprofen isomers.539
Interestingly, ibuprofen currently on the market for therapeutic use is actually a racemic equal
mixture of the two isomers, R(-)-ibuprofen and S(+)-ibuprofen; however, S(+)-enantiomer is able
to inhibit COX whereas R(-)-ibuprofen is not.549
Several studies suggest that Indo elicits this off-target PPAR-activating effect at higher
concentrations, whereas it only has COX inhibiting effects at lower concentrations.540, 541 Several
observations demonstrated that the concentration required to inhibit PG synthesis did not
activate PPAR in reporter gene assays.540 On the other hand, it was observed that higher
concentrations of Indo not only inhibited PG synthesis but also activated PPAR and enhanced
adipocyte differentiation, which PPAR is a critical mediator for.540, 550
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2.5.5

Indomethacin promotes adipocyte differentiation

Indo has been shown to enhance adipocyte differentiation in many studies and is now a
common compound used in adipocyte differentiation cocktails. One of the first of these
observations was made by Williams et al, which demonstrated Indo to stimulate differentiation of
3T3-L1 adipocytes at concentrations ranging from 2.7 – 130 M in an insulin-concentrationdependent manner.551 Using a cell line that will spontaneously differentiate after being confluent
for some time even without hormonal or chemical stimulation, Knight et al demonstrated that
Indo (at 125 M) enhanced TA1 adipocyte differentiation greater than dexamethasone (at 1 M)
alone, in an undetermined COX-independent mechanism.550 Indo was also shown to enhance
mesenchymal stem cell line (C3H10T1/2) adipocyte differentiation in a manner that reflected its
ability to activate PPAR (~100 M).540 Another study demonstrated Indo at as little as 10 M
was able to promote adipogenesis, lipid accumulation, and adipocyte-related genes almost to
the extent of Rosi at 1 M in 3T3-L1 adipocytes.541 A recent study by Hao et al in collaboration
with our lab was the first to demonstrate the possibility of Indo to promote brown adipogenesis
in vitro and in vivo.552 Using a dose-escalation of Indo (2, 5, 10, 20, 50 M), this study
demonstrated a dose-dependent increase in brown adipogenesis in a murine brown cell line as
shown by enhanced ORO lipid accumulation, PPRE activation, mtDNA, UCP1 and PGC1
mRNA and protein expression, as well as Ppar, Prdm16, and Nrf1 mRNA expression.552 Indo is
also a current staple used in the induction media for adipocyte differentiation, usually at 125 M,
along with insulin, IBMX, dexamethasone, Rosi, T3, and sometimes other compounds.553, 554
Indo is used in the media which is used to induce beige adipocyte formation in ASCs isolated
from SVF in mice.555
There have been only a few instances where Indo was shown to inhibit adipogenesis. In one
case, Ob1771 (cell line from ob/ob C57Bl/6J mice), were differentiated in serum-free media in
the presence of exogenous AA and 10 M of Indo.556 The decrease in adipogenesis was solely
measured by reduced glycerol-3-phosphate dehydrogenase (GPDH) activity, which is
responsible for catalyzing the reversible conversion of glycerol-3-phosphate (G3P) to
dihydroxyacetone phosphate (DHAP). Some of the results of this study were not well
understood or explained; however, there are a few confounding factors that may influence these
contradictory outcomes. First, the use of Ob1771, the cell line from genetically transformed
obese mice, may have altered outcomes as compared to wild-type adipocytes due to some
obese WAT having altered PPAR expression.43 Second, the use of serum-free media with
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exogenous AA may have forced the cells to utilize AA for energy rather than convert to PG.
However, none of these explained the findings that cells treated with both Indo and AA were not
able to differentiate. The authors of this study claimed it was due to Indo inhibition of COXproduction of PGs which would stimulate the cAMP rise necessary for serum-free, hormonesupplemented differentiation. Seeing as Indo did not affect GPDH activity when AA was not
added to the media, it seems the effect may be due to AA rather than Indo. Another study
reported that Indo limited insulin signaling and lipogenesis via suppressing autophosphorylation
of the IR and IRS in rat adipocytes when using 1 mM of Indo.557 Although there is no direct
explanation of these effects, there may be cytotoxic effects associated with using very high
concentrations of Indo. Indo’s recommended therapeutic dose ranges from taking 25 mg 1-3
times daily and up to 75 mg once daily, depending on the severity of the disease or ailment.523
Pharmacokinetic studies have shown peak plasma levels in humans after a single 75 mg dose
to be just over 10 M (Cmax = ~14 M)529 which is 70 times less than the 1 mM of Indo used in
this study which demonstrated reduced insulin signaling and lipogenesis.557 Therefore, the dose
used in this study may not be physiologically relevant, and cytotoxicity should be evaluated.
In conclusion, Indo has shown strong partial PPAR agonist binding and activity with the
closest ability similar to TZDs among any other NSAID that was not toxic. Indo has been shown
to enhance adipogenesis, including brown adipocytes; however, its effects on browning of white
adipocytes have not been studied.
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2.7

APPENDIX

Figure 2.1. Positive and negative regulators of adipogenesis. Adapted from: Sarjeant K,
Stephens JM. Adipogenesis. Cold Spring Harb Perspect Biol. 2012;4(9):a008417. (Additional
References: 18, 46-49). Figure Key: Blue-colored arrows represent pro-adipogenic regulatory
effectors. Red-colored bar-headed lines represent anti-adipogenic regulatory effectors.
Abbreviations: AP-1: Activating Protein-1 Family; CHOP: C/EBP Homologous Protein; GATA:
Zinc-Finger DNA-binding proteins; KLF: Kruppel-Like Factor; KROX20: Early Growth Response
Protein 2 (aka EGR2); WNT: Wingless-Integrated.
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Figure 2.2. Anatomical locations of brown and white adipose tissue in humans and mice.
Adapted from: van den Berg SM, van Dam AD, Rensen PCN, de Winther MPJ, Lutgens E.
Immune modulation of browning adipose tissue in obesity. Endocr Rev. 2017;38(1):46-68.
(Additional References: 89, 93, 94). Figure Key: Yellow letters and shapes represent white adipose
tissue. Brown letters and shapes represent brown adipose tissue.
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Figure 2.3. Uncoupling of oxidative phosphorylation. Adapted from: Brondani LA, Assmann
TS, Coutinho G, Duarte K, Gross JL, Canani LH, Crispim D. The role of the uncoupling protein 1
(UCP1) on the development of obesity and type 2 diabetes mellitus. Arq Bras Endocrinol Metab.
2012;56(4):215-225. (Additional References: 26, 27, 105, 106). Figure Key: Green arrows represent
normal function of oxidative phosphorylation and the electron transport chain. The red arrow
represents uncoupling of oxidative phosphorylation, and the production of heat. Abbreviations:
ADP: Adenosine diphosphate; ATP: Adenosine triphosphate; CYTC: Cytochrome Complex; H+:
hydrogen atoms (protons); I-IV: Complex I, II, III, and IV of the ETC; Q: Ubiquinone; UCP1:
Uncoupling protein 1; V: Complex five or ATP Synthase.
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Figure 2.4. Morphological and transcriptional differences between brown, beige, and
white adipocytes. Adapted from: Contreras C, Nogueiras R, Dieguez C, Medina-Gomez G,
Lopez M. Hypothalamus and thermogenesis: Heating the BAT, browning the WAT. Molec Cell
Endocrinol. 2016;438:107-115. (Additional References: 145, 151-153). Figure key: Larger-bold font
represents gene markers that are highly expressed in BAT. Green lettering represents gene
markers which are specific for each respective cell type. Abbreviations: CD137(TNFRRS9):
tumor necrosis factor receptor superfamily, member 9; IGFBP3: insulin growth factor binding
protein 3; MEOX2: mesenchyme homeobox 2; PGC1: peroxisome proliferator-activated
receptor gamma coactivator 1 alpha; PPAR: peroxisome proliferator-activated receptor
gamma; PRDM16: positive regulatory domain containing protein 16; TCF21: transcription factor
21; TMEM26: transmembrane protein 26; UCP1: uncoupling protein 1 ; ZIC1: zinc fingers in the
cerebellum 1; ZFP423: zinc-finger protein 423.
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Figure 2.5. Various signaling pathways Res works to lower plasma glucose and lipid
accumulation. Adapted from: Szkudelska K, Szkudelski T. Resveratrol, obesity and diabetes.
Eur J Pharmacol. 2010;635(1-3):1-8. (Additional References: 275, 330, 331, 333-336, 341, 346, 353, 354).
Figure Key: Thicker lines and outlines represent direct targets of Res. Teal-colored outlined
boxes represent pathways leading to decreased blood glucose. Peach-colored outlined boxes
represent pathways leading to decreased lipid storage. (-) and (+) represent negative and
positive actions by Res on targets, respectively. Abbreviations: AC: Acetyl (SIRT1 de-acetylates
PGC1); ACC: Acetyl CoA Carboxylase; FAO: Fatty Acid Oxidation; FAS: Fatty Acid Synthesis;
GSK: glycogen synthase kinase; GYP: glycogen phosphorylase; IC: Intracellular; LKB1: Liver
Kinase B1; NAD+: Nicotinamide adenine dinucleotide (+ = oxidized); PDE: Phosphodiesterase.

84

CHAPTER III:
RESVERATROL LIPOSOMES AND LIPID NANOCARRIERS:
COMPARISON OF CHARACTERISTICS AND INDUCING BROWNING
OF WHITE ADIPOCYTES
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3.1 ABSTRACT
Trans-resveratrol (Res) has a potential to increase energy expenditure via inducing browning
in white adipose tissue. However, its low levels of aqueous solubility, stability, and poor
bioavailability limit its application. We have successfully synthesized biocompatible, and
biodegradable Res encapsulated lipid nanocarriers (Rnano), and Res encapsulated liposomes
(Rlipo). The mean particle size of Rnano and Rlipo were 140 nm and 110 nm, respectively, and
their polydispersity index values were less than 0.2. Nanoencapsulation significantly increased
aqueous solubility and enhanced chemical stability of Res, especially at 37°C. Rlipo had higher
physical and chemical stability than Rnano while Rnano had more prolonged release than Rlipo.
Both Rnano and Rlipo increased cellular Res content in 3T3-L1 cells. Both Rnano and Rlipo dosedependently induced uncoupling protein 1 (Ucp1) mRNA expression and decreased white
specific marker insulin growth factor binding protein 3 expression under isoproterenol (ISO)stimulated conditions. At the low dose (5 µM), nanoencapsulated compared to native Res
enhanced Ucp1 and beige marker Cd137 expression under ISO-stimulated conditions. Compared
to Rnano, Rlipo had better biological activity, possibly due to its higher physical and chemical
stability at the room and body temperature. Taken together, our study demonstrates that
nanoencapsulation increased Res’ aqueous solubility and stability, which led to enhanced
browning of white adipocytes. Even though both Rlipo and Rnano increased Res’ browning
activities, their differential characteristics need to be considered in obesity treatment.
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3.2 INTRODUCTION
Obesity remains to be the major public health issue in the United States and worldwide,
paralleled by rising rates of co-morbidities such as metabolic syndrome, diabetes, coronary heart
disease, and certain types of cancer.1
Two different adipose tissues are found in mammals: white adipose tissue (WAT), which is
responsible for energy storage; and brown adipose tissue (BAT), which is responsible for
thermogenic energy expenditure.2 BAT has been positively associated with energy expenditure
and negatively associated with adiposity in animal models and humans. Uncoupling protein 1
(UCP1) found in the inner mitochondrial membrane of brown adipocytes in the BAT can dissipate
the proton electrochemical gradient generated by oxidative phosphorylation in the form of heat.3
Emerging data have demonstrated that UCP1 is expressed not only in classical brown adipocytes
but also in “brown-like” or beige adipocytes within WAT upon stimulations, such as a chronic cold
challenge or pharmacological or bioactive compounds.3 To increase adipocyte UCP1 expression
and induce WAT “browning” might result in enhanced thermogenic and fat-burning activities,
which subsequently lead to weight loss.
Trans-resveratrol (3,5,4′-trihydroxy-trans-stilbene, Res) is a polyphenolic compound,
abundant in the skin of grapes and red wine. Many in vitro studies have demonstrated that Res
at concentrations between 10 to 100 µM exhibits anti-obesity activities by modulating adipocyte
differentiation, lipolysis, fatty acid oxidation, and mitochondria biogenesis and activities.4 Res
activates NAD-dependent deacetylase sirtuin 1 (SIRT1), which can deacetylate peroxisomeproliferator-activated receptor γ (PPARγ). This modification is essential for enhancing PPARγbinding activity, recruiting transcription factor PR-domain-containing 16 (PRDM16) to PPARγ, and
activating PPARγ coactivator 1α (PGC1α), which subsequently enhance UCP1 expression and
initiate browning of WAT.4 Native Res (at 10 µM) enhanced mRNA expression of UCP1 and beige
marker CD137 and TMEM26 during brown-like differentiation of primary stromal cells derived from
inguinal WAT (iWAT) of CD1 mice.5 Consistently, in vivo feeding of Res promoted the appearance
of multilocular adipocytes and increased UCP1 expression in iWAT in the mice fed with a high-fat
diet.5 These results suggest that browning WAT may be a new anti-obesity target for Res.
Human studies indicate that Res can maintain metabolic health, but the evidence is
inconclusive.4 The major problems are its low aqueous solubility and bioavailability, and high
metabolism in humans.6 The solubility of Res in water and physiological fluid is very low, less than
0.1 mg/mL.7 When orally administering around 0.3 mg/kg body weight of Res to healthy adult
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males, blood peak concentrations of Res appeared at 0.5 h, and the peak plasma concentrations
were less than 1 μM.8 Even when Res was given a single dose of 5 g, the peak plasma
concentrations were still less than 10 μM.9 Moreover, Res stability is further reduced by various
metabolic transformations, including methylation, glucuronidation and others, primarily in the liver
in vivo.4
Nanoencapsulation has been proven effective in increasing aqueous solubility, chemical
stability, and bioavailability of many bioactive compounds in combating obesity and associated
metabolic disorders.7 Recent animal and human studies indicate that encapsulating Res into
nanocarriers can increase Res’s aqueous solubility, protect Res from metabolic degradation, and
enhance its transport across the plasma membrane, with ultimately augmented absorption and
bioavailability.10
In this study, we synthesized Res encapsulated lipid nanocarriers (Rnano) and Res
encapsulated liposomes (Rlipo), two biodegradable and biocompatible nanocarrier delivery
systems, and compared their physical and physicochemical characteristics and browning
activities with native Res in 3T3-L1 white adipocytes. This study provides a foundation for
developing innovative anti-obesity approaches using natural bioactive compounds and
nanocarrier delivery systems.
3.3 MATERIALS AND METHODS
3.3.1. Chemicals and reagents
Res was purchased from Cayman Chemical Co. (+)-Alpha (α)-tocopherol acetate (αTA),
cholesterol, dexamethasone (Dex), 3-isobutyl-L-methylxanthine (IBMX), insulin, isoproterenol
(ISO) and rosiglitazone (Rosi) were purchased from Sigma-Aldrich Chemical Co. Soy L-αphosphatidylcholine (PC) was purchased from Avanti Polar Lipids Inc. Kolliphor® HS15 was given
as a gift from BASF Chemical. All organic solvents were the high-performance liquid
chromatography (HPLC) grade.
3.3.2. Preparation of Rnano and Rlipo
Rnano was prepared using a mixture containing 1 mg of Res, 70 mg of soy PC, 17.6 mg of
Kolliphor® HS15 and 18 mg of αTA. The mixture was dissolved in ethanol and completely dried
under nitrogen gas. After suspending the mixture with 76°C deionized water, the suspension was
homogenized for 1 min followed by sonication for 1 min. The Rnano tube was put on ice
immediately. After ultrafiltration to remove free-Res, the Rnano was resuspended in phosphate-
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buffered saline (PBS). Rlipo was prepared using 1 mg of Res, 20 mg of soy PC and 2 mg of
cholesterol by a film dispersion method followed by a membrane extrusion method. The void
nanocarriers (Vnano) and void liposomes (Vlipo) were prepared using the above methods
without adding Res.
3.3.3. Particle size, zeta potential, and morphology
The particle size and polydispersity index (PI) values of Rnano, Rlipo and their void
counterparts were measured using a Brookhaven BI-MAS particle size analyzer, and the zeta
potential was measured using a Zeta PALS analyzer. The morphology and size of nanocarriers
and liposomes were determined using a 200kV Hitachi H-8100 transmission electron microscope
(TEM) as described.11
3.3.4. Encapsulation efficiency and loading capacity
One volume of Rnano or Rlipo was dissolved in 9 volumes of methanol, and the total Res
concentrations (Ctotal) in the Rnano or Rlipo solution were measured using a Shimadzu HPLC
system equipped with two LC-20AD solvent delivery units, a SIL-20AC HT autosampler, and a
SPD-M20A photo diode array (PDA) detector (Shimadzu scientific instruments, Inc., Japan) with
a C18 reverse-phase column (Symmetry® C18, 3.5 μm, 4.6×75 mm). The mobile phase was
composed of methanol/water/acetic acid (50/50/0.5, v/v/v) with a flow rate of 1 mL/min. The
detection wavelength was 310 nm. Non-encapsulated Res of Rnano or Rlipo was separated from
nanoencapsulated Res using an ultrafiltration method (Millipore Amicon Ultra-15) and measured
by the HPLC system (Cfree). To calculate the loading capacity, a certain volume of Rnano or
Rlipo (V) was dried using a vacuum freeze-drying system (Labconco, Kansas City, MO). The
weight of dried Rnano or Rlipo was expressed as WNANO. The encapsulation efficiency and
loading capacity of Res in the Rnano or Rlipo were calculated according to the following
equations, respectively:
Encapsulation efficiency = (Ctotal − Cfree)/Ctotal × 100%
Loading capacity = (CtotalV − CfreeV)/WNANO × 100%
3.3.5. Physical and chemical stability
The freshly made Rnano and Rlipo were aliquoted into transparent or black tubes and stored
at 4°C, 22°C, and 37°C for 7 days, and their physical and chemical stability was measured during
this period. The mean particle size, PI and zeta potential were measured every 2 h for the first 10
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h, and every 24 h for 7 days. The chemical stability of Rnano, Rlipo and native Res was measured
using the HPLC system every day for 7 days. Three independent experiments were conducted
for each measure.
3.3.6. Physicochemical characterization
3.3.6.1. In vitro release study
Before the in vitro release study, the stability of Rnano, Rlipo and native Res in the dissolution
medium were measured at 37°C for 24 h. The dissolution medium was composed of PBS and
methanol (80:20, v/v). The in vitro release behaviors of Rnano, Rlipo and native Res containing
0.5 mg of Res were performed in the dissolution medium using a dialysis method.11 Samples
equivalent to 0.5 mg of Res were dispersed in 1 mL of PBS and then placed in the dialysis bags
with Molecular Weight Cut Off (MWCO) 6,000-8,000. The dialysis bags were dipped with the help
of a thread in a conical flask containing 20 mL of dissolution medium and stirred at 200 rpm at
37˚C for 24 h. The dissolution medium was totally replaced by the fresh pre-warmed dissolution
medium every 2 h to protect the released Res from degradation in the medium during a long
period. The Res released into the medium at each time point was determined using the Shimadzu
HPLC system.
3.3.6.2. Raman spectroscopy analysis
All samples were measured using a Bruker Optics Senterra dispersive Raman microscopy at
room temperature. The native Res, Rnano, Rlipo, Vnano, and Vlipo were frozen and then
lyophilized using a vacuum freeze-drying system before taking Raman spectra. The spectral
resolution is 0.5 cm-1, and the measured spectrum range covers 500-1800 cm-1. The excitation
laser has a wavelength of 532 nm and a tunable power for better signal intensity when measuring
different samples.
3.3.6.3 X-ray diffractometry (XRD)
The XRD pattern of lyophilized samples was measured with Siemens/Bruker D5005
diffractometer (Bruker Corporation, Germany) at room temperature. The instrument is equipped
with 2.2 kW Cu X-ray source, and the measurement was conducted with a step size of 0.02° and
a step duration of 1 s. An aluminum sample holder was used, and the measured XRD patterns
were aligned to the aluminum diffraction angle.
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3.3.6.4 Differential scanning calorimetry (DSC) analysis
The DSC analysis of all the samples was carried out on the METTLER Toledo DSC822e
thermal analyzer (Mettler-Toledo, LLC, Columbus, OH) with its STARe software. The
measurements were conducted from 25°C to 400°C with a heating rate of 10°C/min under
nitrogen flow.
3.3.7. Cytotoxicity, cellular Res content and browning activities in 3T3-L1 fibroblasts
3.3.7.1. Cell culture and treatments
Murine 3T3-L1 fibroblasts purchased from ATCC were grown in Dulbecco's modified Eagle’s
medium (DMEM) containing 10% calf serum in a 5% CO2, 37°C environment until they reached
confluence. Cells were differentiated with DMEM containing 10% fetal bovine serum (FBS, Atlas
Biologicals), 1 μM Dex, 0.5 mM IBMX, and 10 μg/mL insulin for 3 days followed by DMEM
containing 10% FBS and 10 μg/mL insulin for additional two days until day 5. The media was then
changed to DMEM containing 10% FBS until day 7. On day 7 the cells were stimulated with ISO
(1 μM) or the vehicle control (H2O) for 6 h before the cells were subjected to total RNA isolation.
All versions of nanocarriers and the controls were added as indicated during each change of the
media. Rosi (1 μM) was used as the positive control.
3.3.7.2. Cell viability
Cell

viability

was

measured

by

the

colorimetric

3-(4,5-dimethylthiazolyl-2)-2,5-

diphenyltetrazolium bromide (MTT) assays. 3T3-L1 cells grown into confluency were treated with
Rnano, Rlipo, and the controls for 24 or 72 h. MTT reagent was added to the cells in the dark and
incubated for additional 2-4 h. The formazan formed was eluted, and OD absorbance at 570 nm
was measured with the Promega GloMax-Multi Detection System. These results were normalized
with protein concentrations of the cell lysate.
3.3.7.3. Cellular Res content studies
3T3-L1 cells were seeded in 6-well plates at a density of 5×104 cells/well. After 24 h, cells
were treated with 10 or 20 μM of Rnano, Rlipo or native Res at 37°C for 4 h. After washing cells
with ice cold PBS twice, the attached cells were scraped and collected in 0.6 M acetic acid in a
glass tube, and 10 μL of quercetin (Q, internal standard, 30 μM) dissolved in methanol was added
to each sample. After mixing, 4 mL of acetone was added into the tube, followed by sonication for
1 min and centrifugation at 5,500×g for 15 min at 4°C. Supernatant volume was accurately
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measured and dried using a nitrogen evaporator at room temperature. After drying, 100 μL
methanol was added into the tube to dissolve Res and internal standard Q. The tubes were
centrifuged at 5,500×g for 10 min at 4°C, and 70 μL clear supernatant samples were transferred
and directly injected into the HPLC system for measuring Res and internal standard (Q)
concentrations. The protein precipitates were dried in the chemical hood, then digested using 0.5
N NaOH overnight. Cellular protein concentrations were measured using a Pierce BCA assay kit.
Total cellular Res content was expressed as μg of Res per mg of protein.
3.3.7.4. Real time-PCR
Total RNA was prepared using the TRI reagent from Molecular Research Center, according
to the manufacturer’s instructions. Total RNA abundance was quantified using NanoDrop ND1000 Spectrophotometer (NanoDrop Technologies, Wilmington, DE). Reverse transcription was
carried out using the High Capacity cDNA Reverse Transcription kit. Expression of target genes
was measured semi-quantitatively by PCR reactions using Power Up SYBR master mix with an
ABI 7300HT instrument (Applied Biosystems, Austin, TX). Relative gene expression was
calculated using the 2(-ΔΔCt) method, which normalizes against the house keeping gene 36b4.
Primer sequences of target genes are listed in Table 3.1. (all tables and figures for Chapter III are
located in 3.6. Appendix).
3.3.7.5. Transfection and reporter gene assays
3T3-L1 cells were transiently transfected with a peroxisome proliferator response element
(PPRE)-driven luciferase reporter (PPRE-Luc) and -galactosidase (-gal) control plasmid with
Lipofectamine 3000 and PLUS Reagent for 24 h. The cells were then treated with nanoparticles
and the controls for an additional 15-18 h. The luciferase activities were measured by a Promega
GloMax-Multi Detection System and normalized by the -gal activities.
3.3.8. Statistical analysis
Statistical analysis was performed using Statistical Package for the Social Sciences and
SigmaPlot 13 (Systat Software, Inc). One-way ANOVA was performed followed by multiple
comparison tests with Student-Newman-Keuls method or Holm-Sidak method to compare with
controls. Each experiment was conducted independently at least three times; each measurement
was performed in triplicates within each experiment. The level of significance was set at p<0.05.
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3.4 RESULTS AND DISCUSSION
3.4.1. Characteristics of Rnano and Rlipo
Rnano and Rlipo were successfully synthesized. Traditional nanostructured lipid carriers
(NLCs) as drug carriers usually contain a large amount of triglyceride.12 In our laboratory, we have
successfully replaced triglyceride with αTA, consequently eliminating exogenous triglyceride and
increasing the anti-oxidative capacity of nanocarriers,11,

13

making them more functional and

beneficial. Fig 3.1.A shows that 1 mg of native Res was hardly dissolved in 1 mL of PBS and
precipitated from the suspension immediately; however, 1 mg of nanoencapsulated Res in both
Rnano and Rlipo was dissolved in the same volume of PBS, which had 25-fold higher aqueous
solubility than native Res. Both Rnano and Rlipo were translucent and opalescent (Fig 3.1.A).
Several studies have demonstrated that entrapment of Res in nanoparticles increases Res’
aqueous solubility and further bioavailability.12 TEM images indicated that both Rnano and Rlipo
were spherical (Fig 3.1.A). The average particle size of Rnano and Rlipo was around 140 nm and
110 nm, respectively (Fig 3.1.A). Recently research data indicate that tissue distribution of
nanocarriers was size-dependent,14 and nanocarriers close to 100 nm was found to be delivered
effectively into adipose tissues of obese mice. The PI values of Rnano and Rlipo were 0.084 and
0.140, respectively. The low PI values indicated a high level of size homogeneity of Rnano and
Rlipo. While higher PI values (> 0.3) indicate higher levels of heterogeneity.12 Surface charges of
nanocarriers play vital roles in cellular uptake, biodistribution, and bioavailability of nanocarriers.12
The Zeta potentials of freshly made Rnano and Rlipo were around -19 and -28 mV, respectively.
Soy PC, the major surface component of Rnano and Rlipo, rendered negative charges on the
surface of particles.12 In general, they can be dispersed stably due to the electric repulsion of
negative charges among particles.
The encapsulation efficiency of Rnano and Rlipo was 96.5% and 96.0%, respectively; and
Res’ loading capacity in Rnano and Rlipo was 28.5% and 25.3%, respectively. Since a high
proportion of hydrophobic αTA on Rnano, we predict that Rnano might have a monolayer of PC
and Kolliphor® HS15 on the surface and a hydrophobic αTA core (Fig 3.1.A). The high
encapsulation efficiency and loading capacity of Rnano were partially due to the hydrophobicity
of αTA, which accommodates more Res in the hydrophobic core. Rlipo might have multiple PC
bilayers and a hydrophilic core. Due to the biphasic characteristics of PC, Res can be embedded
into the sections of hydrophobic fatty acid tails of PC bilayer.15 Multiple PC bilayers on liposomes
also accommodate a good amount of Res.
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3.4.2. Physical and chemical stability
Storage of both Rnano and Rlipo at 4°C for 4 days, their diameters and zeta potentials did not
change significantly, and the PI values remained under 0.2, indicating relatively good
homogeneity and physical stability (Fig 3.1.B). Storage of Rnano at room temperature (22°C) for
4 days, its diameters, and PI values were slightly increased (Fig 3.1.B). At 37°C, Rnano can only
maintain its original size for 8 h, and its PI values were gradually increased (Fig 3.1.B). There
could be two reasons contributing to the poor physical stability of Rnano at 37°C. First, the
hydrophobic lipid core of Rnano was composed of αTA. The melting point of αTA was around
25°C (Sigma T3001) indicated on the product sheet, and the solid core would turn to liquid
resulting in the fragile and unstable structure of Rnano. Second, a high temperature may break
the hydrogen bonds of Kolliphor® HS15,16 the surfactant incorporated on the surface of Rnano,
leading to a reduced stability of Rnano at 37°C. The diameter and zeta potential of Rlipo did not
change significantly at 22°C and 37°C for 7 days, and the PI values remained under 0.2 (Fig
3.1.B), indicating its higher levels of physical stability and homogeneity than Rnano. It should be
emphasized that the cholesterol was incorporated into Rlipo to increase its physical stability. Even
though Rlipo is more stable than Rnano, other characteristics and anti-obesity bioactivities should
be considered and measured.
Rnano and Rlipo also enhanced the chemical stability of Res that is sensitive to light. In a
neutral pH 7.4 condition, native Res was degraded by 40% at 4°C, 60% at 22°C and 96% at 37°C
under the light after 7 days (Fig 3.2.A). Storage of native Res in the dark decreased the Res
degradation rates to 17% at 4°C, 48% at 22°C, and 52% at 37°C after 7 days (Fig 3.2.B). After
incubation at 37°C for 6 days under the light, Res degradation rates were 90%, 80% and 20% in
native Res, Rnano, and Rlipo, respectively (Fig 3.2.A). Both lipo and nanostructures protected
Res from degradation no matter under dark or light, and their protective capability was similar at
4°C and 22°C (Fig 3.2.). Rnano might be solid at the room temperature because the melting
temperatures of αTA (Sigma T3001), soy PC (Avanti 441601) and Kolliphor® HS15 are 25°C and
above. The hydrophobic Res can be encapsulated into the solid core, which can enhance its
stability and prolong its release.17 Rlipo had better protective capacity than Rnano at 37°C. The
higher Res degradation rate in Rnano could be partially due to lack of a solid phase of Rnano at
37°C. Additionally, many research studies have indicated the nanoencapsulation can increase
Res chemical stability via protecting it from light degradation.18, 19
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3.4.3. Physicochemical characterization
3.4.3.1. Raman spectroscopy analysis
Raman spectroscopy is a proved method to quickly and effectively identify the encapsulated
molecules.20 Raman spectra of native Res, Rnano, Vnano, Rlipo, Vlipo, were presented in Fig
3.3. The spectrum of native Res shows three major characteristic bands, including olefinic bands
at 980−1022 cm-1, C-O stretching at 1132−1188 cm-1 and C-C aromatic double-bond stretching
at 1570−1655 cm-1, in addition to several other weak features, which are consistent to the
reference.21 The Raman spectra of Vlipo and Vnano are very similar, dominated by characteristic
peaks of PC, the common component of these two nanocarriers. Since the signatures for native
Res and Vnano/Vlipo have no overlap, it becomes unambiguous to differentiate the compositions
in the encapsulated particles and void nanocarriers. As observed from the spectra, the major
characteristic peaks of native Res were present in Rnano and Rlipo, but absent in Vnano and
Vlipo, while those peaks of Vnano and Vlipo were present in their corresponding Rnano and Rlipo,
but not in native Res. These clearly indicate the encapsulation of Res into Rnano and Rlipo.
3.4.3.2. XRD analysis
The XRD analysis can effectively distinguish between the crystalline and amorphous phases
of Rnano and Rlipo. The crystallinity of nanocarriers is critical because the solubility and
dissolution rate of Rnano and Rlipo in the Res delivery process can be significantly affected by
the degree of crystallinity.22 The XRD patterns of native Res, Rnano, Rlipo and the corresponding
control forms and physical mixtures were shown in (Fig 3.3.). The diffractogram of native Res
exhibited intense peaks between 5° and 35°, indicating the native Res in a highly crystalline form.
In the lyophilized nanocarriers, the sharp peaks from the crystalline native Res were absent,
suggesting less crystallinity or more amorphous state after Res molecules were loaded in the soy
PC shell to form an amorphous complex. More interestingly, although the Raman spectra of Vlipo
and Vnano are very similar, their XRD patterns are dramatically different, suggesting their different
composition and structures, as two different nanocarriers. With the absence of Res crystalline
peaks, XRD patterns of Rlipo and Rnano present the features of Vlipo and Vnano, respectively.
3.4.3.3. DSC analysis
The DSC curves of native Res, Rnano, Rlipo and the corresponding control forms were
presented in Fig 3.3. as a second method to examine the crystallinity. The difference between
Vlipo and Vnano again was notified. The DSC thermogram of native Res showed the
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characteristic endothermic peak at 267°C, corresponding to its melting temperature. However,
Res’ endothermic peak was disappeared in the DSC scans of Rnano and Rlipo, suggesting its
amorphous phase in these nanocarriers.23 Interestingly, the DSC curves of Rlipo and Vlipo and
those of Rnano and Vnano exhibit different features. This difference strongly suggests that Res
molecules were dispersed into the two nanocarriers, resulting in the amorphous phase. This
conclusion is reinforced by the XRD measurements in which only the characteristic crystalline
peaks of the Vnano or Vlipo were observed. All three physicochemical analyses confirm that Res
drug amorphization occurred in both Rnano and Rlipo nanocarriers.
3.4.3.4. In vitro release
Hydrophobic native Res has a low level of aqueous solubility. Methanol was added to make
the dissolution medium to dissolve released native Res. Different methanol contents had been
tested before conducting the release study to ensure to use the minimal amount of methanol. The
dissolution medium containing 20% methanol was the optimal formula, which could dissolve
almost all released native Res without destroying nanostructures (data not shown). The release
study was conducted in the dark to prevent light-induced Res degradation. To minimize the effect
of Res stability, the dissolution medium was changed completely each h for the first 2 h, and every
2 h for the rest 8 h. Native Res showed a burst release phenomenon, while Rnano and Rlipo
exhibited a sustained release behavior (Fig 3.4.). After 1 h, about 0.17 mg, 0.05 mg, and 0.02 mg
of Res was released from dialysis bags containing native Res, Rlipo, and Rnano, respectively
(Fig 3.4.A). At the 2-4 h period, about 0.02 mg, 0.05 mg and 0.04 mg of Res was released from
dialysis bags containing native Res, Rlipo, and Rnano, respectively (Fig 3.4.A). After dialysis for
2 h, the accumulative released Res mass from the native Res dialysis bag reached a plateau (Fig
3.4.B), while for Rlipo and Rnano, Res was continuously released in the 10 h period. Furthermore,
Rlipo released more Res than Rnano (Fig 3.4.B). Hydrophobic compounds like Res might release
faster from the membrane PC bilayers of liposomes than from the hydrophobic core of
nanocarriers.12 The data indicate Res is probably distributed in the PC bilayers of Rlipo, and in
the hydrophobic core of Rnano.
3.4.4. Cytotoxicity
None of the forms of Res at tested doses negatively affected cell viability in 3T3-L1 cells after
24 or 72 h (Fig 3.5.A). The results suggest that two biocompatible and biodegradable
nanostructures are safe to use, at least in 3T3-L1 cells.
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3.4.5. Cellular Res content
To investigate cellular bioavailability, we measured the Res content in 3T3-L1 cells (Fig 3.5.B).
The cellular Res content was dose-dependently increased by all treatments. As compared to
native Res, Rnano and Rlipo only slightly increased Res content at 10 µM; but increased Res
content by more than 20% and 25% at 20 µM, respectively. Due to the instability of native Res at
37°C, 3T3-L1 cells were only treated for 4 h in this experiment. Considering only 4 h treatment,
the increase in cellular Res content by Rnano and Rlipo is significant.
3.4.6. Activation of PPAR responsive reporter
It has been reported that Res (native form) activates PPAR,24 which heterodimerizes with
retinoid X receptor (RXR) to bind to PPRE sites in the promoter regions to transactivate target
genes, including UCP1

25

. All forms of Res significantly activated PPRE-Luc compared to their

controls (p<0.05). No significant differences were detected among the various forms of Res (Fig
3.6.). Rlipo and Rnano had similar activation abilities compared to native Res (Fig 3.6.), a property
that is associated with browning activities of Rosi.26 The results suggest that encapsulation did
not change the biological capability of Res in activating PPAR.
3.4.7. Browning activities
We further studied browning effects of native Res, Rnano, and Rlipo in differentiating 3T3-L1
white adipocytes, a commonly used cell model to study browning.27, 28 The hallmark of beige
adipocytes is induced thermogenesis in response to stimuli, such as β-adrenergic agonist ISO.
We investigated the effects of native Res, Rlipo, and Rnano on the gene expression of markers
of brown and white adipocytes, and mitochondrial biogenesis under either basal (non-stimulated)
or ISO-stimulated conditions.
3.4.7.1. Effects on mRNA expression of brown adipocyte markers
Neither Rosi (positive control) nor any form of Res significantly induced Ucp1 mRNA
expression at basal conditions. However, upon ISO stimulation, all forms of Res significantly and
dose-dependently induced Ucp1 mRNA expression compared to their controls (p<0.05), similar
to Rosi (p<0.05). When compared to various forms of Res, there were no significant differences
between Rlipo and Rnano. However, at 5 µM (the low dose), Rlipo induced a higher Ucp1
expression than native Res under ISO stimulated conditions (p<0.05) (Fig 3.7.).
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Ppar, Pgc1α, and Prdm16 are known core regulators of browning and Ucp1 mRNA
expression (Reviewed in 29, 30). No forms of Res affect Ppar mRNA under the basal condition, in
contrast to Rosi, which suppressed Ppar mRNA 26; Rlipo induced higher Ppar mRNA levels than
Rnano and native Res (p<0.05) (Fig 3.7.).
Under basal conditions, Rosi significantly induced Pgc1α mRNA expression (p<0.05);
however, various forms of Res did not induce significant changes in Pgc1α expression at all tested
doses. Under ISO stimulated conditions, Rlipo significant induced Pgc1α mRNA expression at 20
µM compared to its control (p<0.05) and to a level that is higher than Rnano and native Res at
the same dose (p<0.05). At 5 µM, both Rlipo and Rnano induced higher Pgc1α mRNA than native
Res (p<0.05) (Fig 3.7.).
Rosi significantly induced Prdm16 mRNA expression under both conditions (p<0.05). Under
the basal conditions, native Res did not change Prdm16 mRNA expression. In contrast, both Rlipo
and Rnano dose-dependently increased Prdm16 mRNA expression, reaching significance at 20
µM (p<0.05). Under ISO stimulated conditions, all forms of Res similarly and dose-dependently
increased Prdm16 mRNA expression, reaching significance at 20 µM compared to the controls
(p<0.05) (Fig 3.7.).
3.4.7.2. Effects on mRNA expression of white and beige adipocyte markers
Next, we examined various forms of Res on white and beige marker mRNA expression during
the browning of 3T3-L1 adipocytes. Insulin-like growth factor-binding protein 3 (Igfbp3) was
identified as a white adipocyte specific marker by a transcriptome analysis of brown versus white
adipocyte gene expression.31 Rosi significantly decreased Igfbp3 mRNA expression (p<0.05)
under both conditions, consistent with a previous report
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. Native Res also dose-dependently

decreased Igfbp3 expression compared to the controls under both conditions (p<0.05 at 20 µM
under basal and p<0.05 at all tested doses under ISO stimulated conditions). Comparing to native
Res, both Rlipo and Rnano further decreased Igfbp3 mRNA expression at 20 µM at both
conditions (p<0.05) (Fig 3.8.A).
Cd137 and Tmem26 have been identified as beige-fat specific markers.32 Rosi significantly
increased Cd137 mRNA expression under both conditions (p<0.05). Various forms of Res did not
affect Cd137 mRNA expression compared to the control under basal conditions. However, all
forms of Res dose-dependently increased Cd137 mRNA expression under ISO stimulated
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conditions (p<0.05 for native Res and Rlipo at 20 µM and p<0.05 for all tested doses for Rnano)
(Fig 3.8.B).
Rosi significantly decreased Tmem26 mRNA expression under both conditions (p<0.05).
Native Res decreased Tmem26 mRNA expression under basal conditions (p<0.05 at 5 and 10
µM). In contrast, native Res increased Tmem26 expression under ISO stimulation (p<0.05 at all
tested doses). There were no differences in Tmem26 mRNA expression between Rlipo and
Rnano and their controls under both conditions (Fig 3.8.B)
Using differentiating 3T3-L1 white adipocytes coupled with ISO-induced thermogenic
activation we demonstrate, for the first time, that various forms of Res enhanced ISO-induced
mRNA expression of Ucp1 and other browning markers, such as Prdm16 and Pgc1α. In addition,
various forms of Res enhanced beige marker Cd137 mRNA expression but suppressed white
specific marker Igfbp3 mRNA expression. Our results are consistent with a previous study 5. Of
note, for the first time, we demonstrated that various Res suppressed Igfbp3 and Rnano and Rlipo
had better suppression than native Res at 20 µM under ISO-stimulated conditions. Taken
together, Res-induced browning may contribute to the beneficial effects of Res for obesity and
associated metabolic dysfunction. Whether nanoencapsulated Res can enhance the browning
over native Res in vivo warrant further investigation.
Compared to Rnano, Rlipo induced significantly higher levels of Ucp1 mRNA than native Res
when both used at 5 µM (Fig 3.7.). Moreover, Rlipo induced higher levels of other browning
markers Ppar and Pgc1α than Rnano and native Res under either basal and/or ISO stimulated
conditions (Fig 3.7.). The better browning activities of Rlipo may be due to its higher physical and
chemical stability compared to Rnano and native Res. Moreover, the better biological activities
demonstrated by Rlipo at 5 µM is more physiological relevant since this dose is within the
physiologically achievable dose range of Res for human consumption.8, 9 Compared to native Res,
both Rlipo and Rnano had better suppression of Igfbp3, possibly due to improved overall
bioavailability by nanoencapsulation.
3.4.7.3. Effects on mRNA expression of mitochondrial biogenesis markers
Rosi significantly increased Tfam, Nrf, Cox4a, and Uqcrh under either basal and/or ISO
stimulated conditions (p<0.05). There were minimal differences among the three forms of Res in
any of the mitochondrial biogenesis markers in 3T3-L1 cells except for native Res, which
increased Cox4a mRNA at 20 µM under ISO stimulated conditions (p<0.05) (Fig S.3.1.).
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In contrast to Rosi, all three forms of Res had minimal effects on mitochondrial biogenesis
genes under both basal and ISO stimulated conditions, suggesting that Rosi and Res may induce
browning of 3T3-L1 adipocytes via different molecular mechanisms. Lack of changes in
mitochondrial biogenesis suggests that Res may induce browning of 3T3-L1 by directly
upregulating Ucp1 expression whereas Rosi may increase mitochondrial biogenesis.
Our results suggest that various forms of Res may promote browning by activating PPAR.
Currently, we cannot rule out the possibilities that in addition to activating PPAR responsive
promoters Rlipo and Rnano may activate other signaling pathways, such as SIRT1,33, 34 AMPK,5
or PDE35 to induce browning. Future studies are needed to characterize potential differences in
molecular mechanisms by which Rlipo and Rnano induce enhanced browning. Additionally,
animal studies are required to determine the anti-obesity activity of Rlipo and Rnano in vivo. Oral
administration is the most convenient route, but Rlipo and Rnano might be degraded in the
gastrointestinal tract. Intravenous injection will ensure intact Rlipo and Rnano into the circulation
system, but frequent intravenous injection faces compliance and safety issues, and clinical visits
will be costly. Since animals have subcutaneous WAT, microneedles, skin patches and other
transdermal approaches can be considered. Rosi increased all the mitochondrial biogenesis
markers under both basal and ISO-stimulated conditions compared with the controls (p<0.05).
There were minimal differences in any of the mitochondrial biogenesis markers among the
treatments in differentiated 3T3-L1 cells with the exception of native Res increasing Cox4a mRNA
under both basal and ISO stimulated conditions (p<0.05 at 20 μM). The results are shown in the
Figure S.3.1.
3.5 CONCLUSIONS
We have successfully encapsulated Res into nanocarriers and liposomes, which increased
Res aqueous solubility and stability. Rlipo showed higher physical and chemical stability but with
a less sustained release than Rnano. Both Rnano and Rlipo increased cellular Res content in
3T3-L1 cells, which led to higher expression Ucp1, beige marker Cd137 and other browning
markers, and lower expression of white marker Igfbp3. Our study demonstrates a novel strategy
of using nanoencapsulation of Res to achieve improved browning efficacy with minimal side
effects.
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3.7

APPENDIX

Figure 3.1. Characteristics of Rnano and Rlipo. Visual observation of Rnano, Rlipo, and
native Res containing 1 mg of Res suspended in 1 mL of PBS, transmission electron
microscope (TEM) images of Rnano and Rlipo, and predicted structures of Rnano and Rlipo
(A); changes of particle size, zeta potential, and polydispersity index of Rnano and Rlipo (B) at
different temperatures.
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Figure 3.2. Chemical stability of native Res, Rnano, and Rlipo under the light (A) or the
dark (B) at different temperatures.
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Figure 3.3. Physicochemical characterization. Raman spectra, X-ray diffraction patterns, DSC
thermograms of lyophilized Rnano or Rlipo; lyophilized Vnano or Vlipo; native Res.
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Figure 3.4. In vitro release profiles. Hourly (A) and accumulative (B) Res release for native
Res, Rnano, and Rlipo.
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Figure 3.5. Cytotoxicity and Res content in 3T3-L1 cells. Cytotoxicity was measured by MTT
assays after treating 3T3-L1 cells with native Res, Rlipo, and Rnano (5, 10, 20 µM) or their
respective controls for 24 and 72 h (A); Res content in 3T3-L1 cells after treating them with 10
and 20 µM of native Res, Rnano and Rlipo at 37°C for 4 h (B). Data = means ± SEM (n=3). *,
p<0.05. E, Ethanol containing vehicle control for native Res. R, rosiglitazone, a positive control.
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Figure 3.6. Activation of PPAR responsive reporter by various forms of Res. 3T3-L1 cells
were seeded and transiently transfected with PPRE-Luc and transfection control plasmid β-gal
for 24 h. The cells were then treated with native Res, Rlipo, and Rnano (5, 10, 20 µM) and their
controls for 15 h. Relative luciferase activities were normalized by β-gal activities. Data = means
+ SEM (n=3). E, Ethanol containing vehicle control for native Res. R, rosiglitazone, a positive
control. Different letters on top of the bars indicate significant differences among various forms of
Res. *, p<0.05; **, p<0.01 compared to their controls.
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Figure 3.7. Browning activities. 3T3-L1 cells were induced to undergo white adipocyte
differentiation in the presence of native Res, Rlipo, and Rnano (5, 10, 20 µM) and their controls
for 7 days. Cells were then stimulated with ISO for 6 h. Relative mRNA expression of Ucp1, Ppar,
Pgc1α, and Prdm16 were analyzed by semi-quantitative Real Time-PCR. Data = means + SEM
(n=3). E, Ethanol containing vehicle control for native Res. R, rosiglitazone, a positive control.
Letters of a-c or a’-c’ on top of the bars define differences among various forms of Res under
either basal or ISO-stimulated conditions, respectively. Different letters indicate significant
differences among various Res. *, p<0.05; **, p<0.01; ***, p<0.001 compared to their controls.
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Figure 3.8. Gene expression of white and beige adipocyte markers. 3T3-L1 cells were
induced to undergo white adipocyte differentiation in the presence of native Res, Rlipo, and
Rnano (5, 10, 20 µM) and their controls for 7 days. Cells were then stimulated with ISO for 6 h.
Relative mRNA expression of white marker Igfbp3 (A) and beige markers Cd137 and Tmem26
(B) were analyzed by semi-quantitative RT-PCR. Data = means +SEM (n=3). E, Ethanol
containing vehicle control for native Res. R, rosiglitazone, a positive control. Letters of a-c or a’c’ on top of the bars define differences among various forms of Res under both basal and ISOstimulated conditions, respectively. Different letters indicate significant differences among various
R. * p<0.05 compared to the controls.
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Figure S.3.1. Gene expression of mitochondrial biogenesis markers. 3T3-L1 cells were
induced to undergo white adipocyte differentiation in the presence of native Res, Rlipo, and
Rnano (5, 10, 20 μM) and their controls for 7 days. The cells were then stimulated with ISO for 6
h. Relative mRNA expression of (A) Cidea (brown-fat marker) or (B) Tfam, Nrf, Cox4a, and Uqcrh
(mitochondrial makers) were analyzed by semi-quantitative Real Time-PCR. Data = means +
SEM (n=3). E, Ethanol containing vehicle control for native Res. R, rosiglitazone, a positive
control. Letters of a-c or a’-c’ on top of the bars define differences among various forms of Res
under both basal and ISO-stimulated conditions, respectively. Different letters indicate significant
differences among various Res. *, p<0.05; **, p<0.01 compared to the respective controls.
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Table 3.1. Primer sequences for qRT-PCR using SYBR green.
Gene name
Primer sequences
36b4

Cd137

Cidea

Cox4a

Igfbp3

Nrf1
Pgc1
Ppar

Prdm16

Tfam

Tmem26

Ucp1

Uqcrh

Forward

GCTTCGTGTTCACCAAGGAGGA

Reverse

GTCCTAGACCAGTGTTCTGAGC

Forward

CGTGCAGAACTCCTGTGATAAC

Reverse

GTCCACCTATGCTGGAGAAGG

Forward

GGTGGACACAGAGGAGTTCTTTC

Reverse

CGAAGGTGACTCTGGCTATTCC

Forward

TCATTGGCTTCACTGCGCTCGT

Reverse

TCCAGCATTCGCTTGGTCTGCA

Forward

GTCGCAAATAATGGTGCGCT

Reverse

GAAAAACTGCCTTCCCGCAG

Forward

GGCAACAGTAGCCACATTGGCT

Reverse

GTCTGGATGGTCATTTCACCGC

Forward

GAATCAAGCCACTACAGACACCG

Reverse

CATCCCTCTTGAGCCTTTCGTG

Forward

GTACTGTCGGTTTCAGAAGTGCC

Reverse

ATCTCCGCCAACAGCTTCTCCT

Forward

ATCCACAGCACGGTGAAGCCAT

Reverse

ACATCTGCCCACAGTCCTTGCA

Forward

GAGGCAAAGGATGATTCGGCTC

Reverse

CGAATCCTATCATCTTTAGCAAGC

Forward

ACCCTGTCATCCCACAGAG

Reverse

TGTTTGGTGGAGTCCTAAGGTC

Forward

GCTTTGCCTCACTCAGGATTGG

Reverse

CCAATGAACACTGCCACACCTC

Forward

GTGAGAGAGCACTGTGAACAGC

Reverse

CAATCCTCTTCTGTCTGTGACCG
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CHAPTER IV:

TARGETING NANOPARTICLES ENCAPSULATED WITH
RESVERATROL INDUCE BROWNING OF MURINE PRIMARY
SUBCUTANEOUS WHITE ADIPOCYTES
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4.1.

ABSTRACT

The plant-derived polyphenolic compound, trans-resveratrol (Res), is shown to possess a
plethora of health-promoting and disease-fighting benefits ranging from anti-inflammatory, antibacterial, and anti-aging, to anti-carcinogenic, anti-atherogenic, and anti-obesogenic. However,
poor aqueous solubility and rapid metabolism presents a critical limitation in clinical utility for
human research. Encapsulating Res in nanocarriers has shown to overcome some of these
limitations and demonstrate promising therapeutic potential in vitro and in vivo; however, there
still seems to be non-specific binding and excessive elimination. Targeting the adipose stromal
cells (ASC) found in white adipose tissue (WAT) would help to focus therapeutic potential of
Res to promote beige adipocyte formation, leading to increased energy expenditure and weight
loss. An extra-cellular matrix-associated post-translationally cleaved fragment of decorin lacking
the glycanation site (DCN) is specifically found on the surface of WAT-ASCs. An ASCtargeting peptide and ligand for DCN, GSWKYWFGEGGC, was successfully incorporated in
nanoparticles encapsulated with Res (L-NR). The primary objectives of this study were to
assess the targeting capacity and efficiency as well as the biological effect of L-NR in DCNtransduced 3T3-L1 cells (DCN cells) and freshly isolated murine primary cells from the stromal
vascular fraction (mSVF) of inguinal WAT. Cellular uptake was assessed using Rhodaminelabeled nanocarriers with or without the targeting ligand bound (L-Rhod-nano and Rhod-nano,
respectively). L-Rhod-nano had significantly greater uptake in DCN cells as shown by confocal
microscopy. There was no further activation of peroxisome proliferator response element and
peroxisome proliferator-activated receptor  by L-NR compared to free-Res (FR) in DCN or the
control cells, likely due to the short treatment time. Western analysis confirmed DCN
expression in freshly isolated mSVF, during confluence, and at the beginning of differentiation,
which was reflected by significantly enhanced uptake of L-Rhod-nano in mSVF cells at these
two time points. When mSVF were treated with various forms of Res throughout differentiation,
L-NR promoted browning to a greater extent than the non-ligand bound nanoparticle
encapsulated with Res (NR) and FR at doses as low as 1 M, as shown by enhanced Ucp1,
Pgc1, and Cd137 as well as suppressed Igfbp3 mRNA expression. When fully differentiated
mSVF were treated with various forms of Res, L-NR enhanced browning greater than NR and
FR at 10 M as shown by the same above markers. Taken together, our results suggest that the
targeting nanocarriers encapsulated with Res significantly enhanced delivery and browning in
mouse primary subcutaneous stromal cells and adipocytes. The targeting nanocarrier delivery
system can be a novel and beneficial strategy to combat obesity.
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4.2.

INTRODUCTION

Obesity is a still-growing health burden in developed countries and is becoming more
prevalent in developing countries.1, 2 Obesity can be characterized by individuals having high
body mass index (BMI) combined with a large waist circumference, which is indicative of greater
central adiposity.3-5 Increases in visceral adipose tissue (VAT) is highly associated with
obesity’s comorbidities such as metabolic syndrome, cardiovascular disease, and some types of
cancers,6 which are leaders in causes of preventable morbidity and mortality.7 Therefore,
discovery of novel therapies to treat and prevent obesity is of vital importance and targeting the
culpable tissue is a sensible start.
Although adipose tissue has many functions, including insulation and cushion, its primary
function is as a metabolic and endocrine organ, storing and exchanging energy and nutrients in
response to internal stimuli as well as secreting hormones, cytokines, and chemokines.8-10 The
two main types that are primarily recognized are white adipose tissue (WAT) and brown adipose
tissue (BAT). WAT is the most predominant type of fat in the adult human, with adipocytes
having a large unilocular lipid droplet and is primarily associated with energy storage.11 BAT is a
highly thermogenic tissue whose adipocytes have smaller multilocular lipid droplets and many
mitochondria which express uncoupling protein 1 (UCP1).12 UCP1 disrupts the electron
transport chain (ETC) chemiosmotic gradient, causing substrates which are normally used for
synthesizing ATP to be released as heat instead.12, 13 Due to this characteristic, BAT can act as
a “metabolic sink” for excess glucose and fat, and therefore significantly contribute to energy
expenditure and lead to weight loss.14, 15 A type of intermediate of brown and white adipocytes,
called beige or brite adipocytes, is now recognized to have origins in WAT but function similar to
BAT.16, 17 It is thought that beige adipocytes can either “transdifferentiate” from fully mature
adipocytes,18, 19 or be induced in the adipose stromal cells (ASCs) found in the stromal vascular
fraction (SVF) of WAT in response to metabolic cues and stimuli.20-22 Activation of the brown-fat
program (i.e., UCP1 expression) in these cells has been shown to occur upon cold stimulation
and treatment with β-adrenergic receptor (β-AR) agonists, peroxisome proliferator-activated
receptor- (PPAR) activators, and some nutritional and pharmacological agents.12, 13, 17, 23-25
Studies have shown beige adipocytes from these sources have led to increased energy
expenditure causing weight loss.17, 26 The thermogenicity and inducibility of beige adipocytes
differentiated from ASCs from the ample WAT has made it a desirable target in the hunt for
obesity therapies.27, 28
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Among the nutritional compounds with a variety of health benefits, trans-resveratrol (Res)
stands out as a naturally occurring polyphenol with potent antioxidant properties29, 30 and several
anti-obesity effects31-33 including promoting beige adipocyte formation within WAT.34, 35 Res has
been shown to mediate its beneficial effects via interaction with a variety of transcriptional
factors implicated in signaling pathways responsible for regulating beige adipocyte formation.33,
36

These include, but are not limited to, direct or indirect activation of AMP-activated protein

kinase (AMPK),37-40 NAD-dependent deacetylase sirtuin-1 (SIRT1),37, 41-43 PPAR,44-46 as well as
PPAR coactivator 1 (PGC1),47 among many others.36 Although there are many studies to
support Res’ beneficial effects in vitro and in vivo, the evidence to support anti-obesity effects in
human clinical trials is limited and controversial.48, 49 The extensive hepatic and intestinal
metabolism in addition to the poor aqueous solubility could possibly be the primary limiting
factor in respect to bioavailability, which may provide some explanation for the discrepancies
between human and animal Res studies.30, 35, 49, 50 Nanotechnology has been explored in an
effort to improve bioavailability of several polyphenolic compounds and has shown effective in
the delivery of a variety of disease-fighting therapeutic agents.50-55 Using biodegradable and
biocompatible nanocarriers to encapsulate Res could help to overcome these critical limitations
to enhance efficacy and allow for more targeted delivery, strengthening its clinical utility in the
fight against obesity.50, 52, 56, 57
In a previously published study, we provided evidence to support that nanoparticles
encapsulated with Res (NR) improved chemical stability, aqueous solubility, as well as
promoted browning in 3T3-L1 cells (Chapter III). The results of this study demonstrated that the
encapsulation enhanced its overall bioavailability and further enhanced browning activity in 3T3L1 adipocytes. Recently, a strategy to target ASCs has been reported.58 The targeting system
involves a peptide, GSWKYWFGEGGC, which acts as a ligand for delta-decorin (DCN), an
extracellular matrix (ECM)-associated protein and an isoform of decorin (DCN) lacking the
glycanation site.58 DCN is shown to solely be expressed on the surface of ASCs in WAT.58 We
have successfully inserted this peptide on the nanocarrier surface, thus developing an ASCtargeting ligand-coated NR (L-NR).
The primary objectives of this study were to determine the uptake capacity and biological
response to L-NR using 3T3-L1 cells over-expressing DCN (DCN cells) as well as freshly
isolated murine SVF. In using this novel nanocarrier delivery system with ASC-WAT-targeting
capacity, we expect that we will see greater uptake which will translate into enhanced browning
of mouse primary stromal cells.
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4.3.

MATERIALS AND METHODS

4.3.1. Chemicals and reagents
Dexamethasone (Dex), 3-Isobutyl-L-methylxanthine (IBMX), insulin, triiodothyronine (T3),
and rosiglitazone (Rosi) were purchased from Sigma-Aldrich (St. Louis, MO). Indomethacin
(Indo) was purchased from Cayman Chemical (Ann Arbor, MI). Dulbecco's modified Eagle’s
medium (DMEM) and Calf serum (CS) was purchased from Hyclone (Logan, UT) and fetal
bovine serum (FBS) from Atlanta Biologicals (Flowery Branch, GA). Antibiotics, penicillin and
streptomycin (P/S) were purchased from Gibco by Life Technologies (Burlington, ONT). Mouse
decorin antibody was purchased from R&D Systems, Inc (Minneapolis, MN). Tubulin and antigoat antibodies were purchased from Santa Cruz Biotechnology, Inc (Dallas, TX), and antirabbit horse-radish peroxidase (HRP)-conjugated antibody were from Cell Signaling Technology
(Danvers, MA).
4.3.2. Nanoparticle preparation
Nanoparticles (NP) encapsulated with Res, with or without the targeting peptide-ligand (LNR and NR, respectively) as well as free-Res (FR), were prepared fresh for each change of the
media by collaborators at Texas Tech University. NP’s loading capacity and Res release at
various temperatures have been previously described.46 Res concentration was determined for
L-NR, NR, and FR for each batch made using High Performance Liquid Chromatography
(HPLC) as previously described.46
4.3.3. Cell models
4.3.3.1.

Delta-DCN over-expressed cells

3T3-L1 cells lentivirally transduced to over-express delta-decorin-GFP (DCN cells) or GFP
vector alone (CON cells) were a gift from the Mikhail Kolonin group at the University of Texas
Health Science Center at Houston. DCN and CON cells were grown and maintained in DMEM
containing 10% CS with 1% P/S and 5 g/mL puromycin (selection maintenance) in a 5% CO2,
37°C environment.
4.3.3.2.

Murine stromal cells

4.3.3.2 (1) Isolation procedure
Isolation of SVF from male C57Bl/6J mice was performed as previously described with
minor modifications.59, 60 Briefly, inguinal subcutaneous white fat pads were excised, weighed,
and temporarily stored in ice-cold PBS. Fat pads were minced with razors and added to
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isolation buffer (120 mM NaCl, 0.5 mM KCl, 1.2 mM KH2PO4, 0.6 mM MgSO47H2O, 0.9 mM
CaCl26H2O, 20 mM HEPES, and 2.5% BSA) in a ratio of 1 g tissue : 3 mL buffer. Type I
collagenase was freshly added to the tissue-buffer mixture 60 L of collagenase per 1 mL
buffer. Digestion of the mixture took place in a 37C shaking water bath at 150 rpm for 30 min
(with periodic gentle vortexing and pipette-mixing every 10 min). Digested tissues went through
two filtration steps followed by centrifugation at 500 g for 5 min at 4C, first through 100 m
nylon mesh sterile-cell filter, then through 70 m nylon mesh sterile-cell filter. After filtering and
centrifugation, supernatant was removed, and the cell pellet was washed and resuspended in
isolation buffer. After the two washing and filter steps, the cell pellet was resuspended in DMEM
containing 15% FBS with 1% P/S and counted prior to plating into 60 mm dishes in a 5% CO2,
37°C environment. After 6 h to overnight incubation, non-adherent cells were removed with
gentle washing with culture media. After 48 h, fully adherent cells were maintained in DMEM
with 10% FBS and 1% P/S until induced to differentiate. Where indicated, cell-culture plates
were coated with 5% sterile gelatin solution (Sigma-Aldrich, St. Louis, MO) to help with cell
attachment. Cells were passaged up to two times prior to differentiation, all experiments shown
here were on the same passage, and isolated from mice of matching age, gender (male), and
genetic background.
4.3.3.2 (2) Differentiation protocol
Murine primary stromal cells were differentiated as previously described,28 with minor
modifications. Briefly, confluent cells (designated as D0) were induced to differentiate with
DMEM containing 10% FBS and 1% P/S with 1 μM Dex, 0.5 mM IBMX, 5 μg/mL insulin, 0.5 μM
Rosi, 125 μM Indo, and 1 nM T3 for three days. Differentiating cells were maintained in DMEM
containing 10% FBS and 1% P/S with 5 μg/mL insulin, 0.5 μM Rosi, and 1 nM T3 for the
remainder of cell differentiation. Medium was replenished every two to three days until fully
differentiated at day 10. “Complete Differentiation” (Complete) refers to cells that received
treatment with every change of media. “Transdifferentiation” refers to cells that only received
treatment on day 7 of media change.
4.3.4. Quantifying uptake of nanoparticles using confocal microscopy
Rhodamine-labeled NPs (Rhod-nano) were diluted and florescence quantified using a
BioTek Microplate Reader to establish equal incorporation of Rhodamine between the targeting
and non-targeting NP. DCN and freshly isolated murine primary stromal cells were seeded in
24-well plate (1x105 cells/well) onto sterile Corning BioCoat Poly-D-Lysine Coverslips (Thomas
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Scientific, Swedesboro, NJ) overnight and treated with Rhod-labeled nanocarriers without or
with the targeting-ligand (Rhod-nano and L-Rhod-nano, respectively) at 37C for 2 h. Ice-cold
sterile PBS was used to wash cells three times prior to termination and fixation with 3.7%
formaldehyde in PBS for 15 min at room temperature. After fixing followed an additional threestep washing process with ice-cold PBS. Cells were then stained with 4’, 6-diamindine2’phenylindole dihydrochloride (DAPI) at room temperature for 5 min, followed by one PBS
rinse. Fixed and stained cells’ cover slips were mounted on disposable microscope slides using
ProlongTM Gold Antifade mounting solution (both from ThermoFisher Scientific, Waltham, MA).
Cells were imaged using Leica SP8 White Light Laser Confocal System (Leica Microsystems
Inc, Buffalo Grove, IL). Rhodamine uptake, shown in red, was detected using the white-light
laser (exc: 560 nm, em: 583 nm). DAPI-stained nuclei, shown in blue, was detected using the
“405 laser” (exc: 358 nm, em: 461 nm). All exposure and imaging settings are identical for
comparable analysis. Rhodamine uptake in florescent images were quantified using Image J,
graphs made to represent at least 3 separate experiments each having at least 3 different areas
of cells imaged and quantified, areas were chosen at random.
4.3.5. Transfection and reporter gene assays
Transfection and reporter gene assays were performed as previously described.45-46 PPAR
transactivation reporters were a gift from Dr. Susanne Mandrup (University of Southern
Denmark, Denmark) which consisted of murine PPAR ligand binding domain (LBD) fused with
a Gal4 DNA binding domain (DBD) (mPPAR-Gal4) and a reporter construct comprised of an
upstream activating sequence (UAS) thymidine kinase-linked luciferase, 4xUAS-TK-Luc (hereon
referred to as PPAR-Gal4-Luc or simply PPAR (trans)activation). Another transactivation
reporter used included peroxisome proliferator response element (PPRE)-driven luciferase
reporter (PPRE-Luc). DCN or CON preadipocytes were seeded one day prior to transfection in
a manner so that cells reached approximately 50-70% confluence the day of treatment (1x104
per well in 48-well format). The preadipocytes were then transiently transfected with PPRE-Luc
or PPAR-Gal4-Luc, and -galactosidase (-gal) control plasmid using Lipofectamine 3000 and
PLUS Reagent (ThermoFisher Scientific, Waltham, MA) for 24 h. The cells were then subjected
to treatment with the various forms of Res or the controls for an additional 15-18 h. Cell lysate
was prepared using Reporter Lysis Buffer (Pomega, Madison, WI) with Luciferase substrate and
-gal substrate. Luciferase activity and -gal was quantified using luminescence or absorbance,
respectively by GloMax-Multi Detection System (Promega, Madison, WI).
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4.3.6. Western blot analysis
Western blot analysis was performed as previously described.45 Briefly, protein extraction
was completed using ice-cold PBS with phosphatase inhibitor cocktail (ThermoFisher Scientific,
Waltham, MA) to rinse the cells while cell lysate was prepared using 1x RIPA buffer (Cell
Signaling, Danvers, MA) with freshly added PMSF (Sigma). Protein concentrations were
determined by BCA Protein Assay kit (ThermoFisher Scientific, Waltham, MA). Total cell lysates
were subjected to electrophoresis on 10% SDS-PAGE gel and transferred to polyvinylidene
difluoride membrane (Bio-Rad, Hercules, CA). The membrane was blocked in 20 mM Tris·HCl,
137 mM NaCl, and 0.1% Tween 20 (TBST at pH 7.4) containing 5% nonfat milk. The membrane
incubated with diluted primary antibodies with varying times, followed by incubation with diluted
secondary antibody. Washing steps between antibody incubations included TBST on rocker four
times for 10 min. Each membrane was then incubated with SuperSignal West Pico
Chemiluminescent Substrate (ThermoFisher Scientific, Waltham, MA) for 5 min. Excess
substrate was removed, and protein expression was detected using Odyssey® FC imaging
system (Licor Biosciences, Lincoln, NE) or a x-ray film processor (Konica Corporation, Taiwan)
utilizing HyBlot CL Autoradiography Film (Denville, Holliston, MA) which was exposed to the
substrate-incubated membrane for various times. The membrane was stripped in buffer (62.5
mM Tris-HCl, 2 % SDS, and 100 mM 2-mercaptoethanol) at 50°C for 5-10 min. The signal was
quantified by densitometry using Odyssey® FC imaging system.
4.3.7. mRNA isolation and semi-quantitative RT-PCR analysis
RNA isolation was performed as previously described.45-46 Briefly, total RNA was isolated
using TRI reagent (Molecular Research Center, Cincinnati, OH) according to the manufacturer’s
instructions. NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies, Wilmington, DE)
was used to quantify total RNA. After RNA isolation, High Capacity cDNA Reverse Transcription
kit (Thermo Scientific, Pittsburgh, PA) was used to carry out reverse transcription following the
manufacturer’s instructions. Target genes and the housekeeping gene, 36b4, mRNA expression
was determined quantitatively using Power Up SYBR Green Master Mix following
manufacturer’s instructions (Applied Biosystems, Austin, TX). An ABI 7300HT instrument was
used to run PCR reactions using a 96-well format. The cycle number (Ct) was obtained for each
reaction, the 2(-ΔΔCt) method was used to calculate the relative gene expression, normalizing
against the house keeping genes which is then converted to fold.
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4.3.8. Statistical analysis
Data in figures presented here is shown as means ± SEM. Experiments were performed at
least three times with triplicates. SigmaPlot 14 (Systat Software, Inc) was used to perform
statistical analysis. To determine the differences within and between treatment groups, t-tests,
one-way ANOVA, or mixed model ANOVA was performed followed by post-hoc comparison
tests with Student-Newman-Keuls method. The level of significance was set at p<0.05.
4.4.

RESULTS

4.4.1. Enhanced uptake of rhodamine by ligand-bound nanoparticles in DCN cells
Rhodamine-labeled nanocarriers without or with the targeting-ligand bound (Rhod-nano and
L-Rhod-nano, respectively) were used to treat DCN preadipocytes. This uptake was visualized
by fluorescence and confocal microscopy. L-Rhod-nano had significantly greater uptake of the
Rhodamine-labeled nanocarriers in DCN cells (Fig 4.1.A and B) (all tables and figures for
Chapter IV are located in 4.8. Appendix). There were no differences in uptake of Rhodaminelabeled NPs in 3T3-L1 cells, which were used as a control for the DCN cells (data not shown).
Z-stack confocal 3D-projections with zoomed in image, demonstrates NPs getting into the cells
(Fig 4.1.C).
4.4.2. Enhanced resveratrol-induced PPRE and PPAR transactivation by ligand-bound
nanoparticles in DCN cells
Previous studies have shown FR binds36, 61 to and activates44-46 PPAR, which can
transactivate brown-fat target genes including UCP1 when PPAR heterodimerizes with retinoid
X receptor (RXR) to bind to PPRE sites.62 We have previously determined that FR in addition to
nanoparticle-encapsulated Res in two forms (lipid nanocarriers = Rnano, and liposomes = Rlipo)
significantly activated PPRE compared to their controls.46 Similarly, we showed here that all
forms of Res significantly activated PPRE greater than their controls in DCN cells, and L-NR
produced the greatest PPRE activation of all forms of Res in DCN cells (Fig 4.2.A). FR
significantly activated PPRE in the CON cells, whereas there were no differences between the
nano-encapsulated Res forms and their void controls (Fig 4.2.A). Moreover, the Nanoencapsulated forms of Res also significantly activated PPAR greater than controls in DCN
cells; however, L-NR yielded the greatest PPAR activation among all forms of Res in DCN
cells (Fig 4.2.B). In contrast, there were no significant differences in any form of Res compared
to controls nor between the forms of Res seen in the CON cells (Fig 4.2.B). These results
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suggest that the DCN-targeting nanocarrier is able to deliver and promote Res’ capacity to
bind and activate PPAR greater than the free and non-ligand-bound NP forms of Res, and
significantly activate PPAR downstream target, PPRE, greater than the NR.
4.4.3. Detection of decorin protein expression in murine stromal cells from
subcutaneous fat
Murine primary SVF (mSVF) isolated from subQ iWAT samples were collected at various
time points including the mSVF pellet, when cells reached 70-80% and 100% confluence, as
well as 3 days into differentiation (3-Day Diff) in either gelatin-coated or non-coated plasticculture plating conditions. Our results show that, indeed, DCN expression is high when mSVF
are pelleted, and the expression significantly falls off when cells are plated in culture (i.e., at 7080% confluence) (Fig 4.3.A-B). However, this expression begins to return when cells are 100%
confluent, and this increase is augmented in the beginning stages of differentiation (after postmitotic cell expansion) (Fig 4.3.A-B). These results suggest cells may need cell-cell contact for
the ECM-associated protein to begin to be secreted.
4.4.4. Enhanced uptake of rhodamine by ligand-bound nanoparticles in murine stromal
cells
Rhodamine-labeled nanocarriers without or with the targeting ligand bound (Rhod-nano and
L-Rhod-nano, respectively) were used to treat mSVF at various cell states, including 70-80%
and 100% confluence, and three days into differentiation (3-Day Diff). This uptake was
visualized by fluorescence and confocal microscopy. L-Rhod-nano treated cells had significantly
greater uptake of the Rhodamine-labeled nanocarriers than those of Rhod-nano when the cells
were at 100% confluence and 3-Day Diff, shown visually (Fig 4.4.A) and quantitatively (Fig
4.4.B). There were no significant differences in uptake of Rhodamine-labeled NPs between the
L-Rhod-nano and Rhod-nano when the cells were at 70-80% confluence (Fig 4.4.A-B). Z-stack
confocal 3D-projections with zoomed in image, demonstrate diffused Rhodamine uptake around
the nuclei, suggesting that NPs were taken in by the mSVF cells at 3-Day Diff (Fig 4.4.C).
4.4.5. ASC-targeting nanoparticles enhances resveratrol’s efficiency to promote
browning at lower, physiologically relevant doses in murine stromal cells
When murine primary stromal cells isolated from iWAT were subjected to differentiation in
the presence of various forms of Res and their controls at 1, 5, or 10 M throughout the entire
differentiation program, there was a significant induction in BAT and beige marker mRNA
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expression with a simultaneous suppression of white-fat specific marker mRNA expression. At 1
M, ligand-bound L-NR significantly induced select browning markers and suppressed white-fat
specific marker, Igfbp3, to a greater extent than its vehicle control and other forms of Res. When
cells are treated throughout the differentiation process, as Res concentrations increased (to 5
and 10 M), the differences among the various forms of Res become less apparent. The gene
specific changes are described as follows.
Ppar mRNA expression (Fig 4.5.A)
PPAR is a master adipocyte differentiation regulator, is highly enriched in BAT, and
activation of which has been shown to lead to browning in WAT.25 At 1 and 5 M, only L-NR
significantly induced Ppar mRNA expression greater than its vehicle control and L-NR induced
the highest Ppar mRNA expression among the various forms of Res at 1 M (Fig 4.5.A). There
were no significant differences in Ppar mRNA expression between the forms of Res and their
vehicle controls at 10 M (Fig 4.5.A).
Pgc1 mRNA expression (Fig 4.5.B)
PGC1 is a transcriptional coactivator for energy-metabolism genes and is well known for its
role as a master mitochondrial biogenesis regulator.63, 64 PGC1 is highly expressed in muscle
and BAT and can be induced in the browning of WAT.65 At 1 M, only L-NR significantly induced
Pgc1 mRNA expression greater than its vehicle control and the other forms of Res (Fig 4.5.B).
At 5 M, both NR and L-NR significantly induced Pgc1 mRNA expression greater than their
vehicle controls; however, L-NR induced the highest Pgc1 mRNA expression among various
forms of Res at 5 M (Fig 4.5.B). At 10 M, only NR significantly induced Pgc1 mRNA
expression greater than its vehicle control; however, there were no significant differences
among the various forms of Res (Fig 4.5.B).
Ucp1 mRNA expression (Fig 4.5.C)
UCP1 is the hallmark gene for BAT and beige fat cells, playing a key role in the nonshivering thermogenic program in fat cells.66 At 1 M, both FR and L-NR significantly induced
Ucp1 mRNA expression greater than their vehicle controls; however, only L-NR induced the
highest Ucp1 mRNA expression among the various forms of Res at 1 M (Fig 4.5.C). At 5 M,
all forms of Res significantly induced Ucp1 mRNA expression greater than their vehicle controls;
however, both NR and L-NR were greater than FR (Fig 4.5.C). At 10 M, there were no
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significant differences between the forms of Res and their vehicle controls nor among the
various forms of Res (Fig 4.5.C).
Cd137 mRNA expression (Fig 4.5.D)
CD137 is identified as a specific marker for beige fat cells.17, 67 At 1 M, both FR and L-NR
significantly induced Cd137 mRNA expression greater than their vehicle controls; however, LNR induced the highest Cd137 mRNA expression among the various forms of Res at 1 M (Fig
4.5.D). At 5 M, both NR and L-NR significantly induced Cd137 mRNA expression greater than
their vehicle controls and both were significantly greater than FR (Fig 4.5.D). At 10 M, both FR
and NR were significantly lower than their vehicle controls. In contrast, L-NR not only induced
higher Cd137 mRNA expression than the vehicle control, but also had the highest Cd137 mRNA
expression among the various forms of Res (Fig 4.5.D).
Igfbp3 mRNA expression (Fig 4.5.E)
IGFBP3 is a marker highly expressed and associated with WAT, and therefore, is used here
as a white-fat specific gene marker.68 At 1 M, only L-NR significantly suppressed Igfbp3 mRNA
expression than the vehicle control and induced the lowest Igfbp3 mRNA expression among the
various forms of Res (Fig 4.5.E). At 5 M, only FR significantly suppressed Igfbp3 mRNA
expression compared with its vehicle control. There were no significant differences between NR
and L-NR and their respective controls or between each other in Igfbp3 mRNA expression at 5
M (Fig 4.5.E). At 10 M, NR significantly induced Igfbp3 mRNA expression greater than its
vehicle control and greater than the other forms of Res (Fig 4.5.E).
4.4.6. Ligand-bound nanoparticles encapsulated with resveratrol promote browning at
higher doses when treating fully differentiated murine stromal cells
When murine primary stromal cells isolated from iWAT were subjected to differentiation into
fully mature adipocytes prior to being treated with various forms of Res and their controls at 1, 5,
or 10 M for three days, there was a significant induction in BAT and beige mRNA expression
with a simultaneous suppression of white-fat specific marker, Igfbp3, mRNA expression by
higher doses of the targeting ligand-bound L-NR, but not other forms of Res. In this
“transdifferentiation” program setup, the various forms of Res at 1 and 5 M had less browning
effects when compared to these same treatments given throughout the entire differentiation
process.
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Ppar mRNA expression (Fig 4.6.A)
Only L-NR at 10 M significantly induced Ppar mRNA expression greater than its vehicle
control and greater than the other forms of Res (Fig 4.6.A). Although NR and L-NR at 1 M
were greater than FR in inducing Ppar mRNA expression, they were not greater than their
vehicle controls (Fig 4.6.A).
Pgc1 mRNA expression (Fig 4.6.B)
Similar to the Ppar mRNA expression results, only L-NR at 10 M significantly induced
Pgc1 mRNA expression greater than its vehicle control and the other forms of Res (Fig 4.6.B).
Ucp1 mRNA expression (Fig 4.6.C)
Consistently, L-NR at 10 M significantly induced Ucp1 mRNA expression greater than its
vehicle control and the other forms of Res (Fig 4.6.C). Interestingly, only NR at 1 M
significantly induced Ucp1 mRNA expression greater than its vehicle control and the other forms
of Res (Fig 4.6.C).
Cd137 mRNA expression (Fig 4.6.D)
Unlike Ppar, Pgc1, and Ucp1 mRNA expression results, there was a greater response at
lower doses of Res in Cd137 mRNA gene expression. At 1 M, all tested forms of Res
significantly induced Cd137 mRNA expression greater than their vehicle controls; however, the
induction by NR and L-NR were greater than that of FR (Fig 4.6.D). At 5 M, FR and NR
significantly induced Cd137 mRNA expression greater than their vehicle controls; however, the
induction by NR and L-NR were greater than that of FR (Fig 4.6.D). At 10 M, NR and L-NR
significantly induced Cd137 mRNA expression greater than their respective vehicle controls and
that of FR (Fig 4.6.D).
Igfbp3 mRNA expression (Fig 4.6.E)
At 1 M, FR and NR significantly suppressed Igfbp3 mRNA expression compared to their
vehicle controls; however, NR and L-NR suppressed Igfbp3 mRNA expression to a greater
extent than that of FR (Fig 4.6.E). At 5 M, all tested forms of Res significantly suppressed
Igfbp3 mRNA expression, with NR and L-NR being greater at suppressing than FR (Fig 4.6.E).
At 10 M, only L-NR significantly suppressed Igfbp3 mRNA expression compared to its vehicle
control, with NR and L-NR being greater at suppressing than FR (Fig 4.6.E).
4.5.

DISCUSSION

Res is a stilbene phytoalexin and a popular natural compound often used experimentally in
the context of inflammation, cancer, and obesity and its comorbidities.29-35 Due to its rapid
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metabolism to lesser compounds which have been conjugated and marked for removal from the
body, studies utilizing the compound and measuring its effectiveness have been inconsistent,
making translating the results for human therapeutic use controversial.30, 35, 48-50 Nanoparticles
encapsulated with Res, which was shown to slow the release of Res which could help protect it
from quick metabolism and excretion, have been used to successfully induce browning in 3T3L1 cells.46 In this study, we have expanded upon this line of research by inserting a peptide
whose receptor has been found to be specific for SAT-ASCs onto the surface of the
nanoparticle encapsulated with Res in hopes to further enhance its targeting specificity and
effectiveness.
The results of this study have demonstrated that there is enhanced uptake of rhodamine by
using ligand-bound nanoparticles in DCN cells. The ligand-bound nanoparticles also enhanced
resveratrol-induced PPRE responsive reporter and PPAR transactivation in DCN cells. We
have confirmed protein expression of decorin in murine stromal cells from subcutaneous fat at
various stages of cell growth. Consistently, we show enhanced uptake of rhodamine by ligandbound nanoparticles in murine stromal cells. Lastly, our results indicate that the ASC-targeting
nanoparticles enhances Res’s efficiency to promote browning at lower, physiologically
achievable doses in murine stromal cells when treated throughout differentiation and also
promoted browning at higher doses when treating fully differentiated murine stromal cells.
Targeting nanoparticles does not further enhance resveratrol’s PPAR or PPRE activity
One of the many advantages of nanoparticles is to promote extended release of its’
contents.69 Among the various disadvantages of resveratrol, is its quick metabolism in vitro and
in vivo.30, 49, 70, 71 Although there is some evidence to suggest Res metabolites can have their
own beneficial effects, measuring outcomes can be difficult to assess, making the literature
controversial and difficult to translate.72, 73 Encapsulating resveratrol in nanoparticles to extend
the release, and therefore extending its stability and time of effectiveness, provides benefits
over longer periods of treatment time. As shown in Chapter III, FR is dramatically released
within the first 2 h of incubation and falls thereafter, whereas Res encapsulated in nanocarriers
displayed an extended and stable release over the course of a 10 h measurement, showing no
dramatic decrease as compared to FR.46 Therefore, when treatment times are shorter (1-24 h),
the advantages nanoparticles have over the free form of Res is limited.
In the case of reporter gene assays, whose time under treatment is within this limited timerange (15-18 h treatment), this diminished advantage of encapsulation or targeting of Res is
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observed. Results from a previous study showed that the various forms of Res were all better
than their vehicle control when treating 3T3-L1 cells which were transiently transfected with
PPRE-Luc; however, there were no differences among the forms of Res, showing no benefit of
the nanoparticle encapsulation within this brief treatment time period.46 It was also concluded
from that study that the formulation of the nanoparticles did not seem to affect the biological
capacity for Res to activate PPAR.46
The results of our study show that, similar to the previous results, neither forms of NPs
(ligand bound or not) displayed an advantage over FR in transactivating either PPRE-Luc nor
PPAR-Gal4-Luc in either the DCN nor CON cells (Fig 4.2.A-B). Although L-NR had greater
PPRE activation than both NR and FR, it was only found to be significant when compared to NR
in the DCN cells. There were no significant differences or benefits of NP or targeting seen in
the CON cells, which makes sense since this cell does not contain the receptor the ligand is
designed to target.
The literature on Res interaction with PPAR is controversial. There are many reports
showing that Res binds to and activates,44-46 binds to and inhibits,36, 39, 40, 43, 61, 74 or indirectly
inhibiting PPAR (i.e., via SIRT1).43 It is also suggested that the inhibition of PPAR
transcriptional activity by Res leads to suppression in adipogenesis.36, 39, 40, 43 Considering that
some PPAR-agonists can not only promote differentiation, but also lead to suppression of its
own expression.75-77 Therefore, it is critical to investigate PPAR activation by Res in addition to
PPAR and adipogenic gene expression. Furthermore, the literature demonstrating the inhibition
of adipogenesis by Res typically utilizes supraphysiological doses (i.e., 20-100 M) which are
unachievable in vivo.78, 79 This may again point towards the pleiotropic and biphasic effects of
Res; behaving like an agonist or activator at lower doses and an antagonist at higher doses.80
These discrepancies and misunderstandings make result-translatability and clinical utility of Res
controversial.
Decorin is expressed in murine primary stromal cells at various stages of confluence, which is
reflected in enhanced uptake of targeting-ligand-bound nanoparticle
The term ‘DCN’ was first coined and discovered by the Kolonin group, which described the
membrane-bound N-terminally truncated isoform of DCN, DCN, to be specifically and solely
expressed by WAT ASCs.58 The authors also suggested that there was a loss of DCN cell
surface expression when ASCs are plated in plastic culture-conditions as quickly as over-
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night.58 However, there remained the question of whether the secreted protein isoform
expression returns at various stages of confluence or how its expression might change during
differentiation of stromal cells.
Our data suggests that, although there is a loss of DCN expression in freshly isolated cells
plated in plastic conditions for about 2 days (samples collected when 70-80% confluent), the
expression comes back when cell-to-cell contact is re-established (100% confluent) and in the
beginning of differentiation (3-Day Diff). Recently, it has been established that human ASCs
also express DCN.81 We also found that, similar to the murine ASCs, human primary cells also
have an increase in DCN expression upon 100% confluence and in the beginning of
differentiation, but that this expression begins to fall off further into differentiation (data not
shown). Therefore, our data does not contradict the Kolonin group’s data, rather, it further
corroborates that this ECM-associated protein is specific to ASC’s. These results may suggest
that DCN expression requires cell-to-cell contact and reaches a maximal expression after postmitotic expansion, whereas end-of-term differentiating and fully mature stromal cells begin to
lose DCN expression.
After expression was confirmed, the targeting capacity and uptake of nanoparticles which
have the targeting ligand bound to the surface was tested using 3T3-L1 over-expressing this
receptor (DCN cells) as well as murine primary stromal cells at various stages of confluence.
Labeling the NPs with Rhodamine, a tracer dye that can be visualized using fluorescence
confocal microscopy, is used to represent cellular uptake of nanocarrier contents. Fluorescence
confocal microscopy determined significantly enhanced uptake of Rhoda-labeled NPs with the
ligand bound (L-Rhod-nano) by the DCN cells and mSVF at 100% confluence and even moreso in the 3-Day Diff sets of cells. Interestingly, the L-Rhod-nano uptake reflected the DCN
expression patterns in mSVF cells. The 3D z-stack images further demonstrate that Rhodamine,
which is representative of Res, is being taken up into the cells and are not just attached to the
cell-surface.
Ligand-bound nanoparticles encapsulated with resveratrol promote browning of murine primary
adipocytes
After targeting capacity, efficiency, and uptake of ligand-bound NPs was confirmed, murine
primary stromal cells were differentiated using two different experimental approaches: complete
and transdifferentiation programs. The literature suggests differential effects of Res on
adipogenesis based on dose and timing.70 These effects range from promotion or suppression
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of adipogenesis when treated throughout the differentiation process (i.e., complete program) as
well as promote lipolysis, apoptosis, or possibly browning when treating fully mature adipocytes
(i.e., transdifferentiation program). Therefore, we tested the effects of timing and dose using free
and targeting or non-targeting NP-Res using murine primary stromal cells.
Via several mechanisms, Res is shown to increase cAMP levels in cells (i.e., as a
phosphodiesterase inhibitor,31, 82 and through SIRT1-AMPK-PGC1 axis83-86). In vitro
differentiation of several adipocyte models, especially 3T3-L1 cells, have a cAMP-dependent
induction of differentiation, therefore, Res should lead to enhanced differentiation when
treatments start during confluent preadipocyte stage.87 However, these effects may be time and
dose-dependent. It has been previously shown that 10 M of Res can promote differentiation
and browning of 3T3-L1 adipocytes45, 46 as well as induce browning of mSVF.39, 88 However,
much of the literature utilizing higher, supraphysiological concentrations of Res have shown
inhibition of adipogenesis.33, 39, 40, 43, 61, 74 Unfortunately, many groups have not utilized lower,
physiologically relevant doses, perhaps due to the endorsement that “more is better” and for
fear of negative results.
The results of our study demonstrate that the ligand-bound NP enhances the effectiveness
of Res to induce browning, as shown by Ucp1, Pgc1, and Cd137 mRNA expression, of mSVF
using concentrations as low as 1 M as compared to FR and NR at the same concentration.
However, the advantage of the ASC targeting peptide is diminished at the higher dose of Res at
5 M, when NR is just as successful as the L-NR in inducing Ucp1, and Cd137 mRNA
expression, but both forms of NP are more successful than FR.
Interestingly, the cell’s health status strongly influences the response to Res when treated
throughout differentiation. 3T3-L1 cells treated with as much as 20 M of free-Res and two other
nanoparticle forms encapsulated with Res did not inhibit differentiation or adipogenesis.46
However, when freshly isolated murine primary stromal cells displayed signs of stress by not
responding to a well-characterized differentiation program, Res treated throughout the
differentiation process (5-10 M) led to severe hinderance in differentiation and adipogenesis
(data not shown). On the other hand, when freshly isolated murine primary stromal cells are
healthier and responding to the differentiation program, Res treated throughout the same
differentiation process (5-10 M) did not hinder differentiation or adipogenesis (data not shown).
Therefore, it is imperative to ensure proper health and differentiation when using bioactive
molecules and phytochemicals, as to not lead false conclusions.
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Studies using Res to treat fully mature adipocytes have shown increased lipolysis43 as well
as inducing apoptosis.78, 79 There still seems to be a debate of whether there is the possibility
that fully differentiated white adipocytes could “transdifferentiate” into brown-like adipocytes or
whether beige adipocyte formation is limited to de novo synthesis.89, 90 However, our results
demonstrate that there is a possibility for fully mature adipocytes to become more “brown-like”
using some-what higher doses of Res (10 M) when encapsulated in NPs with the targeting
ligand bound. It remains to be determined whether lower doses of L-NR with longer treatment
time would be effective in inducing browning in these fully mature adipocytes
4.6.

CONCLUSIONS AND LIMITATIONS

In conclusion, the results of this study reveal that freshly isolated murine primary stromal
cells regain DCN expression when confluent and in the beginning of differentiation, and that
attaching a peptide specific for DCN to the surface of NPs significantly enhances uptake of
NPs and their contents. The targeting ligand proved especially beneficial in the biological
response in mSVF, when lower, physiological doses of Res successfully induced browning in
these cells as shown by Ppar, Ucp1, Pgc1, Cd137, and Igfbp3 mRNA expression when
treated throughout the differentiation process.
Although compelling, the results of this study are preliminary, and require further
experimentation to substantiate enhanced browning phenotype and functionality of L-NR treated
mSVF adipocytes. This can be done by using experiments such as western blotting to confirm
translation of browning genes into protein and Seahorse assay to measure oxygen consumption
rate and proton leak, among other functional mitochondrial measures. Nonetheless, the results
of this study lay solid foundation on which the convincing argument can be made for the
therapeutic potential of ASC-targeting NPs encapsulated with Res used for the treatment and
prevention of obesity.
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4.8.

APPENDIX

Figure 4.1. Greater rhodamine uptake of ligand-bound nanoparticles by DCN cells.
DCN preadipocytes were evenly seeded in 24-well plate (1x105 cells/well) onto sterile
coverslips overnight and treated with Rhod-labeled nano-carriers without or with the targetingligand (Rhod-nano and L-Rhod-nano, respectively) at 37C for 2 h. Cells were then rinsed,
fixed, rinsed, and stained with DAPI for 5 min. After another rinsing step, cells were mounted on
disposable microscope slides and imaged using Leica SP8 White Light Laser Confocal System.
Rhodamine uptake, shown in red, was detected using the white-light laser set at  561nm.
DAPI-stained nuclei, shown in blue, was detected using the “405 laser”. (A) Fluorescent images
of DCN cells treated without (image to left) or with (image to right) the targeting-ligand-bound
NP. DAPI and Rhod filters are merged for this view; all settings for images were the same for
equal comparison. The scale bars represent 25 m. (B) Rhodamine uptake from fluorescent
images quantified. Data shown here represent at least 3 separate experiments each having at
least 3 different areas of cells imaged and quantified, areas were chosen at random. DCN cells
treated with Rhod-nano is set at fold-1. (C) Z-stack confocal 3D-projections with zoomed in
image, demonstrating NP getting into the cell. The scale bars represent 20 m. Statistical
significance is indicated by *, **, ***, p<0.05, p<0.01, and p<0.001, respectively.
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Figure 4.2. Enhanced resveratrol-induced PPRE and PPAR transactivation by ligandbound nanoparticles in DCN cells.
DCN and its scrambled control cell line (Control) preadipocytes were transiently transfected
with (A) PPAR-Gal4-Luc or (B) PPAR-Gal4-Luc and -gal for 24 h, then treated with free-Res
(FR) or its Kolliphor vehicle Control (KC), Nanoparticle encapsulated with Res (NR) or its Void
control (NV), or Ligand-bound Nanoparticle encapsulated with Res (L-NR) or its Ligand-bound
Void control (L-NV) at 10 M, or Rosi (1 M) or nothing (-) for an additional 18 h. Luciferase
activity was normalized to -gal activity, the non-treated (-) “Control Cells” sample was set at
fold-1. (*: p<0.05; **: p<0.01; ***: p<0.001) indicates significant difference between the treatment
and its vehicle control within the same cell line. (#: p<0.05; ##: p<0.01; ###: p<0.001) indicates
significant difference of the same treatment between Control and DCN cells. (: p<0.05)
indicates significant difference between types of Res within the same cell line.
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Figure 4.3. Detection of decorin protein expression in murine stromal cells from
subcutaneous fat.
Murine primary stromal cells from 10-12 week old male C57Bl/J6 mice were isolated from the
inguinal subcutaneous fat tissue, and the stromal vascular fraction (SVF) was pelleted,
collected, and plated on 60 mm dishes. In addition to the SVF pellet, samples were collected
when cells reached 70-80% confluence, 100% confluence, and three days into differentiation (3Day Diff). (A) Immunoblot of total-cell-lysate of various states of murine stromal cells probed
with DCN antibody, showing expression of decorin protein at various states of glycanation
(gDcn = glycanated DCN, ngDcn = nonglycanated DCN, DCN = 40 kDa protein lacking the
dermatan/chondroitin sulfate glycosaminoglycan chain) and their densitometry (B).
Densitometry of each protein was normalized to the loading control, Tubulin, with the SVF Pellet
sample set as fold-1. One-Way ANOVA was performed followed by multiple comparison tests
with Student-Newman-Kewls method for confluence-state-dependent expression differences. (*:
p<0.05) indicates significant difference of coated vs non-coated within the same cell-confluence
group. (#: p<0.05) indicates significant difference of the non-coated (-) from each cellconfluence group compared to SVF Pellet. (: p<0.001) indicates significant difference
between the 3-Day Diff (-) (non-coated sample) compared to the 70-80% confluent group’s (-)
(non-coated sample). (: p<0.01; : p<0.001) indicates significant difference between
the 3-Day Diff (-) (non-coated sample) compared to the 100% confluent group’s (-) (non-coated
sample).
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Figure 4.4. Enhanced uptake of ligand-bound nanoparticles by murine stromal cells.
mSVF from 10-12 week old male C57Bl/J6 mice were isolated from the inguinal subcutaneous
fat tissue, and the SVF was pelleted, collected, and plated on 24-well plates onto sterile
coverslips. Cells were seeded so that they reached 70-80% confluence, 100% confluence, and
three days into differentiation (3-Day Diff) at time of treatment. Cells were treated with Rhodlabeled nano-carriers without or with the targeting-ligand (Rhod-nano and L-Rhod-nano,
respectively) at 37C for 2 h. Cells were then rinsed, fixed, and stained with DAPI for 5 min.
Imaging was completed using Leica SP8 White Light Laser Confocal System. Rhodamine
uptake, shown in red, was detected using the white-light laser set at  561nm. DAPI-stained
nuclei, shown in blue, was detected using the “405 laser”. (A). Fluorescent images of murine
primary cells at various states of confluence, cells treated without (image to left) or with (image
to right) the targeting-ligand-bound NP. DAPI and Rhod filters are merged for this view; all
settings for images were the same for equal comparison. The scale bars represent 25 m. (B)
Rhodamine uptake from fluorescent images quantified; data shown represents at least 3
separate experiments each having at least 3 different areas of cells imaged and quantified,
areas were chosen at random. mSVF at 70-80% confluence treated with Rhod-nano is set at
fold-1. (C) Z-stack confocal 3D-projections with zoomed in image, demonstrating NP getting into
the cell. The scale bars represent 20 m. Statistical significance is indicated by * p<0.05.
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Figure 4.5. ASC-targeting nanoparticles enhance resveratrol’s efficiency to promote
browning at lower, physiologically relevant doses.
Murine primary stromal cells from 10-12 week old male C57Bl/J6 mice were isolated from the
inguinal subcutaneous fat tissue, and the SVF was pelleted, collected, and plated in 6-well
plates. Confluent mSVF were induced to differentiate in the presence free-Res (FR) or its
Kolliphor vehicle Control (KC), Nanoparticle encapsulated with Res (NR) or its Void control
(NV), or Ligand-bound Nanoparticle encapsulated with Res (L-NR) or its Ligand-bound Void
control (L-NV) at 1, 5, or 10 M, or Rosi (1 M) or nothing (-) for 10 days. Media was changed
with freshly prepared Res and NPs every 2-3 days, on day 10 cells were terminated for further
analysis. Relative mRNA gene expression (A-C) of brown (Ppar, Pgc1, Ucp1), (D) beige
(Cd137), and (E) white (Igfbp3), were normalized to the housekeeping gene, 36b4. Each graph
is expressed as fold-1 of that of the (-) sample for each gene. One-Way ANOVA was performed
followed by multiple comparison tests with Student-Newman-Kewls method for treatment vs its
vehicle (statistical significance is indicated by *, **, ***, p<0.05, p<0.01, and p<0.001,
respectively), as well as types of Res within its concentration group (statistical significance is
indicated with a bar adorned by #, ##, ###, p<0.05, p<0.01, and p<0.001, respectively; longer
vertical lines assign significance compared to the shorter vertical lines).
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Figure 4.6. Ligand-bound nanoparticles encapsulated with resveratrol promote browning
at higher doses when treating fully differentiated murine stromal cells.
Murine primary stromal cells from 10-12 week old male C57Bl/J6 mice were isolated from the
inguinal subcutaneous fat tissue, and the SVF was pelleted, collected, and plated in 6-well
plates. Confluent mSVF were induced to differentiate as described for 7 days, media was
changed every 2-3 days without treatment. On day 7, fully differentiated cells were treated with
freshly prepared free-Res (FR) or its Kolliphor vehicle Control (KC), Nanoparticle encapsulated
with Res (NR) or its Void control (NV), or Ligand-bound Nanoparticle encapsulated with Res (LNR) or its Ligand-bound Void control (L-NV) at 1, 5, or 10 M, or Rosi (1 M) or nothing (-) for 3
days. On day 10 cells were terminated for further analysis. Relative mRNA gene expression (AC) of brown (Ppar, Pgc1, Ucp1), (D) beige (Cd137), and (E) white (Igfbp3), were normalized
to the housekeeping gene, 36b4. Each graph is expressed as fold-1 of that of the (-) sample for
each gene. One-Way ANOVA was performed followed by multiple comparison tests with
Student-Newman-Kewls method for treatment vs its vehicle (statistical significance is indicated
by *, **, ***, p<0.05, p<0.01, and p<0.001, respectively), as well as types of Res within its
concentration group (statistical significance is indicated with a bar adorned by #, ##, ###,
p<0.05, p<0.01, and p<0.001, respectively; longer vertical lines assign significance compared to
the shorter vertical lines).
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CHAPTER V:

INDOMETHACIN PROMOTES BROWNING AND BROWN
ADIPOGENESIS IN BOTH MURINE AND HUMAN FAT CELLS

146

5.1 ABSTRACT
Indomethacin (Indo), a non-steroidal anti-inflammatory drug, has been shown to promote
brown adipogenesis in murine brown fat cells and in brown adipose tissue in mice; however, it is
unclear whether Indo can induce browning of white adipocytes in murine or human cell models.
To bridge the gap, this study investigated the effects of increasing concentrations of Indo on
murine 3T3-L1, and human primary subcutaneous and brown adipocytes. Indo dosedependently enhanced 3T3-L1 adipocyte differentiation and upregulated both mRNA and
protein expression of brown and beige adipocyte markers, while simultaneously suppressing
white-adipocyte-specific marker mRNA gene expression. mRNA and protein expression of
mitochondrial biogenesis and structural genes were dose-dependently enhanced in Indo treated
3T3-L1 adipocytes; which was accompanied by augmented mitochondrial DNA, enhanced
oxygen consumption rate, proton leak, and maximal and spare respiratory capacity. Dosedependent transactivation of peroxisome proliferator-activated receptor gamma (PPAR)
confirmed Indo’s PPAR-agonist activity in 3T3-L1 cells. Knockdown of PPAR significantly
attenuated Indo activities in selective browning genes, confirming a receptor dependence of
these effects. Moreover, Indo enhanced mRNA and protein expression of brown markers in
primary stromal cells derived from human subcutaneous white adipose tissue. Interestingly,
Indo induced differential effects on individual PPAR isoforms with significant dose-dependent
induction of PPAR2 and suppression of PPAR1. Finally, Indo also promoted brown
adipogenesis in a human brown cell line. Taken together, these results demonstrate Indo to be
a potent thermogenic compound in both murine and human fat cells, showing a potential to be
used as a therapeutic agent for obesity treatment and prevention.
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5.2

INTRODUCTION
Energy-dense diets and sedentary lifestyles are strong contributing factors to the still-

growing obesity epidemic faced in the United States and worldwide.1-3 Obesity-related
conditions such as diabetes, heart disease, and cancer are among the leading causes of
preventable deaths in America.3 Advocating for improved diet and lifestyle factors while also
increasing physical activity is always the first line of treatment. However, these heavily funded
pursuits are difficult to maintain and may not be feasible for ill or disabled individuals. Thus, it is
imperative to develop novel strategies for obesity treatment and prevention, while also
promoting increased energy utilization via enhanced thermogenesis is an alluring therapeutic
avenue.
Promoting brown adipogenesis of brown adipose tissue (BAT) and browning of white
adipose tissue (WAT) are considered novel approaches to combat obesity and associated
conditions. BAT is a highly thermogenic tissue, with the potential to significantly contribute to
total energy expenditure.4, 5 Targeting treatments to enhance BAT activity, mass, and function
can be an effective attempt to restore energy balance in obesity, promote fat loss, and improve
the metabolic profile.3-6 BAT is a highly vascularized, mitochondria-enriched tissue that rapidly
burns fat, producing heat in lieu of fuel via uncoupling protein 1 (UCP1)-mediated dissociation of
the proton gradient.4, 6 Peroxisome proliferator-activated receptor gamma (PPAR) is
upregulated in brown fat and its activation triggers a series of downstream signaling events
causing increased UCP1 and PPAR-coactivator 1-alpha (PGC1α) expression, resulting in
increased thermogenesis and mitochondrial biogenesis which ultimately leads to increased
energy expenditure.7
Similar to brown adipocytes, beige or brite (“brown in white”) adipocytes generated by
browning are characterized by their multilocular lipid droplet morphology, larger volume of
functional mitochondria, and expression of brown-fat marker genes such as UCP1, PPAR,
PGC1, PR Domain-containing 16 (PRDM16), and cell death inducing DFFA like effector a
(CIDEA).4-6 These UCP1 expressing adipocytes are formed within WAT in response to cold
exposure, β-adrenergic receptor (β-AR) agonists (e.g., norepinephrine, isoproterenol), and
some nutritional and pharmacological agents.4, 8, 9 Initial screening of various pharmacological
agents for their potential to induce browning and brown adipogenic effects revealed that a
variety of non-steroidal anti-inflammatory drugs (NSAIDs) may be promising, of these, however,
indomethacin stuck out as a strong contender.
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Indomethacin (Indo) is a non-selective cyclooxygenase (COX)-1/COX-2 inhibitor which
blocks arachidonic acid from entering the catalytic site, thus suppressing the production of proinflammatory metabolites.10 Indo is a well-studied FDA approved drug used to treat and relieve
inflammatory states of the body such as fever, pain, swelling, and stiffness, in addition to more
serious disease states including pleurisy and pericarditis.10, 11 Several NSAIDs, including Indo,
have been shown to have off-target effects, such as activation of PPAR.12-14 However, Indo is
distinct from other NSAIDs in that it acts as a strong partial PPAR agonist, having one of the
greatest abilities to bind and activate PPAR similar to that of the well-known PPAR-agonist,
Rosiglitazone (Rosi).12, 13 Rosi and other thiazolidinedione (TZD) analogs have been and still
are used as insulin-sensitizing drugs in the treatment of Type 2 Diabetes Mellitus (T2DM).15
Rosi is commonly used in cell culture to promote adipogenesis as well as induce browning of
white adipocytes.16-19 It is postulated that this browning effect occurs as a result of this PPARagonist action.19, 20 Therefore, having ability to act as a strong partial PPAR agonist makes Indo
of particular interest in the hunt for browning agents.
It has been previously demonstrated that Indo promotes brown adipogenesis in murine
brown adipocytes in vitro as well as in vivo in the BAT of C57Bl/6J mice when Indo was
delivered via osmotic-pumps.21 However, it is not clear whether Indo induces browning of white
adipocytes or whether it exhibits similar effects in human fat cells. Therefore, to bridge the gap,
the effects of Indo on murine white fat cells and human white and brown fat cells are
investigated here.
5.3

MATERIALS AND METHODS

5.3.1

Reagents

Dexamethasone (Dex), 3-Isobutyl-L-methylxanthine (IBMX), insulin, triiodothyronine (T3),
rosiglitazone (Rosi), and isoproterenol (ISO) were purchased from Sigma-Aldrich (St. Louis,
MO). Indo was purchased from Cayman Chemical (Ann Arbor, MI). Dulbecco's modified Eagle’s
medium (DMEM) and Calf serum (CS) was purchased from Hyclone (Logan, UT) and fetal
bovine serum (FBS) from Atlanta Biologicals (Flowery Branch, GA). Penicillin and streptomycin
(P/S) were purchased from Gibco by Life Technologies (Burlington, ONT). UCP1 and -Actin
antibody was purchased from Sigma-Aldrich (St. Louis, MO), PGC1 from Millipore Sigma
(Darmstadt, Germany), Perilipin, VDAC, CYTC, and MNSOD from Santa Cruz (Dallas, TX), and
ERK1/2, PPAR, -AR3, and anti-rabbit horse-radish peroxidase (HRP)-conjugated antibody
were from Cell Signaling Technology (Danvers, MA).
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5.3.2

Cell culture, induction of adipocyte differentiation, and treatments

5.3.2.1 3T3-L1 preadipocyte maintenance and differentiation
3T3-L1 differentiation was performed as previously described.22 Murine 3T3-L1 fibroblasts
(ATCC, Manassas, VA) were grown in DMEM containing 10% CS and 1% P/S in a 5% CO2,
37°C environment until they reached confluence. Fully confluent cells were induced to
differentiate with DMEM containing 10% FBS, 1 μM Dex, 0.5 mM IBMX, and 10 μg/mL insulin
for 3 days. The differentiating cells were then maintained with DMEM containing 10% FBS and
10 μg/mL insulin for additional two days until day 5 when the media was changed to DMEM
containing only 10% FBS until day 7. On day 7 the cells were stimulated with -AR-agonist, ISO
(1 μM), or the vehicle control (DMSO) for 6 h (for mRNA and mitochondrial DNA (mtDNA)
analysis) or 24 h (for western blot). Indo was added fresh during each change of the media at
concentrations of 0, 2, 5, 10, 20, and 50 μM. PPAR-agonist, Rosi (1 μM), was used as the
positive control.
5.3.2.2 Human primary subcutaneous adipocytes
Human primary subcutaneous cell pools (HPsubQ) originating from 6 female obese, nondiabetic donors (Lot: SL0031) and their media were obtained from ZenBio (Research Triangle
Park, NC). Cells were maintained and differentiated for 14 days, according to the
manufacturer’s instructions. Indo was added fresh during each change of the media at
concentrations of 0, 2, 5, 10, and 20 μM. Rosi (1 μM) was used as the positive control.
5.3.2.3 Human brown cell line differentiation
The human brown cell line (HBr) was a gift from Dr. Yu-hua Tseng at Joslin Diabetes
Center. HBr preadipocytes were grown in DMEM containing 10% FBS and 1% P/S in a 5% CO2,
37°C environment until they reached confluence. Fully confluent cells were induced to
differentiate with DMEM containing 10% FBS, 0.5 mM IBMX, 33 μM biotin, 17 μM pantothenate,
0.5 μM insulin, 0.1 μM Dex, and 2 nM T3 for 4 weeks. Treatments were added fresh to each
change of media, which was changed every 2-3 days for a total of 21 days prior to lysis for
further analysis.
5.3.3

Cell viability

Cell viability was measured via the colorimetric MTT (yellow tetrazolium MTT (3-(4, 5dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide) metabolic activity assay (RPI, Mt
Prospect, IL). 3T3-L1 cells were seeded in 48-well plates so they would be 50-70% confluent
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the following day. The cells were then treated with varying concentrations of Indo (0, 2, 5, 10,
20, and 50 μM) for 24 h. At 24 h MTT reagent was added to cell media in a 1:5 ratio in dark
conditions for a 3 h incubation at 37°C. To quantify the insoluble formazan, the media was
removed, and the formazan was eluted in 60% isopropanol. After rocking the cells with
isopropanol for 5 min, a portion of the formazan-solution was added to a clear 96-well plate
where absorbance was measured at 570 nm using GloMax-Multi Detection System (Promega,
Madison, WI). These results were normalized with cell lysate total protein concentration using
BCA Protein Assay Kit (ThermoFisher Scientific, Waltham, MA).
5.3.4

ORO staining and quantification

Lipid accumulation in differentiated 3T3-L1 cells was assessed using Oil Red O (ORO)
staining as previously described.22 Briefly, on day 7 of differentiation, mature 3T3-L1 adipocytes
were imaged prior to fixing with 4% paraformaldehyde overnight. Fixed cells were then rinsed
with deionized (DI) water and subsequently stained with 60% ORO solution diluted with
isopropanol for 20 min, which was then followed by solution removal and further rinsing with DI
water. Images of stained cells were obtained via an integrated digital camera linked to a
Micromaster inverted phase contrast microscope (Thermo Fisher Scientific). The stain uptake
by lipids was quantified by eluting ORO stain with 100% isopropanol for 5 min, and absorbance
was measured at 500 nm using GloMax-Multi Detection System (Promega, Madison, WI).
These results were normalized with cell lysate total protein concentration using BCA Protein
Assay Kit (ThermoFisher Scientific, Waltham, MA).
5.3.5

RNA and DNA isolation and semi-quantitative RT-PCR analysis

RNA and DNA isolation and quantification were performed as previously described.21, 22
Briefly, total RNA and DNA was prepared and isolated using TRI reagent (Molecular Research
Center, Cincinnati, OH) following the manufacturer's instructions. NanoDrop ND-1000
Spectrophotometer (NanoDrop Technologies, Wilmington, DE) was used to quantify total RNA
and DNA abundance. After RNA isolation, reverse transcription was carried out using High
Capacity cDNA Reverse Transcription kit (Thermo Scientific, Pittsburgh, PA) following the
manufacturer’s instructions. Target genes and the housekeeping gene, 36b4, mRNA expression
was then measured quantitatively using Power Up SYBR Green Master Mix following
manufacturers protocol (Applied Biosystems, Austin, TX). Similarly, mtDNA abundance was
measured via PCR amplification of mtDNA marker CoxIIa and subsequently normalized to the
mtDNA housekeeping gene, 18S. Primer sequences are shown in Table 5.1-5.3 (all tables and

151

figures for Chapter V are located in 5.7. Appendix). PCR reactions were run in a 96-well format
using an ABI 7300HT instrument and the cycle number (Ct) was obtained for each reaction.
Relative gene expression was calculated using the 2(-ΔΔCt) method, which normalizes against
the housekeeping genes and then converted to fold.
5.3.6

Western blot analysis

Western blot analysis was performed as previously described.21 Briefly, protein extraction
was completed using ice-cold PBS with phosphatase inhibitor cocktail (ThermoFisher Scientific,
Waltham, MA) to rinse the cells and cell lysate was prepared using 1x RIPA buffer (Cell
Signaling, Danvers, MA) with freshly added PMSF (Sigma). Protein concentrations were
determined by BCA Protein Assay kit (ThermoFisher Scientific, Waltham, MA). Total cell lysates
were subjected to electrophoresis on 10-12% SDS-PAGE gel and transferred to polyvinylidene
difluoride membrane (Bio-Rad, Hercules, CA). The membrane was blocked in 20 mM Tris·HCl,
137 mM NaCl, and 0.1% Tween 20 (tris-buffered saline with tween 20; TBST at pH 7.4)
containing 5% nonfat milk. The membrane incubated with diluted primary antibodies with
varying times, followed by incubation with diluted secondary antibody. Washing steps between
antibody incubations included TBST on rocker four times for 10 min. Each membrane was then
incubated with SuperSignal West Pico Chemiluminescent Substrate (ThermoFisher Scientific,
Waltham, MA) for 5 min. Excess substrate was removed, and protein expression was detected
using Odyssey® FC imaging system (Licor Biosciences, Lincoln, NE) or a x-ray film processor
(Konica Corporation, Taiwan) utilizing HyBlot CL Autoradiography Film (Denville, Holliston, MA)
which was exposed to the membrane for varying times. Membranes were re-probed using
stripping buffer (62.5 mM Tris-HCl, 2 % SDS, and 100 mM 2-mercaptoethanol) at 50°C for 5-10
min. The signal was quantified by densitometry using Odyssey® FC imaging system.
5.3.7

Flux experiment

Seahorse XF24 Analyzer (Agilent Technologies, Santa Clara, CA) was used to measure
changes in oxygen consumption rate (OCR) in 3T3-L1 adipocytes. 3T3-L1 preadipocytes were
seeded in a 6-well format and differentiated in the presence of indicated treatments. On day 6,
cells were re-seeded (at an identical cell number per well) into XF24 Microplates (Agilent
Technologies, Santa Clara, CA) in maintenance media only (no treatment was added) for 24 h.
On day 7, cells were treated with ISO (1 M) without Indo or Rosi treatment for an additional 24
h. In preparation for cells to undergo mitochondrial stress tests, cells were washed 3 times and
incubated with sterile-filtered 37C XF-Assay DMEM media with 1 mM sodium pyruvate, 2 mM
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Glutamax, 10 mM D-glucose, and 2% BSA (pH 7.4 +/- 0.1) in 37C non-CO2 incubator for 1 h.
During this incubation, mitochondrial stress test chemical compound injections were prepared
using XF assay buffer in the following manner [final concentration]: Port A = Oligomycin [1.25
M], Port B = Carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone (FCCP) [5 M], and Port
C = Rotenone and Antimycin [1 M]. The diluted compounds were loaded into their respective
ports in a pre-hydrated sensor cartridge. Following sensor cartridge calibration, the calibration
plate was replaced with the experimental cell-plate and began the assay using company
recommended template design. Respiration calculations were performed as previously
described.23, 24
5.3.8

Transfection and reporter gene assays

Reporter gene assays were performed as previously described.21, 22, 25 Briefly, PPAR
transactivation reporters consist of murine PPAR or PPARα ligand binding domain (LBD) fused
with a Gal4 DNA binding domain (DBD) (mPPAR-Gal4 or mPPARα-Gal4) and a reporter
construct comprised of an upstream activating sequence (UAS) thymidine kinase-linked
luciferase, 4xUAS-TK-luc. 3T3-L1 preadipocytes were seeded one day prior to transfection in a
manner so that cells were approximately 50-70% confluence the day of treatment (1x104 per
well in 48-well format). The preadipocytes were then transiently transfected with mPPARα-Gal4
or mPPAR-Gal4, 4xUAS-TK-Luc (hereon referred to as PPAR or PPAR-Gal4-Luc), and galactosidase (-gal) control plasmid using Lipofectamine 3000 and PLUS Reagent
(ThermoFisher Scientific, Waltham, MA) for 24 h. The cells were then subjected to Indo or the
controls for an additional 15-18 h. Cell lysate was prepared using Reporter Lysis Buffer
(Promega, Madison, WI) with Luciferase substrate and -gal substrate. Luciferase activity and
-gal were quantified using luminescence or absorbance respectively by GloMax-Multi
Detection System (Promega, Madison, WI).
5.3.9

Lentiviral shRNA particle infection generating stably-infected cell pools

PPAR knockdown (PPAR-KD) and scrambled non-targeting control (SCR) in 3T3-L1
stable-cell lines were generated as previously described.25 Briefly, 3T3-L1 preadipocytes were
seeded at 50% confluence in 6-well plates, and subsequently infected with MISSION shRNA
lentiviral transduction particles for PPAR or control (Sigma Aldrich) according to manufacturer’s
instructions. Puromycin (2 g/mL) was used to select stably infected cells.
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5.3.10 Statistical analysis
Data in figures were presented as mean ± SEM. Experiments were performed at least three
times with triplicates. SigmaPlot 14 (Systat Software, Inc) was used to perform statistical
analysis. T-tests, one-way ANOVA, mixed model ANOVA, or ANOVA with repeated measures
was performed followed by post hoc comparison tests with Student-Newman-Keuls method or
Tukey method to determine the differences within and between treatment groups. The level of
significance was set at p<0.05.
5.4

RESULTS

5.4.1

Indomethacin is not cytotoxic to 3T3-L1 preadipocytes

To eliminate the possibility of potentially harmful effects concerning the multi-target chemical
compound, Indo (Fig 5.1.A), 3T3-L1 preadipocytes were treated with increasing concentrations
(2, 5, 10, 20, and 50 M) of Indo for 24 h as described above. Utilizing MTT assays, it was
determined that there were no significant changes in cell viability, indicating that the range of
concentrations of Indo used is not cytotoxic to 3T3-L1 cells, justifying further experimentation
(Fig 5.1.B).
5.4.2

Differentiation of 3T3-L1 adipocytes is augmented by indomethacin treatment

Treating 3T3-L1 cells with Indo throughout the differentiation process led to a significant
increase in differentiation, as demonstrated by increased lipid accumulation and induction of
differentiation markers. Indo dose-dependently promoted lipid accumulation as shown by ORO
staining, which is shown both visually (Fig 5.1.C) and quantitatively (Fig 5.1.D). In addition to
lipid accumulation, adipocyte-differentiation markers were assessed in mature 3T3-L1 cells,
which also showed significant induction in CCAAT enhancer binding protein alpha (C/ebp) and
fatty acid binding protein-4 (Fabp4) mRNA expression, while fatty acid synthase (Fasn) mRNA
expression was downregulated (Fig 5.1.E). Differentiation markers, Perilipin-1 (PLIN1) and
FABP4, protein expression were also significantly induced (Fig 5.1.F-G).
5.4.3

Induction of browning markers mRNA expression in 3T3-L1 adipocytes by

indomethacin
In addition to augmented differentiation, Indo-treated mature 3T3-L1 adipocytes also had
increased expression of brown-fat, beige-fat, and mitochondrial markers and decreased
expression of white adipocyte-specific markers. Master adipocyte differentiation marker, Ppar
mRNA expression was not changed by Indo treatment; however, under ISO stimulated
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conditions, Rosi downregulated Ppar mRNA expression (Fig 5.2.A). mRNA expression of
Ucp1, the keystone marker for browning and brown adipogenesis, was dose-dependently
induced by Indo treatment, which was further augmented by ISO stimulation (Fig 5.2.B). Brownenriched marker, Cidea, also showed significant induction by both Indo and Rosi treatment (Fig
5.2.C). Indo treatment also led to a dose-dependent suppression of white-adipocyte specific
marker, Insulin Growth Factor Binding Protein 3 (Igfbp3), both in basal and ISO stimulated
conditions, with no additional suppression by ISO (Fig 5.2.D). Beige specific marker, Tumor
Necrosis Factor Receptor Superfamily, Member 9 (Cd137), also was induced by Indo treatment
but did not have similar dose-dependent relationships as seen with other markers (Fig 5.2.E).
Mitochondrial biogenesis marker, Pgc1 mRNA is significantly induced by Indo treatment
(Fig 5.2.F). mRNA expression of nuclear respiratory factor-1 (Nrf1), a gene encoding for a
transcription factor to activate genes required for mitochondrial DNA transcription and
replication, was also significantly induced by Indo treatment (Fig 5.2.G). Indo also led to a
significant dose-dependent increase in cytochrome c oxidase subunit IV isoform 1 (Cox4a)
mRNA expression, which as an important structural component of the electron transport chain,
further demonstrating enhanced mitochondrial biogenesis (Fig 5.2.H). These results were
reinforced by quantifying the relative abundance of mtDNA, which was also significantly
increased by Indo treatment (Fig 5.2.I).
5.4.4

PPAR-agonist suppresses PPAR expression and diminishes response to -

adrenergic receptor agonist in 3T3-L1 adipocytes
Indo treated 3T3-L1 adipocytes also significantly induced UCP1 protein expression under
basal conditions; however, the augmentation seen in mRNA expression by ISO stimulation (Fig
5.2.B) was not reflected in the protein expression (Fig 5.3.A-B). Treatment of 3T3-L1 adipocytes
with Indo and Rosi throughout the entire differentiation process revealed a significant
suppression of PPAR protein expression (Fig 5.3.A-B). This also led to a dose-dependent
decrease in the -3 adrenergic receptor (Adrb3) mRNA expression (Fig 5.3.C) which was
further suppressed upon ISO stimulation (Fig 5.3.C). Although not in such a uniform manner,
ADRB3 protein expression was also suppressed (Fig 5.3.D-E). Removal of Indo and Rosi 24 h
prior to ISO stimulation successfully recovers the expression of both PPAR and ADRB3 (Fig
5.4.A-B).
Moreover, removal of Indo and Rosi 24 h prior to the ISO stimulation also led to increased
protein expression of brown markers which were more consistent with their corresponding
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mRNA expression. As shown in Fig 5.4., Indo significantly induced UCP1 and PGC1 protein
expression in both basal and ISO stimulated conditions (Fig 5.4.A-B). In addition, protein
expression of other mitochondrial biogenesis markers was assessed, including voltagedependent anion channel 1 (VDAC1), cytochrome complex (CYTC), and manganese-containing
superoxide dismutase (MNSOD), which were all dose-dependently increased in response to
Indo in both basal and ISO stimulated conditions (Fig 5.4.A-B). To further confirm the enhanced
mitochondrial functionality, cellular bioenergetics assays were used to evaluate respiratory
capacity.
5.4.5

Enhanced flux capacity of indomethacin treated 3T3-L1 adipocytes

To assess the competency of these brown-like adipocytes, fully differentiated 3T3-L1
adipocytes treated with or without increasing concentrations of Indo underwent flux
measurements using the Seahorse XF Analyzer. Mitochondrial stress tests revealed that Indotreated 3T3-L1 adipocytes not only had greater basal OCR, but also had increased proton leak,
maximal respiration, and spare respiratory capacity (Fig 5.5.A-B). Furthermore, ISO stimulation
led to significantly enhanced spare respiratory capacity when Indo and Rosi were removed 24 h
prior to ISO stimulation (Fig 5.5.C-D).
5.4.6

Indomethacin activates PPAR in 3T3-L1 cells

Indo has previously been reported to act as a PPAR-agonist in C3H10T1/214 and HeLa
cells13. Similarly, Indo significantly activated PPAR in a dose-dependent manner in 3T3-L1
preadipocytes using PPAR transactivation assays (Fig 5.6.A). This activity was not mirrored
when testing PPAR transactivation, further demonstrating its specificity for PPAR (Fig 5.6.B).
5.4.7

Browning genotype induced by indomethacin is attenuated by PPAR-knockdown

To confirm Indo’s ability to operate as a browning agent via its action as a PPAR-agonist,
PPAR knockdown (PPAR-KD) was generated in 3T3-L1 cells. Ppar protein expression
analysis confirmed an 86% knockdown efficiency in the selected KD cell pools compared to the
parental cells (Fig 5.6.C). PPAR-KD cells and non-targeting control (SCR) cells were
differentiated in the presence of increasing concentrations of Indo, Rosi, or vehicle control,
DMSO. Ucp1 mRNA expression was significantly suppressed in the PPAR-KD as compared to
the SCR cells (Fig 5.6.E). Pgc1α mRNA expression was not significantly reduced in PPAR-KD
cells as compared to the control cells. In fact, in some cases, PPAR-KD cells displayed an
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ability to enhance Pgc1α mRNA expression (Fig 5.6.F). There was over-all lower Ppar mRNA
expression in PPAR-KD cells as compared to SCR cells; however, in the basal, non-ISO
stimulated condition there was a dose-dependent increase in Ppar mRNA expression in
PPAR-KD cells, whereas there was no difference in response to increasing concentrations of
Indo in SCR cells (Fig 5.6.G). Interestingly, in ISO-stimulated conditions, both PPAR-KD cells
and SCR cells dose-dependently induced Ppar mRNA expression in response to increasing
concentrations of Indo (Fig 5.6.G). Expression of beige-fat-specific marker, Cd137, was
significantly attenuated in PPAR-KD cells compared to the SCR cells (Fig 5.6.H). Suppression
of white-fat-specific marker, Igfbp3, was significantly hindered in PPAR-KD cells compared to
the SCR cells (Fig 5.6.I).
5.4.8

Indomethacin also induces browning in primary stromal cells derived from human

subcutaneous fat
The browning phenomena demonstrated in 3T3-L1 adipocytes is similarly apparent in
HPsubQ cells treated with Indo. Indo dose-dependently increased brown-fat marker, UCP1
mRNA (Fig 5.7.A), with simultaneous suppression of white-fat-specific marker, IGFBP3 mRNA
(Fig 5.7.A). Similar to what was previously shown here in 3T3-L1 cells, there is no significant
change in PPAR mRNA expression (Fig 5.7.A). In contrast, there was no significant increase,
but rather a decrease, in PGC1α mRNA expression (Fig 5.7.A).
Additionally, Indo dose-dependently increased UCP1 and VDAC1 protein expression in
response to increasing concentrations of Indo (Fig 5.7.B-C). However, PGC1α and PLIN1
protein expression did not show a significant response to Indo treatment (Fig 5.7.B-C). There is
no significant change in total PPAR protein expression (Fig 5.7.B-C); however, independent
analysis of PPAR isoforms reveals a significant dose-dependent suppression of PPAR1 and a
reciprocal dose-dependent increase in PPAR2 protein expression (Fig 5.7.B,D).
5.4.9

Indomethacin promotes brown adipogenesis in human brown cell line

Previous studies demonstrated that Indo promotes brown adipogenesis in murine brown cell
line and C57Bl/6J mice when Indo was delivered via an osmotic pump directly onto BAT.21 In
our study, a HBr cell line was used to further investigate the potential for Indo to promote brown
adipogenesis in human brown fat cells. Indo dose-dependently induced UCP1 mRNA and
protein expression in HBr adipocytes (Fig 5.8.C, E-F). Moreover, Indo at 20 M significantly
increased mRNA expression of BAT enriched markers, PPAR, PGC1, and Deiodinase
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Iodothyronine Type II (DIO2) (Fig 5.8.A-E). PGC1 protein expression was also dosedependently increased by Indo (Fig 5.8.E-F).
5.5

DISCUSSION
In this study, we investigated the dose-dependent effects of Indo on murine and human

white adipocytes and human brown adipocytes. The results of this study showed that Indo is not
cytotoxic to 3T3-L1 preadipocytes at concentrations as high as 50 M. Indo augmented
differentiation of 3T3-L1 cells as shown by ORO lipid-staining and absorbance in addition to
mRNA and protein expression of critical differentiation markers. Treating 3T3-L1 adipocytes with
Indo led to a significant induction in mRNA and protein gene expression of brown and beige
markers. Browning of the 3T3-L1 adipocytes was accompanied by enhanced mitochondrial
biogenesis and functionality as shown by desirable cellular bioenergetics profiles. Indo was
shown to activate PPAR in 3T3-L1 cells, knock-down of which led to an attenuation of the
browning effect. Indo was also shown to induce browning in human subcutaneous primary
adipocytes as well as promote brown adipogenesis in a human brown cell line.
Although some literature suggests inhibiting adipogenesis and promoting adipocyte
apoptosis to be an effective means to combat obesity, it is actually contraindicative. Limiting
adipose tissue expansion without alteration in energy intake can lead to ectopic lipid
depositions, increased levels of free fatty acid (FFA) in the circulation, and exacerbated release
of pro-inflammatory signals from hypertrophied and dying adipocytes. All the aforementioned
are pathologies which are directly associated with metabolic disturbances including
hyperlipidemia and insulin resistance.26, 27 Evidence showing existence of ‘metabolically healthy
obese’ describes individuals who have BMIs that categorize them as obese, but do not have the
associated comorbidities, suggesting that sustained insulin sensitivity is more critical than
quantity of fat-mass itself.28, 29 On the other hand, allowing slight expansion to accommodate
excess energy while inducing browning in WAT may promote normal organ function, reduce
hyperlipidemic and inflammatory circumstances, enhance insulin sensitivity, and increase
energy expenditure, possibly leading to weight loss.27, 30, 31 TZDs are common pharmacological
drugs used in the treatment of T2DM which elicit outcomes that demonstrate the beneficial
effects of the expansion hypothesis.15, 32-34
Although there is some hesitation in the clinical utility of TZDs due to some adverse sideeffects including weight gain due to fluid retention and some increase in adiposity, patients still
see favorable outcomes.15, 32-34 In addition to its tremendous insulin-sensitizing effect, TZDs
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have also been shown to exhibit anti-inflammatory, antioxidant, and antiproliferative beneficial
effects.33 Due to its pleiotropic nature, not one single mechanism can be attributed to TZDs
therapeutic benefits; however, it is partly due to both the insulin-sensitizing effect and the
increase in adiposity that these individuals show improvements in glycemic control, blood-lipidprofiles, blood pressure, endothelial function, as well as decreased inflammation markers,
thereby reducing the comorbidities typically associated with inflated AT.15, 32-34 These beneficial
metabolic effects were also attributed to TZDs ability to promote browning of WAT and brown
adipogenesis in BAT.16, 17, 19, 31, 35, 36 Several studies suggest partial agonists or ligands with
similar high-affinity binding with PPAR may have the ability to retain desired insulin sensitizing
function without the unwanted side effects.37, 38 Therefore, compounds with partial PPARagonist activities could offer viable alternative strategies.
Consistent with previous reports demonstrating that TZDs and Indo promote white adipocyte
differentiation in vitro and in vivo,13, 20, 39, 40 our results similarly demonstrate that Indo dosedependently promoted differentiation in 3T3-L1 adipocytes. This enhanced differentiation is
demonstrated by ORO lipid accumulation and absorbance, as well as mRNA and protein
expression of differentiation markers (Fig 5.1.C-G).
In addition to its ability to augment differentiation, Indo also significantly induced browning in
3T3-L1 adipocytes as shown by enhanced UCP1 mRNA and protein expression as well as
beige and brown fat specific markers, Cd137 and Cidea, respectively, with simultaneous
suppression of white-fat-specific marker, Igfbp3. It is worth noting that continuous treatment of
Indo increased Ucp1 mRNA expression under basal and ISO stimulated conditions; however,
removal of Rosi and Indo for 24 h prior to ISO stimulation is required for Indo to augment UCP1
protein expression. This is likely due to the observation that continuous PPAR activation by
Rosi and Indo suppressed protein expression of PPAR and ADRB3, which is the receptor for
ISO (Fig 5.3.A and D). The downregulation of PPAR protein expression by Rosi and Indo may
be explained by self-regulation, feedback inhibition, and/or protection of the receptors from overutilization.41 Taking into consideration that adipogenesis was not inhibited, but rather enhanced
by continuous treatment with Rosi or Indo, may suggest that there is a threshold of receptor
expression required for sufficient differentiation of adipocytes.42 Furthermore, Indo dosedependently suppressed Adrb3 mRNA expression in 3T3-L1 adipocytes, which was further
suppressed by ISO stimulation. These results are consistent with a previous report which
demonstrated HIB-1B cells treated with TZD, troglitazone, led to acute suppression of Adrb3
mRNA levels, which was accompanied by decreased responses to various β-AR agonists.43
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Slight adjustment in the differentiation program by removal of Rosi or Indo for 24 h prior to ISO
stimulation led to recovery and subsequent increase of both PPAR and ADRB3 protein
expression (Fig 5.4.A-B). Furthermore, there was no longer a suppression in UCP1 protein
expression in response to ISO stimulation, which was accompanied by sustained protein
expression of other mitochondrial markers (PGC1, VDAC1, CYTC, MNSOD) (Fig 5.4.A-B).
Among the critical differences between brown and white adipocytes, is BAT’s relatively large
abundance of functional mitochondria expressing UCP1.4-7 The results of our study reveal that
treating 3T3-L1 cells with Indo led to enhanced synthesis, quantity, and function of adipocyte
mitochondria, as shown by increased mRNA and/or protein expression of mitochondrial marker
genes, mtDNA, and mitochondrial respiration. Regulation of quality and abundance of
mitochondria is a tightly controlled and highly coordinated process involving hyperplasia and
hypertrophy of pre-existing mitochondria.44-46 Master regulator of mitochondrial biogenesis,
PGC1, interacts with the mitochondrial-gene transcription factor, NRF1, to further promote
mitochondrial biogenesis and regulate genes involved in energy expenditure and metabolism.31,
45

The increased demand for mitochondria is accompanied by increased need for mitochondrial

enzymes and structural components, such as COX4A.44 mRNA expression of BAT-enriched
mitochondrial markers Pgc1, Nrf1, and Cox4a were all dose-dependently increased in
response to Indo treatment in 3T3-L1 cells. Together with the elevated mtDNA abundance,
these results suggest an overall amassed total mitochondrial quantity, which have greater UCP1
expression. However, increase in mitochondria abundance alone is not generally a sufficient
marker for browning; rather, abundance, quality, and functionality are critical for proper
assessment.46 Therefore, upon confirmation of heightened mitochondrial quantity, cellular
bioenergetic assays were used to substantiate the functionality and uncoupling capacity of 3T3L1 adipocytes treated with Indo.
Results of mitochondrial stress tests showed that Indo dose-dependently increased basal
OCR, proton leak, and maximal and spare respiratory capacity in 3T3-L1 adipocytes under
basal (non-ISO-stimulated) conditions (Fig 5.5.A-B). Under ISO stimulated conditions, Indo
treated 3T3-L1 adipocytes still showed increases in all of the respiratory calculations; however,
only spare respiration was significantly augmented by ISO stimulation compared to the basal
(unstimulated) conditions. Enhanced basal OCR demonstrate that the mitochondria of Indo
treated cells to have remarkably greater functionality.46 Pharmacological interrogation with
FCCP confirmed the UCP1 enhanced phenotype, which was shown by increases in oligomycininsensitive respiration, otherwise known as proton leak.46, 47 By itself, increased basal OCR and
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proton leak could merely indicate physiological adaptation or a response to stress.46 However,
these values in combination with increased maximal and spare respiratory capacity indicates
cells to have a larger and healthier network of mitochondria having a heightened ability to
withstand oxidative damage and stress.46 Therefore, together with gene expression data, our
results demonstrate that Indo has a significant capacity to promote browning and give way to a
larger population of healthy and functional mitochondria. However, the manner in which Indo is
able to elicit these browning effects has yet to be determined until now.
Although primarily recognized as an NSAID, which inhibits COX-1 and COX-2, Indo has also
been shown to act as a PPAR-agonist in several cell types, including C3H10T1/214 and HeLa13
cells. Similarly, our results show that Indo dose-dependently activates PPAR, but not PPAR
in 3T3-L1 preadipocytes as shown by PPAR transactivation assays (Fig 5.6.A-B). Several
studies have suggested that Indo effects may vary based on concentration. It was shown that
Indo acts as a PPAR agonist at higher concentrations (10 – 100 M), 13, 14 whereas it only has
COX inhibiting effects at lower concentrations (0.1 – 1.5 M).48 Studies have demonstrated that
COX-2 expression/activity is required for UCP1 expression and browning of white adipocytes.49
Therefore, it is sensible to assume that Indo’s browning effects seen here are not due to its
COX inhibition capacity.
As previously mentioned, many reports demonstrate Rosi as a robust adipocyte “browning
agent” via its action as a potent full PPAR-agonist,31, 36 at least in part by induction of PGC1
expression.9 Therefore, it is conceivable that Indo’s browning effects may work through the
PPAR-PGC1 axis as well. To investigate the role of PPAR in Indo’s browning effects, PPAR
knockdown (KD) in 3T3-L1 cells was generated and differentiated with or without Indo. These
results revealed upregulated mRNA expression of Ucp1 and Cd137 by Indo which were
significantly attenuated by PPAR-KD as compared to the control (SCR) cells (Fig 5.6.E-F). In
contrast, although similar in pattern, there was a significantly hindered downregulation of Igfbp3
mRNA expression by Indo in PPAR-KD cells (Fig 5.6.G). There were minimal differences in
Pgc1 mRNA expression between PPAR-KD and SCR cells, suggesting that Pgc1 mRNA
expression is independent of PPAR regulation (Fig 5.6.H). As shown in the wild-type mRNA
results, continuously treating 3T3-L1 cells with Indo and Rosi led to either no change or a
suppression of Ppar expression. However, treating PPAR-KD cells with Indo led to a dosedependent increase in Ppar mRNA expression, albeit the overall expression was
understandably lower than SCR (Fig 5.6.I). These results demonstrate the PPAR receptor-
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dependence for the browning effects and provide strong evidence to suggest that Indo’s
capacity to induce browning in 3T3-L1 cells is due to its PPAR-agonist activity.
Differences on PPAR-agonist capacity of Rosi and Indo have previously been
characterized revealing that Rosi is a full PPAR-agonist whereas Indo is a strong partial
PPAR-agonist.12-14 Although it has been reported that partial PPAR-agonists did not induce
the browning program in murine primary subcutaneous WAT,35 the results of our study reveal
that Indo’s strong partial PPAR-agonist activity is, in fact, able to significantly induce browning
in both murine and human white adipocytes. This browning is demonstrated by dose-dependent
increases in UCP1 mRNA and protein expression as well as dose-dependent suppression of
mRNA expression of white-fat-specific marker, IGFBP3, in HPsubQ adipocytes. Moreover, Indo
also led to increased protein expression of VDAC1, a major mitochondrial structural component.
However, there was little to no change or rather a slight decrease in PGC1 mRNA and protein
expression in HPsubQ adipocytes as compared to 3T3-L1 adipocytes, further suggesting that
Indo’s browning effects in HPsubQ adipocytes may be PGC1-independent.
Interestingly, whereas 3T3-L1 adipocytes continuously treated with Indo led to dosedependent suppression of total PPAR, HPsubQ cells had differential expression of the
PPAR isoforms. When both PPAR1 (55kDa) and PPAR2 (57kDa) are taken together, there
were seemingly no differences among the treatments; however, when assessed separately, it
becomes evident that Indo led to a significant dose-dependent increase in PPAR2 and
reciprocal dose-dependent decrease of PPAR1 protein expression in HPsubQ adipocytes.
Although the literature on the differential expression of PPAR isoforms is dearth and
controversial, a large study of 50 obese female patients demonstrated that PPAR2, an
adipose-specific isoform, has overall higher expression compared to PPAR1, in both visceral
adipose tissue (VAT) and subcutaneous adipose tissue (SAT).50 Moreover, it was found that
PPAR2 is inversely correlated with BMI and weight, and that higher expression of PPAR1 in
SAT is associated with higher circulating insulin levels.50 Therefore, our results demonstrating
an inverse relationship of PPAR1 and PPAR2 suggest that Indo treatment induces beneficial
profiles of PPAR isoforms in HPsubQ adipocytes which may be associated with enhanced
insulin sensitivity.50 Further studies are required to confirm Indo-induced insulin sensitivity in
HPsubQ adipocytes.
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Lastly, Indo significantly enhanced brown adipogenesis in the HBr cell line, as demonstrated
by augmented UCP1 and PGC1 mRNA and protein expression as well as increased PPAR
and DIO2 mRNA expression when using 20 M of Indo. Taken together, the results of HPsubQ
and human brown cells treated with Indo show similar increases of UCP1 expression as Indotreated 3T3-L1 adipocytes and murine brown adipocytes. Future studies to examine the UCP1
mediated functionality of these cells, such as cellular flux measurements would help to further
confirm the metabolic benefit of Indo treatment in human adipocytes.
In conclusion, for the first time, the results presented here provide evidence that Indo,
through its PPAR-agonist activity, possesses the capacity to dose-dependently promote
browning in murine and human white adipocytes as well as enhance brown adipogenesis in
human brown adipocytes. Indo’s browning effect on 3T3-L1 adipocytes is further demonstrated
by increased UCP1 expression, mitochondrial biogenesis, proton leak, as well as maximal and
spare respiratory capacity. In light of Indo’s potential to induce browning and brown
adipogenesis, and taking into consideration possible contraindications, it would be interesting to
explore the possibilities of local delivery of Indo to be used as a therapeutic agent for obesity
treatment and prevention.
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5.7 APPENDIX

Figure 5.1. Indomethacin does not cause toxicity and enhances adipogenesis and lipid
accumulation in 3T3-L1 cells.
(A) Indo chemical structure. (B) MTT cell proliferation assay in 3T3-L1 preadipocytes seeded in
48-well format were treated with increasing concentrations of Indo and the control for 24 h
followed by 3 h incubation with MTT reagent. Confluent 3T3-L1 preadipocytes were induced to
differentiate in the presence or absence of increasing concentrations of Indo, vehicle control
DMSO (Indo 0 M), or Rosi (1 M) for 8 days prior to lysis and further analysis. (C) Oil Red O
(ORO) stained cell morphology of 3T3-L1 adipocytes at day 8 of differentiation. (D) 3T3-L1
adipocyte lipid accumulation at day 8 measured by ORO stain absorbance. (E) Differentiation
marker mRNA gene expression of C/ebp, Fabp4, and Fasn. The relative mRNA expression
was normalized to 36b4 and expressed as fold-1 of the (-) sample for each gene. (F) Western
blotting of PLIN1 and FABP4. (G) Densitometry of PLIN1 and FABP4 protein expression
normalized to loading control, total ERK1/2 with the (-) sample set at fold-1 for each gene. A
second loading control -Actin is provided. Statistics were computed using one-way ANOVA
followed by multiple comparison tests with Student-Newman-Kewls method, significant
differences between control and treatment, unless otherwise noted, are indicated with *, **, ***,
p<0.05, p<0.01, and p<0.001, respectively.
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Figure 5.2. Indomethacin promotes browning as well as mitochondrial biogenesis in 3T3L1 adipocytes.

Confluent 3T3-L1 preadipocytes were induced to differentiate in the presence or absence of
increasing concentrations of Indo, vehicle control DMSO (Indo 0 M), or Rosi (1 M) for 7 days.
On day 7, in addition to treatments, cells were stimulated for 6 h with ISO (1 M) prior to lysis
and further analysis. Relative mRNA gene expression (A-H) of brown (Ppar, Ucp1, Cidea),
beige (Cd137), white (Igfbp3), and mitochondrial markers (Pgc1, Nrf1, Cox4a), normalized to
36b4. (I) Mitochondrial DNA, CoxIIa normalized to 18S. Each graph is expressed as fold of that
of the (-), non-ISO stimulated sample (set at 1). One-Way ANOVA was performed followed by
multiple comparison tests with Student-Newman-Kewls method for treatment and ISOresponsive relationship. The bar indicates the statistical significance of the non-ISO group
compared to ISO group. Statistical significance is indicated by *, **, ***, p<0.05, p<0.01, and
p<0.001, respectively.
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Figure 5.3. Suppression of PPAR and ADRB3 by Rosi and Indo in differentiating 3T3-L1
adipocytes.
Confluent 3T3-L1 preadipocytes were induced to differentiate in the presence or absence of
increasing concentrations of Indo, vehicle control DMSO (Indo 0 M), or Rosi (1 M) for 7 days.
On day 7, in addition to treatments, cells were stimulated for 6 h (C) or 24 h (A,D) with ISO (1
M) prior to lysis and further analysis. (A) PPAR and UCP1 protein expression and their
densitometry (B), as well as Adbr3 mRNA (C) and ADRB3 protein expression (D) and its
densitometry (E). Densitometry of PPAR and UCP1 (B) and ADRB3 (D) protein expression
were normalized to loading control, total ERK1/2 with the (-), non-ISO stimulated sample, set at
fold-1 for each gene. (C) Relative mRNA expression of Adbr3 normalized to 36b4 and
expressed as fold-1 to the (-), non-ISO stimulated sample. One-Way ANOVA was performed
followed by multiple comparison tests with Student-Newman-Kewls method for treatment and
ISO-responsive relationship. The bar indicates the statistical significance of the non-ISO group
compared to ISO group. Statistical significance is indicated by *, **, ***, p<0.05, p<0.01, and
p<0.001, respectively.
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Figure 5.4. Timely removal of Rosi and Indo rescues browning phenotype in 3T3-L1
adipocytes.
Confluent 3T3-L1 preadipocytes were induced to differentiate in the presence or absence of
increasing concentrations of Indo, vehicle control DMSO (Indo 0 M), or Rosi (1 M) for 6 days.
On day 6, the Indo or Rosi treatment were removed for 24 h, after which the cells were
stimulated with ISO (1 M) or vehicle for 24 h prior to lysis and further analysis. (A) Protein
expression of brown-marker (UCP1), rescued adipocyte genes (ADRB3 and PPAR),
mitochondrial biogenesis (PGC1), and mitochondrial structural (VDAC, CYTC, MNSOD), as
well as their densitometry (B). Densitometry of each protein was normalized to loading control,
total ERK1/2 with the (-), non-ISO stimulated sample, set at fold-1 for each gene. A second
loading control -Actin is provided. Mixed model ANOVA was performed followed by multiple
comparison tests with Student-Newman-Kewls method for treatment and ISO-responsive
relationship. The bar indicates the statistical significance of the non-ISO group compared to ISO
group. Statistical significance is indicated by *, **, ***, p<0.05, p<0.01, and p<0.001,
respectively.
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Figure 5.5. Indomethacin significantly enhances oxygen consumption in 3T3-L1
adipocytes.
Confluent 3T3-L1 preadipocytes in a 6-well format were induced to differentiate in the presence
or absence of increasing concentrations of Indo, vehicle control DMSO (Indo 0 M), or Rosi (1
M) for 6 days. On day 6, cells were evenly re-seeded into XF-24 well plate. (A-B) Re-seeded
cells were maintained Indo and Rosi treatment until flux-experiment initiation on day 8. (C-D)
Re-seeded cells were maintained in maintenance media without Indo or Rosi for 24 h. On day 7,
cells were treated with ISO (1 M) or vehicle for 24 h prior to flux-experiment. Mitochondrial
stress tests were performed as described in the materials and methods. Respiration calculations
(B,D) were performed, and are displayed so that the (-), non-ISO sample average is set at fold-1
for each type of respiration calculation group. Statistical differences in (D) are treatment
compared to its (-) control. The bar indicates the statistical significance of the non-ISO group
compared to ISO group. ANOVA with repeated measures and one-way ANOVA was performed
to show statistical differences between treatment and controls indicated by *, **, ***, p<0.05,
p<0.01, and p<0.001, respectively.
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Figure 5.6. Indomethacin dose-dependently activates PPAR, deficiency of which
attenuates browning.
(A-B) 3T3-L1 preadipocytes were transiently transfected with PPAR or PPAR-Gal4-Luc and
-gal for 24 h, then treated with increasing concentrations of Indo for an additional 18 h.
Luciferase activity was normalized to -gal activity, the non-treated (-) sample was set at fold-1.
(C) 3T3-L1 preadipocytes were stably infected with lentiviral shRNA particles targeting PPAR
or a scrambled control (SCR). Knockdown (KD) efficiency was determined by western blot
analysis. (D) Densitometry of Ppar average protein expression was normalized to the loading
control, -Actin, with the parental 3T3-L1 cells set as fold-1. (E-I) Confluent 3T3-L1 cells with
stable knockdown of PPAR (PPAR-KD) or SCR were induced to differentiate in the presence
of absence of increasing concentrations of Indo, vehicle control DMSO (Indo 0 M), or Rosi (1
M) for 7 days. Relative mRNA expression (E-I) of Ucp1, Pgc1, Ppar, Cd137, and Igfbp3
normalized to 36b4 are shown, the (-)-non-ISO-stimulated SCR sample and (-)-ISO-stimulated
SCR sample was set at fold-1 for each group, independently. Mixed model ANOVA was
performed followed by multiple comparison tests with Student-Newman-Kewls method for
treatment, KD, and ISO-responsive relationship. The bar indicates the statistical significance
between PPAR-KD and SCR for each treatment. Statistical significance is indicated by *, **,
***, p<0.05, p<0.01, and p<0.001, respectively.
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Figure 5.7. Indomethacin induces browning in primary stromal cells derived from human
subcutaneous fat.
Human primary stromal cells from subcutaneous fat were induced to differentiate in the
presence or absence of increasing concentrations of Indo, vehicle control DMSO (Indo 0 M), or
Rosi (1 M) for 14 days. (A) mRNA gene expression of PPAR, PGC1, UCP1, and IGFBP3,
normalized to human 36B4. (B) PGC1, UCP1, PLIN1, total PPAR, and VDAC protein
expression and their densitometry (C). (D) PPAR1 and PPAR2 quantified separately, graphing
raw data to demonstrate relative expression levels of each gene. Unless otherwise noted, all
densitometric comparison of the average expression normalized to loading control, total
ERK1/2. A second loading control -Actin is provided. Each graph is expressed as fold-1 of that
of the 0 M (mRNA) or (-) (protein) sample for each gene. One-Way ANOVA was performed
followed by multiple comparison tests with Student-Newman-Kewls method for concentrationresponsive relationships. The bar indicates the significant or non-significant (NS) state for
individual samples compared to their control within each gene group. Statistical significance is
indicated by *, **, ***, p<0.05, p<0.01, and p<0.001, respectively.
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Figure 5.8. Indomethacin promotes brown adipogenesis in human brown cell line.
Human brown cells were induced to differentiate in the presence or absence of increasing
concentrations of Indo and vehicle control DMSO (Indo 0 M) for 21 days. Relative mRNA gene
expression (A-D) of PPAR, PGC1, UCP1, and DIO2, normalized to human 36B4. (E) PGC1
and UCP1 protein expression and their densitometry (F). Densitometry of PGC1 and UCP1
protein was normalized to loading control, total ERK1/2. Each graph is expressed as fold-1 of
that of the 0 M sample. One-Way ANOVA was performed followed by multiple comparison
tests with Student-Newman-Kewls method for concentration-responsive relationship. Statistical
significance is indicated by *, **, ***, p<0.05, p<0.01, and p<0.001, respectively.
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Table 5.1. Murine primer sequences for qRT-PCR using SYBR green.

Gene name
36B4
-AR3
CD137
C/EBP
CIDEA
COX4a
FABP4
FASN
IGFBP3
NRF1
PGC1
PPAR
UCP1

Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse

Primer sequences
GCTTCGTGTTCACCAAGGAGGA
GTCCTAGACCAGTGTTCTGAGC
AGGCACAGGAATGCCACTCCAA
GCTTAGCCACAACGAACACTCG
CGTGCAGAACTCCTGTGATAAC
GTCCACCTATGCTGGAGAAGG
GCAAAGCCAAGAAGTCGGTGGA
CCTTCTGTTGCGTCTCCACGTT
GGTGGACACAGAGGAGTTCTTTC
CGAAGGTGACTCTGGCTATTCC
TCATTGGCTTCACTGCGCTCGT
TCCAGCATTCGCTTGGTCTGCA
TGAAATCACCGCAGACGACAGG
GCTTGTCACCATCTCGTTTTCTC
CACAGTGCTCAAAGGACATGCC
CACCAGGTGTAGTGCCTTCCTC
GTCGCAAATAATGGTGCGCT
GAAAAACTGCCTTCCCGCAG
GGCAACAGTAGCCACATTGGCT
GTCTGGATGGTCATTTCACCGC
GAATCAAGCCACTACAGACACCG
CATCCCTCTTGAGCCTTTCGTG
GTACTGTCGGTTTCAGAAGTGCC
ATCTCCGCCAACAGCTTCTCCT
GCTTTGCCTCACTCAGGATTGG
CCAATGAACACTGCCACACCTC
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Table 5.2. Human primer sequences for qRT-PCR using SYBR green.

Gene name
36B4
-AR3
DIO2
IGFBP3
PGC1
PPAR
PRDM16
UCP1

Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse

Primer sequences
GCTTCGTGTTCACCAAGGAGGA
GTCCTAGACCAGTGTTCTGAGC
AGCCCAGGCTTTGCCAACGGC
GGGACTCATTCAGAACAGAGGC
AGTGCAGAAGGAGGTGACAACAGT
AAAGTCAAGAAGGTGGCATGTGGC
CGCTACAAAGTTGACTACGAGTC
GTCTTCCATTTCTCTACGGCAGG
AGTGGTGCAGTGACCAATCA
CTGCTAGCAAGTTTGCCTCA
AGCCTGCGAAAGCCTTTTGGTG
GGCTTCACATTCAGCAAACCTGG
CAGCCAATCTCACCAGACACCT
GTGGCACTTGAAAGGCTTCTCC
AGTTCCTCACCGCAGGGAAAGA
GTAGCGAGGTTTGATTCCGTGG

Table 5.3. Murine mitochondrial DNA primer sequences for qRT-PCR using SYBR green.
Gene name
Mouse mtCox-II

Forward
Reverse

Primer sequences
GCTCTCCCCTCTCTACGCAT
AGCAGTCGTAGTTCACCAGG
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CONCLUSIONS AND FUTURE DIRECTIONS
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6.1. CONCLUSIONS
The contents of this dissertation included three primary experiments: Chapter III, IV, and V.
Chapter III demonstrates successful encapsulation of trans-resveratrol (Res) within two forms of
nanocarriers, nanoparticle (Rnano) and liposome (Rlipo). Nanotechnology in this case led to
greater aqueous solubility, chemical stability, and cellular uptake, which led to greater biological
effects in browning 3T3-L1 murine adipocytes. Both Rnano and Rlipo enhanced PPREresponsive luciferase reporter gene activity and increased mRNA expression of browning
markers including uncoupling protein-1 (Ucp1), peroxisome proliferator-activated receptor
coactivator 1 alpha (Pgc1), beige maker Cd137, and mitochondrial markers, while markedly
decreasing white-fat specific marker, Igfbp3.
Chapter IV added to these novel findings by demonstrating the effects of the addition of an
adipose stromal cell (ASC)-targeting peptide (GSWKYWFGEGGC) onto the surface of
nanoparticles encapsulated with Res. The resulting ligand-bound nanoparticle encapsulated
with Res was referred to as (L-NR), and was shown to have high-binding affinity to ASCs due to
its specificity for the extra-cellular matrix protein, delta-decorin (DCN). DCN is an isoform of
decorin (DCN) that lacks a glycanation site and is only expressed in ASCs of the stromal cell
population in subcutaneous white adipose tissue (WAT). As compared to the non-ligand bound
nanocarrier (NR), L-NR had increased uptake in 3T3-L1 preadipocytes overexpressing DCN
and in murine primary stromal cells isolated from 10-12 week old male C57Bl/6J mice. L-NR
induced browning in murine primary stromal cells when treated throughout differentiation at 1
M as shown by brown and beige-fat marker mRNA expression (i.e., Ucp1, Pgc1, Cd137).
When treating fully mature adipocytes differentiated from the primary stromal cells from murine
inguinal WAT, only L-NR, but not NR or FR, was able to induce the brown-like phenotype using
10 M.
Finally, in Chapter V, the effects of non-steroidal anti-inflammatory drug (NSAID),
indomethacin (Indo), were tested using 3T3-L1 murine white fat cell line, human primary
subcutaneous WAT cells (HPsubQ), and human brown fat cell line. Indo dose-dependently
induced browning in 3T3-L1 adipocytes, as demonstrated by increased brown- and beige-fat
marker mRNA and protein expression as well as decreased white-fat-specific marker mRNA
expression. Indo led to increased mitochondrial biogenesis as shown by enhanced mRNA and
protein expression of mitochondrial biogenesis and structural markers, as well as increased
mitochondrial DNA and functionality in 3T3-L1 adipocytes. Indo also led to enhanced basal
oxygen consumption rate, proton leak, and maximal and spare respiratory capacity in 3T3-L1
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adipocytes. Indo dose-dependently enhanced transactivation of PPAR, knockout of which
attenuated the browning effects. Moreover, Indo led to browning in HPsubQ adipocytes as
shown by mRNA and protein expression of brown-fat markers. Indo also enhanced brown
adipogenesis in a human brown fat cell line.
In summary, nanoparticle encapsulation increased solubility, extended the release, and
enhanced the bioavailability and biological activity of Res. The targeting peptide further
augmented the capacity of Res nanoparticles to induce browning in white adipocytes using
lower, physiological-relevant doses. Finally, providing an alternate mechanism and beneficial
effect for an FDA approved drug, Indo is now shown to work in both murine and human white
and brown fat cells to induce browning and brown adipogenesis.
6.2. SIGNIFICANCE OF STUDY
Obesity is a multi-factorial disease, and therefore, requires a multi-factorial approach. The
use of both pharmaceutical and nutraceutical compounds should be investigated for the
treatment and prevention of obesity.
Res has been shown to promote beige adipocyte formation within WAT; however, the poor
bioavailability has been a critical limitation for clinical utility. In this dissertation, the ASCtargeting, ligand-bound nanoparticles encapsulated with Res significantly increased the
solubility, stability, and bioavailability of Res while simultaneously increasing its targeting
capacity for the subcutaneous tissue within WAT. This resulted in enhanced white adipocyte
browning and improved thermogenic capacity using lower, physiologically-relevant doses of Res
(i.e., 1-10 M). Enhanced targeting specificity is expected to minimize side-effects by being able
to use lower-doses of Res with reduced interaction or filtration with off-target organs. Therefore,
we have shown that the use of targeting-nanotechnology in this case has overcome the
previously recognized limitations of Res and provides proof for a potential breakthrough for its
therapeutic use in preventing and treating obesity.
Indo has previously been used for the treatment of inflammatory disorders and diseases
based on its non-specific cyclooxygenase (COX)-inhibitory actions. Until now, Indo has never
been used to treat or prevent obesity by inducing browning of white adipocytes. The results of
our study demonstrate a great potential of Indo to promote browning, comparable to that of the
insulin sensitizing drug, rosiglitazone. Our results suggest that Indo could be used as a
therapeutic adjunct in obese patients to possibly promote energy expenditure and weight loss
and improve insulin sensitivity. Many drugs must go through years of costly human clinical trial
testing to confirm efficacy or obtain approval. However, Indo is an already FDA approved drug,
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and would therefore not have to undergo expensive and time-consuming testing.
Considering obesity is still burgeoning disease rising to pandemic levels, finding adjuncts to
lifestyle changes is critical to prevent and treat obesity. Both targeting nanoparticles
encapsulated with Res and Indo show promise as novel nutritional and pharmaceutical
strategies to combat obesity, which could not only help to reduce medical costs but also
promote health and quality of life.
6.3 LIMITATIONS AND FUTURE DIRECTIONS
There are several limitations to this project which should be acknowledged. The time and
cost associated with nanocarrier production as well as the therapeutic delivery route of
nanocarriers are of concern when considering use in human clinical trials. Generating
nanoparticles is a time-consuming, technically difficult, and expensive, which may not be
feasible or cost-efficient for wide-spread use. However, over time, the cost and production
methods should reciprocally progress in parallel with technology progression. The current
methods of delivery for nanoparticles are oral or intravenous injection. Oral administration would
not be effective in enhancing the delivery of Res or reducing the metabolism, since the outershells are composed of inert lipids which the body would recognize and digest as any other
dietary lipid. Intravenous (IV) injection is routine in animal studies; however, IV injections may
not be feasible for human testing. Depending on injections site, there is a considerable amount
of nanocarriers filtered out and trapped by the liver.1 One strategy to overcome the issue with IV
injection, is the use of injectable hydrogels primarily composed of biodegradable hyaluronic acid
and alginate.2 Using this, the nanocarrier-hydrogel mixture can be injected directly into the
subcutaneous WAT through the skin. Therefore, generation and testing for the targeting-delivery
and the anti-obesity biological effect of L-NR using IV compared to subcutaneous injection in
animal studies would be the logical next step.
Although the results of Chapter IV were compelling and novel, they are preliminary and
require more in-depth analysis of the gene expression, mechanism, and function elicited in
murine stromal cells by L-NR using various doses and timing. This analysis would include
protein expression of brown and beige fat markers, inhibitor and/or knock-down studies, as well
as glucose/insulin-tolerance and mitochondrial respiration assays to confirm beige-phenotype
and function.
Finally, a primary limitation for the use of Indo is its unwanted toxic side effects seen after
oral administration. Similar to other NSAID long-term use, Indo has been shown to have toxic
side effects, which primarily includes gastrointestinal (GI) distress and ulceration. Therefore, it
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would be pertinent to find alternative routes to oral administration to reduce GI exposure and
therefore, reduce toxic side effects. Fortunately, there have been many attempts made in this
therapeutic-field for other drug compounds which could possibly be applied to Indo.
Surgically implanted pumps have been used in rodent studies to locally deliver Indo to
brown adipose tissue (BAT) fat pads.3 A similar approach is used in some human-based
therapies, including internal insulin pumps,4 some types of birth control,5 as well as newer
vaccine-based implant approaches.6-9 Topical ointments and patches are also shown to help
with local joint, bone, and muscle delivery.6, 10-13 Small, pre-measured sterile injection-pens are
used to deliver a wide-variety of drug-compounds.14, 15 Therefore, the use of any of these
already established drug-delivery methods would be viable options for helping with local and/or
sustained release of Indo. It would be interesting to establish an Indo-based compound possibly
in combination with a proton-pump inhibitor (PPI) (to help reduce ulceration and GI distress),16
with one of the aforementioned drug-delivery methods to further reduce side effects and
enhance tissue-targeting.
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